Clinical trial NCT02393755
Conditions: Colon Adenocarcinoma Rectal Adenocarcinoma Recurrent Colon Carcinoma Recurrent Rectal Carcinoma Stage IVA Colon Cancer Stage IVA Rectal Cancer Stage IVB Colon Cancer Stage IVB Rectal Cancer
Sponsor: Roswell Park Cancer Institute
Start date: 2015-05-08; Completion date: 2021-05-18
Enrollment: 42 participants; Allocation: NON_RANDOMIZED; Intervention model: SINGLE_GROUP

Brief summary:
This phase I/II trial studies the side effects and best dose of nintedanib when given together with capecitabine and to see how well they work in treating patients with colorectal cancer that has not responded to previous treatment (refractory) and has spread to other places in the body (metastatic). Nintedanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It may also block the growth of new blood vessels necessary for tumor growth. Drugs used in chemotherapy, such as capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving nintedanib with capecitabine may be a better treatment for colorectal cancer.

Detailed description:
PRIMARY OBJECTIVES:

* I. To estimate the maximum tolerated dose (MTD) and examine the dose-limiting toxicities of nintedanib when administered with capecitabine within the study population and, establish the recommended phase II dose (RP2D). (Phase I)
* II. To assess progression free survival at 18 weeks. (Phase II)

SECONDARY OBJECTIVES:

* I. To assess median progression free survival. (Phase II)
* II. To assess median overall survival from the date of enrollment to the time of death will be documented. (Phase II)
* III. To assess the objective response rate as measured by Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1. (Phase II)
* IV. To assess the toxicity of dose regimen using the Cancer Therapy Evaluation Program (CTEP) National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE version 4.0). (Phase II)

TERTIARY OBJECTIVES:

* I. Measurement of circulating angiogenic cytokines (CAFs): vascular endothelial growth factor (VEGF), soluble vascular endothelial growth factor receptor (sVEGFR) 1/2, placental growth factor (PlGF), granulocyte macrophage colony-stimulating factor (GMCSF), leptin, interleukin (IL)-1 alpha (a), IL-8, IL-6, fibroblast growth factor basic (FGFb), osteopontin and pentraxin-3. (Phase II)
* II. Measurement of drug levels and pharmacokinetic (PK)/pharmacodynamic (PD) modeling. (Phase II)

OUTLINE: This is a phase I, dose-escalation study of nintedanib followed by a phase II study.

Patients receive capecitabine orally (PO) twice daily (BID) (every 12 hours) on days 1-14 and nintedanib PO BID (every 12 hours) on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up at 30 days, every 28 days until resolution or satisfactory stabilization of persistent drug-related toxicity, and then every 6 months thereafter.

Arms: arm 1: Patients received capecitabine PO BID (every 12 hours) on days 1-14 and nintedanib PO BID (every 12 hours) on days 1-21. Courses repeated every 21 days in the absence of disease progression or unacceptable toxicity. arm 2: Patients receive the highest safe dose of the combination of nintedanib and capcitabine.
Interventions: intervention 1: Capecitabine intervention 2: Laboratory Biomarker Analysis intervention 3: Nintedanib intervention 4: Pharmacological Study
Intervention descriptions: intervention 1: Given PO intervention 2: Correlative studies intervention 3: Given PO intervention 4: Correlative studies

Protocol documents:
Prot_SAP_000.pdf: 
PRIVATE AND CONFIDENTIAL INFORMATION OF ROSWELL PARK CANCER INSTITUTE
02.16.16
Page 1 of 90
TITLE: A Phase I/ II Study of Nintedanib and Capecitabine in Refractory Metastatic 
Colorectal Cancer
Roswell Park Cancer Institute
Study Number:
I 265514
Initial Date:
Amendment #1:
Amendment #2:
Amendment #3:
Amendment #4:
07 November 2014
03.23.15
04.17.15
01.29.16
02.16.16
Principal Investigator:
Patrick M. Boland, MD
Roswell Park Cancer Institute
Elm & Carlton Streets
Buffalo, New York 14263
716-845-3099
Partick.Boland@RoswellPark.org
Sponsor:
Funding:
Industry/Other Supporter:
Roswell Park Cancer Institute
NCCN
Boehringer Ingelheim
Confidentiality Statement
Any and all information presented in this document shall be treated as confidential and 
shall remain the exclusive property of the party (ies) mentioned above. The use of such 
confidential information must be restricted to the recipient for the agreed purpose and 
must not be disclosed, published, or otherwise communicated to any unauthorized persons, 
for any reason, in any form whatsoever without the prior written consent of the party (ies) 
above.


Roswell Park Cancer Institute Study No.: 
                                                                                       I 265514
PRIVATE AND CONFIDENTIAL INFORMATION OF ROSWELL PARK CANCER INSTITUTE
02.16.16
Page 2 of 90
List of Abbreviations
5-HT3
5-Hydroxy-Tryptamin receptor 3
AE
Adverse Event
ALT
Alanine Aminotransferase
AST
Aspartate Aminotransferase
bFGR
basic Fibroblast Growth Factor
BIBF 1120
Nintedanib
BIBF 1202
metabolite of nintedanib
BID
twice daily
Cmax
maximum measured concentration of the analyte in plasma
CAF
Circulating Angiogenic Factor/Cytokine 
CEA
Carcinoembryonic Antigen
CRF/eCRF
Case Report Form / electronic Case Report Form
CSF-1R
Colony Stimulating Factor 1 Receptor
CT
Computed Tomography
CTCAE
Common Terminology Criteria for Adverse Events
DLT
Dose Limiting Toxicity
DNA
Deoxyribonucleic Acid
ECG
Electro Cardio Gram
ECOG
Eastern Cooperative Oncology Group
EDTA
Ethylenediaminetetraacetic Acid
ELISA
Enzyme-Linked Immunosorbent Assay
FGF
Fibroblast Growth Factor
APPROVED RPCI Institutional Review Board: 10/17/2016


Roswell Park Cancer Institute Study No.: 
                                                                                       I 265514
PRIVATE AND CONFIDENTIAL INFORMATION OF ROSWELL PARK CANCER INSTITUTE
02.16.16
Page 3 of 90
FGFR
Fibroblast Growth Factor Receptor
Flt-1
synonym for vascular endothelial growth factor receptor 1
Flt-3
synonym for vascular endothelial growth factor receptor 3
Flt-4
synonym for vascular endothelial growth factor receptor 4
GGT
Gamma Glutamyl Transpeptidase
GI
Gastrointestinal 
GM-CSF
Granulocyte Macrophage Colony-Stimulating Factor
HDPE
High Density Polyethylene 
IL
Interleukin
INR
International Normalized Ratio
KIT
Gene that encodes for a protein that is a type 3 transmembrane receptor for 
MGF (mast cell growth factor, also known as stem cell factor)
Lck
Lymphocyte-specific protein-tyrosine kinase, member of the Src family of 
kinases
LDH
Lactate Dehydrogenase
Lyn
Yamaguchi sarcoma viral (v-yes-1) oncogene homolog, cellular protein 
tyrosine kinase member of the Src family of kinases
mFOLFOX-6
An abbreviation for a combination chemotherapy regimen that is used to 
treat colorectal cancer
mg
milligram
min
minute
ml/mL
Milliliter
mm
millimeter
MRI
Magnetic Resonance Imaging
NSCLC
Non-Small Cell Lung Cancer
APPROVED RPCI Institutional Review Board: 10/17/2016


Roswell Park Cancer Institute Study No.: 
                                                                                       I 265514
PRIVATE AND CONFIDENTIAL INFORMATION OF ROSWELL PARK CANCER INSTITUTE
02.16.16
Page 4 of 90
OS
Overall Survival
PD
Progressive Disease
PDGF
Platelet Derived Growth Factor
PDGFR
Platelet Derived Growth Factor Receptor
PFS
Progression Free Survival
P1GF
Placenta derived growth factor: an angiogenic factor involved in tumor 
neovascularization
PK
Pharmacokinetic(s)
PR
Partial Response
PT
Prothrombin Time
PTT
Partial Thromboplastin Time
RECIST
Response Evaluation Criteria in Solid Tumors
RET
Gene that encodes for a tyrosine kinase transmembrane receptor
RP2D
Recommended Phase II Dose
RTKI
Receptor Tyrosine Kinase Inhibitor
SAE
Serious Adverse Event
SD
Stable Disease
SRC
Src tyrosine kinase
TKI
Tyrosine Kinase Inhibitor
TSH
Thyroid Stimulating Hormone
VEGF
Vascular Endothelial Growth Factor
VEGFR
Vascular Endothelial Growth Factor Receptor
APPROVED RPCI Institutional Review Board: 10/17/2016


Roswell Park Cancer Institute Study No.: 
                                                                                       I 265514
PRIVATE AND CONFIDENTIAL INFORMATION OF ROSWELL PARK CANCER INSTITUTE
02.16.16
Page 5 of 90
SYNOPSIS
Title / Phase
A Phase I/ II Study of Nintedanib and Capecitabine in Refractory 
Metastatic Colorectal Cancer
Roswell Park Cancer Institute Study 
Number
I 265514
Roswell Park Cancer Institute Investigator
Patrick M. Boland, MD
Sponsor
Roswell Park Cancer Institute
Funding Organization
NCCN
Industry Support
Boehringer Ingelheim
Study Drug(s)
Nintedanib Provided by Boehringer Ingelheim)
Capecitabine
Objectives
Primary: 
•
Phase I: To estimate the maximum tolerated dose (MTD) and 
examine the dose-limiting toxicities of nintedanib when 
administered with capecitabine within the study population 
and, establish the Recommended Phase II Dose (RP2D).. 
•
Phase II: To assess progression free survival at 18 weeks. This 
will be assessed via the Response Evaluation Criteria in Solid 
Tumors (RECIST) version 1.1 guidelines after every 3 cycles 
(9 weeks) of therapy.
Secondary (phase II): 
•
To assess median progression free survival (at 18 weeks). This 
will be assessed via the Response Evaluation Criteria in Solid 
Tumors (RECIST) version 1.1 guidelines [after every 3 cycles 
(9 weeks) of therapy].
•
To assess median overall survival from the date of enrollment 
to the time of death will be documented.
•
To assess the objective response rate as measured by 
RECIST v 1.1.
•
To assess the toxicity of dose regimen using the CTEP NCI 
Common Terminology Criteria for Adverse Events (CTCAE 
Version 4.0).
Tertiary:
•
Measurement of circulating angiogenic cytokines (CAFs): 
VEGF, sVEGFR 1/2, PlGF, GMCSF, Leptin, IL-1a, IL-8, IL-6, 
FGFb, Osteopontin, and Pentraxin-3.
•
Measurement of drug levels and PK/PD modeling
Study Design
Multicenter phase I/II study of nintedanib and capecitabine in 
refractory metastatic colorectal cancer
APPROVED RPCI Institutional Review Board: 10/17/2016


Roswell Park Cancer Institute Study No.: 
                                                                                       I 265514
PRIVATE AND CONFIDENTIAL INFORMATION OF ROSWELL PARK CANCER INSTITUTE
02.16.16
Page 6 of 90
Target Accrual and Study Duration
Between 9 and 18 patients will be treated in the phase I portion of 
this study. Phase I patients (n=6) treated at the recommended phase 
II dose will be included in the phase II portion of the study. Up to 
an additional 30 patients will be recruited to the phase II study, for a 
phase II sample size of 36. The study is expected to accrue 9 
patients to the phase I portion for a total sample size of 39 patients 
(9 + 36 - 6). If 18 patients were necessary for enrollment to the 
Phase I study, a maximum of 48 patients might be required (18+36-
6). Accrual is expected to take up to 2 years, with patients 
remaining on study for 18 weeks.
Study Procedures
Physical Examination (including vital signs, and body weight): 
Baseline, Day 1 of all Cycles, Cycle 1-Day 8and Cycle 2-Day 8 ( 
physical exam for phase I only), End of Treatment
Medical History: Baseline
Hematology: Baseline, Day 1 of all Cycles, End of Treatment
Chemistry: Baseline, Day 1 of all Cycles, Cycle 1-Day 8and 
Cycle 2-Day 8 (Day 8 chemistry for phase I only), End of 
Treatment
PT/INR, PTT: Baseline
Urine Sample for UPCR: Baseline
CEA: Cycle 1-Day 1, Cycle 4-Day 1, every 3 cycles from Cycle 4 
onward.
PK/PD Sampling: Cycle 1-Day 1, Day 2 and Day 15
Biomarker (CAF) Sampling; Cycle 1-Day 1 and Day 15, 
Cycle 3 -Day 1
Pregnancy Test (serum): Baseline
ECOG Performance Status: Baseline, Day 1 of all cycles
CT Scan (chest, abdomen, pelvis): Baseline, every 9 weeks after 
cycle 1-day 1 (± 7 days)
Concomitant Medications: Baseline, Day 1 of all Cycles, Cycle 1-
Day 8and Cycle 2-Day 8 (for phase 1 only), End of Treatment
Adverse Events: Day 1 of all Cycles, Cycle 1-Day 8and Cycle 2-
Day 8 (for phase 1 only), End of Treatment.
APPROVED RPCI Institutional Review Board: 10/17/2016


Roswell Park Cancer Institute Study No.: 
                                                                                       I 265514
PRIVATE AND CONFIDENTIAL INFORMATION OF ROSWELL PARK CANCER INSTITUTE
02.16.16
Page 7 of 90
Statistical Analysis
Sample Size Determination: Sample size determination for the 
phase I portion will depend upon the dose-toxicity profile, but is 
expected to be between 9-18 patients. For the phase II portion, with 
an alpha of 0.1, assessment of 36 patients allows for a power of 0.8 
to detect a minimum difference of 17% in the PFS at 18 weeks, 
assuming a rate of 25% under standard of care.
Randomization: No randomization is required.
Efficacy Analysis: Primary interest is in the PFS at 18 weeks after 
enrollment. The PFS at 18 weeks will be described by binomial 
proportion estimates and 90% confidence intervals. All patients in 
the phase II study and those treated at the RP2D in the phase I study 
will be included for analysis.
Safety Analysis: Adverse events will be tabulated. AE rates will be 
described using binomial proportions and 90% confidence intervals. 
Correlative Data Analysis: Mechanistic PK/PD modeling will be 
employed, examining the relationship between nintedanib 
pharmacokinetics, modulation of CAFs and PFS. 
APPROVED RPCI Institutional Review Board: 10/17/2016


Roswell Park Cancer Institute Study No.: 
                                                                                       I 265514
PRIVATE AND CONFIDENTIAL INFORMATION OF ROSWELL PARK CANCER INSTITUTE
02.16.16
Page 8 of 90
INVESTIGATOR STUDY ELIGIBILITY VERIFICATION FORM
Participant Name: ___________________________
Medical Record No.: _____________________________
Title: A Phase I/ II Study of Nintedanib and Capecitabine in Refractory Metastatic 
Colorectal Cancer
INCLUSION CRITERIA
Yes
No
N/A
All answers must be “Yes” or “N/A” for participant enrollment.
Date
1.
Age ≥ 18 years of age.
2.
Have an ECOG Performance Status of 0 – 1. Refer to Appendix B.
3.
Have the following clinical laboratory values:
•
Hemoglobin ≥ 9 g/ dL
•
Absolute neutrophil count ≥ 1500/ mm3
•
Platelet count ≥ 100,000/ mm3
•
Creatinine ≤ 1.5 x ULN AND CrCl > 50 mL/min by Cockcroft 
and Gault equation
o
Males 
= 
(140 
– 
age 
[yrs])(Body 
weight 
[kg])/(72)(serum creatinine [mg/dL])
o
Females = 0.85 * (140 – age [yrs])(Body weight 
[kg])/(72)(serum creatinine [mg/dL]) 
•
Bilirubin < ULN
•
AST / ALT ≤ 1.5 ULN if without liver metastases
•
AST/ ALT ≤ 2.5 x ULN if with liver metastases
•
Coagulation 
parameters: 
International 
normalized 
ratio 
(INR) ≤ 2, prothrombin time (PT) and partial thromboplastin 
time (PTT) < 1.5 X institutional ULN, unless the abnormality is 
related to anticoagulant. 
4.
Have measurable disease per RECIST 1.1 criteria.
5.
Histologically or cytologically proven adenocarcinoma of the colon or 
rectum.
6.
Prior progression following a fluoropyrimidine-based therapy and 
progression following or intolerance to irinotecan and oxaliplatin, as well 
as anti-EGFR therapy (e.g., panitumumab or cetuximab) for RAS wild-
type patients.
APPROVED RPCI Institutional Review Board: 10/17/2016


Roswell Park Cancer Institute Study No.: 
                                                                                       I 265514
PRIVATE AND CONFIDENTIAL INFORMATION OF ROSWELL PARK CANCER INSTITUTE
02.16.16
Page 9 of 90
INCLUSION CRITERIA
Yes
No
N/A
All answers must be “Yes” or “N/A” for participant enrollment.
Date
7.
Ability to swallow and retain oral medication.
8.
Participants of child-bearing potential must agree to use adequate 
contraceptive methods (e.g., hormonal or barrier method of birth control; 
abstinence) prior to study entry and for three months following 
completion of therapy. Should a woman become pregnant or suspect she 
is pregnant while she or her partner is participating in this study, she 
should inform her treating physician immediately.
9.
Participant or legal representative must understand the investigational 
nature of this study and sign an Independent Ethics 
Committee/Institutional Review Board approved written informed 
consent form prior to receiving any study related procedure.
Investigator Signature: ___________________________________
Date: ___________
APPROVED RPCI Institutional Review Board: 10/17/2016


Roswell Park Cancer Institute Study No.: 
                                                                                       I 265514
PRIVATE AND CONFIDENTIAL INFORMATION OF ROSWELL PARK CANCER INSTITUTE
02.16.16
Page 10 of 90
INVESTIGATOR STUDY ELIGIBILITY VERIFICATION FORM
Participant Name: ___________________________
Medical Record No.: _____________________________
Title: A Phase I/ II Study of Nintedanib and Capecitabine in Refractory Metastatic 
Colorectal Cancer
EXCLUSION CRITERIA
Yes
No
N/A
All answers must be “No” or “N/A” for participant enrollment.
Date
1.
Prior treatment with nintedanib.
2.
Prior treatment with regorafenib. 
3.
Major injuries or surgery within the 4 weeks prior to initiation of therapy 
with incomplete wound healing or planned surgery during the on-study 
treatment period.
4.
Uncontrolled hypertension: systolic blood pressure ≥ 160, diastolic blood 
pressure ≥ 90.
5.
Urine Protein/creatinine ratio ≥ 1.0 Refer to Appendix E.
6.
History of clinically significant hemorrhagic or thrombotic event within 
the past 6 months, not including uncomplicated catheter-associated 
venous thrombosis. Patients on anti-coagulation are not permitted to be 
on any oral formulations of anticoagulation (warfarin, rivaroxaban, 
dabigatran, etc.) due to concern for drug-drug interaction.
7.
Unstable angina, symptomatic congestive heart failure or cardiac 
arrhythmia requiring anti-arrhythmic therapy (Beta-blockers, calcium 
channel blockers and digoxin are allowed).
8.
History of cerebrovascular or myocardial ischemia within 6 months of 
initiation
9.
Known inherited predisposition to bleeding or thrombosis
10. Known active or chronic hepatitis B or C, or HIV
11. Untreated brain metastases.
12. History of second primary malignancy diagnosed within 3 years prior to 
enrollment, excluding: 
a.
In-situ cervical carcinoma
b.
Superficial bladder cancer
c.
Non-melanoma skin cancer
d.
Stage I breast cancer
APPROVED RPCI Institutional Review Board: 10/17/2016


Roswell Park Cancer Institute Study No.: 
                                                                                       I 265514
PRIVATE AND CONFIDENTIAL INFORMATION OF ROSWELL PARK CANCER INSTITUTE
02.16.16
Page 11 of 90
EXCLUSION CRITERIA
Yes
No
N/A
All answers must be “No” or “N/A” for participant enrollment.
Date
e.
Low grade (Gleason ≤ 6) localized prostate cancer
f.
Any additional malignancy which has been in clinical 
remission for at least 1 year.
13. Pregnant or nursing female participants.
14. Unwilling or unable to follow protocol requirements.
15. Any condition which in the Investigator’s opinion deems the participant 
an unsuitable candidate to receive study drug.
16. Received an investigational agent within 4 weeks prior to enrollment
17. Phase I: History of intolerance to capecitabine at doses ≤ 1000 mg/m2 
BID, as defined by documented ≥ grade 3 hand-foot syndrome, 
documented severe diarrhea requiring hospitalization, or other 
documented severe AEs attributable to capecitabine 
18. Phase II: History of intolerance to capecitabine at doses below 
1000 mg/m2 BID, as defined by documented ≥ grade 3 hand-foot 
syndrome; documented severe diarrhea requiring hospitalization; or other 
documented severe AEs attributable to capecitabine.
Participant meets all entry criteria:
  Yes
  No
If “NO”, do not enroll participant in study.
Investigator Signature: ___________________________________
Date: __________


Roswell Park Cancer Institute Study No.: 
                                                                                       I 265514
PRIVATE AND CONFIDENTIAL INFORMATION OF ROSWELL PARK CANCER INSTITUTE
02.16.16
Page 12 of 90
TABLE OF CONTENTS
1
Background ............................................................................................................................18
1.1
Colorectal Cancer ...............................................................................................................18
1.2
Angiogenesis.......................................................................................................................18
1.3
Treatment for Metastatic Colorectal Cancer.......................................................................18
1.4
Nintedanib (BIBF1120)......................................................................................................19
1.5
Preclinical Development and Pharmacokinetics of Nintedanib .........................................19
1.6
Clinical Development of Nintedanib..................................................................................21
1.6.1
Phase I.............................................................................................................................22
1.6.2
NSCLC............................................................................................................................22
1.6.3
Ovarian Cancer ...............................................................................................................24
1.6.4
Renal Cell Cancer ...........................................................................................................24
1.6.5
Hepatocellular Cancer.....................................................................................................24
1.6.6
Colorectal Cancer............................................................................................................24
1.7
Correlative Studies..............................................................................................................25
1.8
Risks and/or Benefits..........................................................................................................25
1.8.1
Nintedanib (BIBF1120) ..................................................................................................25
1.8.2
Capecitabine....................................................................................................................26
2
Rationale.................................................................................................................................26
3
Objectives...............................................................................................................................27
3.1
Phase 1................................................................................................................................27
3.1.1
Primary Objective ...........................................................................................................27
3.2
Phase II ...............................................................................................................................28
3.2.1
Primary Objective ...........................................................................................................28
3.2.2
Secondary Objectives......................................................................................................28
3.2.3
Tertiary Objectives..........................................................................................................28
4
Methodology ..........................................................................................................................28
4.1
Study Design.......................................................................................................................28
4.1.1
Phase I.............................................................................................................................29
4.1.2
Phase II............................................................................................................................29
4.1.3
Correlative Studies..........................................................................................................29
4.2
Target Accrual and Study Duration....................................................................................29
5
Participant Selection...............................................................................................................30
5.1
Inclusion Criteria ................................................................................................................30
5.2
Exclusion Criteria ...............................................................................................................31
5.3
Inclusion of Women and Minorities...................................................................................32


Roswell Park Cancer Institute Study No.: 
                                                                                       I 265514
PRIVATE AND CONFIDENTIAL INFORMATION OF ROSWELL PARK CANCER INSTITUTE
02.16.16
Page 13 of 90
6
Treatment Plan .......................................................................................................................32
6.1
Dosing and Administration.................................................................................................32
6.2
Cohort Management ...........................................................................................................32
6.3
Criteria for Retreatment......................................................................................................34
6.4
Definition of Dose-Limiting Toxicity ................................................................................34
6.5
Dose Modifications.............................................................................................................35
6.5.1
Treatment Delay..............................................................................................................35
6.5.2
Dose Reduction...............................................................................................................37
6.5.3
Management of specific AEs ..........................................................................................38
6.5.4
Management of all other AEs: ........................................................................................40
6.6
General Concomitant Medication and Supportive Care.....................................................41
6.6.1
Additional precautions and supportive care....................................................................41
6.6.2
Concomitant medications................................................................................................42
6.7
Duration of Treatment ........................................................................................................43
6.8
Treatment Discontinuation .................................................................................................43
6.9
Compliance.........................................................................................................................43
7
Investigational Product...........................................................................................................43
7.1
Active Substance and Source..............................................................................................43
7.2
Drug Shipment....................................................................................................................44
7.3
Storage and Stability...........................................................................................................44
7.3.1
Nintedanib.......................................................................................................................44
7.4
Handling and Disposal........................................................................................................44
8
Study Procedures....................................................................................................................45
8.1
Participant Registration ......................................................................................................45
8.2
Baseline Evaluations...........................................................................................................45
8.3
Evaluations Performed On Therapy (Day 1 of each cycle, +/- 3 days)..............................45
8.4
Evaluations Performed On Therapy (Day 2 cycle 1)..........................................................46
8.5
Evaluations Performed On Therapy (Day 8 of cycles 1 and 2, phase I only, +/- 3 days) ..46
8.6
Evaluations Performed On Therapy (Day 15 of cycle 1) ...................................................46
8.7
Evaluations Performed at End of Treatment (30 +/- 7 days post last dose of study drug).47
8.8
Medical Record Review .....................................................................................................47
8.9
Schedule of Procedures and Observations..........................................................................47
8.10
Pharmacokinetic Blood Sample Collection and Processing...............................................52
8.11
Biomarker Blood Sample Collection and Processing.........................................................53
9
Efficacy Evaluations...............................................................................................................55
9.1
Objective Tumor Response.................................................................................................55
APPROVED RPCI Institutional Review Board: 10/17/2016


Roswell Park Cancer Institute Study No.: 
                                                                                       I 265514
PRIVATE AND CONFIDENTIAL INFORMATION OF ROSWELL PARK CANCER INSTITUTE
02.16.16
Page 14 of 90
9.2
Target Lesions ....................................................................................................................55
9.3
Non-Target Lesions ............................................................................................................56
9.4
Evaluation of Response ......................................................................................................56
9.5
Confirmation Measurement................................................................................................58
9.6
Guidelines for Evaluation of Measurable Disease..............................................................58
10
Safety Evaluation................................................................................................................60
10.1
Adverse Events ...................................................................................................................60
10.1.1
Definition ........................................................................................................................60
10.1.1.1
Diagnosis Versus Signs and Symptoms ......................................................................60
10.1.1.3
Abnormal Laboratory Values......................................................................................60
10.1.1.4
Preexisting Medical Conditions (Baseline Conditions) ..............................................61
10.2
Adverse Events of Special Interests (AESI).......................................................................61
10.2.1
Grading and Relationship to Drug ..................................................................................62
10.2.2
Reporting Adverse Events ..............................................................................................63
10.3
Serious Adverse Events ......................................................................................................64
10.3.1
Definition ........................................................................................................................64
10.3.2
Reporting Serious Adverse Events .................................................................................64
10.4
Investigator Reporting: Notifying Boehringer Ingelheim (BI) and NCCN........................65
10.5
Follow-Up for Serious Adverse Events..............................................................................65
10.6
Unanticipated Problems......................................................................................................66
10.6.1
Definition ........................................................................................................................66
10.6.2
Reporting Unanticipated Problems .................................................................................66
10.7
FDA Reporting ...................................................................................................................66
11
Data and Safety Monitoring................................................................................................67
12
Statistical Methodology......................................................................................................67
12.1
Sample Size Determination ................................................................................................68
12.2
Demographics and Baseline Characteristics.......................................................................69
12.3
Efficacy Analysis................................................................................................................69
12.4
Safety Analysis ...................................................................................................................70
12.4.1
Adverse Event.................................................................................................................70
12.5
Interim Analysis and Criteria for Early Termination of the Study.....................................70
12.6
Pharmacokinetic or Pharmacokinetic/Pharmacodynamic Analysis ...................................70
13
Ethical and Regulatory Standards.......................................................................................71
13.1
Ethical Principles................................................................................................................71
13.2
Informed Consent ...............................................................................................................72
14
Study Responsibilities ........................................................................................................72
APPROVED RPCI Institutional Review Board: 10/17/2016


Roswell Park Cancer Institute Study No.: 
                                                                                       I 265514
PRIVATE AND CONFIDENTIAL INFORMATION OF ROSWELL PARK CANCER INSTITUTE
02.16.16
Page 15 of 90
14.1
Data Collection ...................................................................................................................72
14.2
Maintenance of Study Documents......................................................................................73
15
Administrative Rules ..........................................................................................................73
15.1
Revisions to the Protocol....................................................................................................73
15.2
Termination of the Study....................................................................................................73
15.3
Confidentiality ....................................................................................................................73
16
Appendices .........................................................................................................................74
17
References...........................................................................................................................87
APPROVED RPCI Institutional Review Board: 10/17/2016


Roswell Park Cancer Institute Study No.: 
                                                                                       I 265514
PRIVATE AND CONFIDENTIAL INFORMATION OF ROSWELL PARK CANCER INSTITUTE
02.16.16
Page 16 of 90
IN-TEXT TABLES
Table 1
Potency [IC50, nM] of Nintedanib in in vitro Kinase Assays.....................................20
Table 2
Available Dose Levels.................................................................................................32
Table 3
Dose Escalation Scheme .............................................................................................33
Table 4
Criteria to Interrupt Nintedanib and capecitabine due to an Adverse Event...............36
Table 5
Criteria to Restart Nintedanib and Capecitabine after Interruption ............................36
Table 6
Criteria for Interruption of Capecitabine Alone..........................................................37
Table 7
Nintedanib Dose Level Reduction Scheme1 ...............................................................37
Table 8
Capecitabine Dose Level Reduction Scheme1 ............................................................38
Table 9
Recommended Dose Adjustments for Nintedanib (BIBF1120) and Capecitabine.....38
Table 10
Management of Additional Adverse Events for Either Drug......................................40
Table 11
Phase I: Schedule of Procedures and Observations.....................................................48
Table 12
Phase II: Schedule of Procedures and Observations ...................................................50
Table 13
Time Point Response Criteria (+/- non-target disease) ...............................................57
Table 14
Time Point Response Criteria (non-target disease only).............................................57
Table 15
Guidelines for Routine Adverse Event Reporting for Phase 1 Studies (Regardless of 
Expectedness) ................................................................................................................................63
Table 16
Guidelines for Routine Adverse Event Reporting Phase 2 Studies (Regardless of 
Expectedness) ................................................................................................................................64
APPROVED RPCI Institutional Review Board: 10/17/2016


Roswell Park Cancer Institute Study No.: 
                                                                                       I 265514
PRIVATE AND CONFIDENTIAL INFORMATION OF ROSWELL PARK CANCER INSTITUTE
02.16.16
Page 17 of 90
APPENDICES
Appendix A
Instructions for Network Sites .............................................................................75
Appendix B
ECOG Performance Status Scores.......................................................................79
Appendix C
Drug-Induced Liver Injury Follow-Up Procedures .............................................80
Appendix D
Study Medication Diary for Nintedanib...............................................................84
Appendix E
Procedure for Obtaining a Urine Protein/ Creatinine Ratio.................................86
APPROVED RPCI Institutional Review Board: 10/17/2016


Roswell Park Cancer Institute Study No.: 
                                                                                       I 265514
PRIVATE AND CONFIDENTIAL INFORMATION OF ROSWELL PARK CANCER INSTITUTE
02.16.16
Page 18 of 90
1
BACKGROUND
1.1
Colorectal Cancer
It is estimated that almost 140,000 new colorectal cancers will be diagnosed in 2014. Despite 
advances in early detection, surgical technique, and adjuvant treatment, colorectal cancer 
remains the 2rd most common cause of cancer-related death in the United States with >50,000 
attributable mortalities annually(1). In the metastatic setting, improvements in systemic therapy 
have improved the median survival of patients from less than six months to nearly 30 months. 
Bevacizumab, a monoclonal antibody targeting VEGF-A, has become routinely integrated into 
treatment regimens in combination with chemotherapy, demonstrating a survival benefit when 
utilized in the first or second line setting (2, 3). More recently, the data from the TML18147 trial 
demonstrated a modest survival benefit of 1.4 months when bevacizumab was continued through 
lines of therapy, specifically when administered with second-line chemotherapy after utilization 
in the first-line setting (4). Interestingly, nearly identical survival advantages (approximately 
1.4 months) emerged with utilization of the VEGF-TRAP (aflibercept) with second-line 
chemotherapy, as well as with the multi-targeted small molecule tyrosine kinase inhibitor (TKI), 
regorafenib, as a single agent in the refractory setting(5, 6). The precise mechanism by which 
regorafenib confers benefit remains unclear, though there is speculation that inhibition of pro-
angiogenic signaling is the major driver. To some, these data have suggested that angiogenic 
blockade should be continued throughout therapy.
1.2
Angiogenesis
Angiogenesis is involved in tumour growth and development of metastases. Vascular Endothelial 
Growth Factor (VEGF) and its high affinity receptor VEGFR-2 are crucial for the formation of 
new tumour vessels. In addition, there is preclinical evidence that fibroblast growth factor (FGF) 
and platelet-derived growth factor (PDGF) and their associated receptor tyrosine kinases 
substantially contribute to tumour angiogenesis. The VEGF - VEGFR-2 axis, besides promoting 
angiogenesis, may also be involved in stimulating growth of tumour cells themselves via an 
autocrine growth factor loop. This is suggested by in vitro data and immunohistochemical 
studies, e.g. for non-small cell lung cancer, ovarian carcinoma, gastric carcinoma, and malignant 
mesothelioma. Therefore, suppression of neoangiogenesis via inhibition of VEGFR-2 is a 
promising strategy for the treatment of human solid cancers. A substantial number of clinical 
trials with various inhibitors of VEGF or VEGFRs in various types of malignant tumors 
demonstrated this approach can convey clinical benefit, in particular in combination therapy with 
standard chemotherapeutic drugs.
1.3
Treatment for Metastatic Colorectal Cancer
Bevacizumab and other VEGF targeting agents have been explored in the refractory colorectal 
cancer setting to a lesser extent than traditional cytotoxic drugs, predominantly in small phase I 
and phase II studies. By traditional response criteria, very limited activity has been noted, though 
a sub-set of patients appear to achieve prolonged stable disease; this may reflect selection bias 
for patients with more indolent disease or perhaps, a group of colorectal cancer patients with 
tumors persistently dependent upon pro-angiogenic signaling. The NCI TRC-0301 study 
APPROVED RPCI Institutional Review Board: 10/17/2016


Roswell Park Cancer Institute Study No.: 
                                                                                       I 265514
PRIVATE AND CONFIDENTIAL INFORMATION OF ROSWELL PARK CANCER INSTITUTE
02.16.16
Page 19 of 90
evaluated 5-FU and bevacizumab in patients who were refractory to irinotecan and oxaliplatin-
based therapies. Independent review demonstrated a response rate of only 1%, with a median 
PFS of 3.5 months and OS of 9 months (7). A slightly smaller study utilizing bevacizumab and 
infusional 5-FU in 48 patients with refractory disease showed nearly identical results: a response 
rate of 6.5%, median PFS of 3.5 months and median OS of 7.7 months (8). A third study which 
evaluated the duo of capecitabine and sunitinib, a small molecule TKI of VEGF, KIT, RET, 
CSF-1R, and FLT3, replicated these results - 47% of patients achieved stable disease, with a 
median PFS of 137 days (~4.6 months) and a median OS of 291 days (9.7 months), though 
increased toxicity, namely fatigue and hand-foot syndrome, was demonstrated(9).
Trials of monotherapy with anti-angiogenic agents have seemingly conferred slightly shorter 
progression free survival advantages. In the refractory setting, aflibercept and sunitinib have 
separately demonstrated a median PFS of 2-2.4 and 2.2-2.5 months with a median OS of 8.5-10.4 
and 7.1 – 10.2 months, respectively (10).These numbers are very similar to that achieved by use of 
regorafenib, comparing favorably refractory trials where best-supportive care has supported a 
progression-free survival of less than 2 months and an overall survival of just 4.5-5 months(6, 11). 
The lack of improvement by metrics such as objective response has resulted in a general 
reluctance to pursue randomized trials to more definitively evaluate the benefit of continued anti-
angiogenic therapies in the refractory setting. While regorafenib has recently been approved in 
the chemotherapy refractory setting, the perception of marked toxicity and provision of modest 
clinical benefit has significantly dampened the initial enthusiasm. Additional regimens which 
provide clinical benefit with improved tolerability are desperately needed. 
1.4
Nintedanib (BIBF1120)
Nintedanib (BIBF 1120) is a small molecule TKI of VEGFR 1/2/3 (IC50 34/21/13 nM), FGFR 
1/2/3 (IC50 69/37/109 nM), and PDGFR A/B (IC50 59/65 nM), with additional activity against 
Flt-3, RET, Src, Lck, and Lyn. In preclinical colorectal cancer models, anti-tumor efficacy has 
been demonstrated, with a marked reduction in tumor vessel density. Maximum plasma 
concentrations occur 2-4 hours following administration with a terminal half-life of 7-19 hours. 
Based upon phase I data, the recommended phase II dose is 200 mg orally twice daily, as a single 
agent as well as in combination with chemotherapy. When administered as monotherapy, the 
most common side effects are nausea, diarrhea, vomiting, abdominal pain and fatigue. Liver 
enzyme increases were the most common DLT in early phase trials and a common AE in later 
stage studies, though predominantly seen at higher doses (> 200 mg bid) and largely reversible 
with cessation of therapy.
1.5
Preclinical Development and Pharmacokinetics of Nintedanib
Nintedanib (BIBF 1120) is an oral small molecule triple receptor tyrosine kinase inhibitor that 
potently blocks VEGFR 1-3 (vascular endothelial growth factor-receptor), FGFR 1 and 3 
(fibroblast growth factor/receptor), as well as PDGFR α/β (platelet derived growth factor 
receptor) in low nanomolar concentrations (Table 1). These receptors are expressed on 
perivascular cells, such as pericytes and smooth muscle cells, that are also involved in tumour 
angiogenesis and therefore their inhibition may contribute to the overall efficacy of nintedanib. 
In addition, Nintedanib also inhibits the kinase activity of Flt-3, one of the most frequently 
APPROVED RPCI Institutional Review Board: 10/17/2016


Roswell Park Cancer Institute Study No.: 
                                                                                       I 265514
PRIVATE AND CONFIDENTIAL INFORMATION OF ROSWELL PARK CANCER INSTITUTE
02.16.16
Page 20 of 90
mutated genes in acute myeloid leukemia (AML) and Ret. More than 20 other kinases were also 
analyzed and showed no inhibition by the compound (e.g. insulin receptor, HER2, and several 
cyclin dependent kinases) with the exception of the three members of the Src family of tyrosine 
kinases: Src, Lck, and Lyn (Table 1). Src is one of the most intensively studied oncogenes and is 
functionally involved in the control of a variety of cellular processes such as proliferation, 
differentiation, motility, and adhesion. c-Src has been shown to be involved in the development 
and progression of human tumors (12). Lck is functionally required for T-cell activation through 
the T-cell antigen receptor (TCR) (13) and possibly T-cell survival (14). Lyn is involved in B-cell 
antigen receptor (BCR) signalling both positively and negatively, i.e. in the initiation of the BCR 
signal and in B cell proliferation.
Table 1
Potency [IC50, nM] of Nintedanib in in vitro Kinase Assays
Kinase
IC50 (nmol/L)
huVEGFR-1
34
huVEGFR-2
21
muVEGFR-2
13
PDGFRα
59
PDGFRβ)
65
FGFR 1
69
FGFR2
37
FGFR3
108
Flt-3
26
RET
35
Src
156
Lck
16
Lyn
195
Nintedanib inhibits the signalling cascade mediating angiogenesis by binding to the adenosine 
triphosphate (ATP) binding pocket of the receptor kinase domain, thus interfering with cross-
activation via auto-phosphorylation of the receptor homodimers.
The specific and simultaneous abrogation of these pathways results in effective growth inhibition 
of both endothelial and, via PDGF- and FGF-receptors of perivascular cells which may be more 
effective than inhibition of endothelial cell growth via the VEGF pathway alone. Furthermore, 
signalling by FGF-receptors has been identified as a possible escape mechanism for tumour 
angiogenesis when the VEGF pathway is disrupted.
Besides inhibition of neo-angiogenesis, it may alter tumour maintenance by inducing apoptosis 
of tumour blood vessel endothelial cells. Inhibition of receptor kinases may also interfere with 
autocrine and paracrine stimulation of tumour angiogenesis via activation loops involving 
VEGF, PDGF, and bFGF (basic fibroblast growth factor) utilized by vascular and perivascular 
cells such as pericytes and vascular smooth muscle cells.
APPROVED RPCI Institutional Review Board: 10/17/2016


Roswell Park Cancer Institute Study No.: 
                                                                                       I 265514
PRIVATE AND CONFIDENTIAL INFORMATION OF ROSWELL PARK CANCER INSTITUTE
02.16.16
Page 21 of 90
In addition preclinical models show that nintedanib (BIBF1120) may have a direct anti-tumour 
effect on those malignant cells which overexpress PDGFR and/or FGFR (e.g. H1703 NSCLC 
cells).
In vitro, the target receptors are all inhibited by nintedanib in low nanomolar concentrations. In 
in vivo nude mouse models, nintedanib showed good anti-tumour efficacy at doses of 50 – 100 
mg/kg, leading to a substantial delay of tumour growth or even complete tumour-stasis in 
xenografts of a broad range of differing human tumour types. Histological examination of treated 
tumors showed a marked reduction of tumour vessel density by approximately 80% (15).
The metabolism of nintedanib (BIBF1120) was predominantly characterized by the ester 
cleavage of the methyl ester moiety yielding BIBF 1202, which was further metabolized by 
conjugation to glucuronic acid yielding the 1-O-acylglucuronide.  Data collected in this study 
show that nintedanib (BIBF1120) has a favorable PK and excretion profile with almost no 
elimination via the urine, only 0.7% of total [14C] radioactivity was eliminated via the urine. The 
metabolic characteristics are predominantly independent of cytochrome P450-catalysed 
metabolic pathways (16).
A soft gelatin capsule formulation of nintedanib is used in man. After oral administration, 
nintedanib is absorbed quickly. Maximum plasma concentrations (Cmax) generally occur 2 to 4 
hours after administration. So far, no evidence for a deviation from dose proportionality of the 
PK of nintedanib has been observed. Steady state is reached latest after one week of dosing. The 
terminal half-life of nintedanib is in the range of 7 to 19 hr. Nintedanib is mainly eliminated via 
faeces (16).
Nintedanib (BIBF1120) is non-mutagenic, even at high doses.
Two exploratory studies in rats revealed a teratogenic effect of nintedanib (BIBF1120) with a 
steep dose/effect relationship and an early onset of embryofetal deaths at low dosages. This 
effect was observed at dose levels resulting in plasma drug concentrations comparable to or 
below those in humans. Because the concentration of nintedanib (BIBF1120) in semen is 
unknown, males receiving nintedanib (BIBF1120) and having sexual intercourse with females of 
childbearing potential should use latex condoms. Women of childbearing potential should be 
advised to use adequate contraception during and at least 3 months after the last dose of 
nintedanib.
A detailed discussion of the preclinical pharmacology, pharmacokinetics, and toxicology of 
nintedanib (BIBF1102) can be found in the Investigator’s Brochure.
1.6
Clinical Development of Nintedanib
Nintedanib is being evaluated in several cancers. Additionally, nintedanib has been FDA 
approved for the non-cancer indication idiopathic pulmonary fibrosis (IPF). As of 15 Feb 2013, 
3556 cancer patients, over 1000 patients with IPF, and 140 healthy volunteers had been treated 
with nintedanib or nintedanib matching placebo, in monotherapy or in combination with 
chemotherapy.
APPROVED RPCI Institutional Review Board: 10/17/2016


Roswell Park Cancer Institute Study No.: 
                                                                                       I 265514
PRIVATE AND CONFIDENTIAL INFORMATION OF ROSWELL PARK CANCER INSTITUTE
02.16.16
Page 22 of 90
1.6.1
Phase I
Phase I dose selection studies revealed that nintedanib (BIBF1120) is generally well tolerated 
with mild to moderate adverse effects such as gastrointestinal symptoms (nausea, diarrhoea, 
vomiting, abdominal pain) and reversible elevations of liver enzymes. Initial signs of clinical 
activity including an encouraging rate of patients with stabilization of their tumour of 54% and 
68%, respectively; have been observed in patients with various solid tumors (17).
Based on the Phase I dose escalation trials with nintedanib (BIBF1120) monotherapy, the 
maximum tolerated dose was defined to be 250 mg for twice daily dosing in Caucasians and 
200 mg twice daily in Japanese patients with a manageable safety profile in advanced cancer 
patients. Based on the overall safety profile, the RP2D for nintedanib as monotherapy is 200 mg 
bid.
The maximum tolerated dose for combination therapy of nintedanib (BIBF1120) in combination 
with pemetrexed, docetaxel, paclitaxel/carboplatin and FOLFOX is 200 mg bid. Combination of 
nintedanib (BIBF1120) with other anti-cancer drugs revealed a similar adverse event profile as 
compared to nintedanib (BIBF1120) monotherapy except for the chemotherapy related toxicities. 
There was no change of the pharmacokinetic parameters of nintedanib (BIBF1120) or of the 
cytotoxic compounds due to the combined treatment. Dose limiting toxicity consisted mostly of 
liver transaminase elevations as in the monotherapy phase I trials with the exception of the 
combination of nintedanib (BIBF1120) with pemetrexed, where fatigue was the most relevant 
dose limiting toxicity.
Available pharmacokinetic data indicate that the systemic exposure needed for biological activity 
can be achieved starting with doses of 100 mg nintedanib (BIBF1120) once daily.
The predominant adverse events were nausea, diarrhoea, vomiting, abdominal pain and fatigue 
of mostly low to moderate severity. Dose limiting toxicities (DLT) were mainly confined to 
reversible hepatic enzyme elevations (AST, ALT, GGT) which increased dose-dependently. 
Most cases occurring at doses of 250 mg and above, and a very low incidence at doses below 
200 mg and were reversible after discontinuation of nintedanib treatment. All adverse events 
observed after single administration of single doses of nintedanib to healthy volunteers were only 
of CTCAE grade 1 severity and fully reversible (16).
1.6.2
NSCLC
In a phase II trial in NSCLC patients the safety profile of nintedanib (BIBF1120) observed in 
phase I trials could be confirmed. Most commonly reported drug-related AEs were nausea 
(57.5%), diarrhoea (47.9%), vomiting (42.5%), anorexia (28.8%), abdominal pain (13.7%) and 
reversible alanine transaminase (13.7%) and aspartate aminotransferase elevations (9.6%) In 
conclusion it was generally well tolerated and displayed single agent activity in advanced or 
recurrent NSCLC patients. Median overall survival (OS) was 21.9 weeks. Eastern Cooperative 
Oncology Group (ECOG) 0–1 patients (n = 56) had a median PFS of 11.6 weeks and a median 
OS of 37.7 weeks. Tumour stabilization was achieved in 46% of patients (ECOG 0–1 patients: 
59%), with one confirmed partial response (250 mg bid.)(18).
APPROVED RPCI Institutional Review Board: 10/17/2016


Roswell Park Cancer Institute Study No.: 
                                                                                       I 265514
PRIVATE AND CONFIDENTIAL INFORMATION OF ROSWELL PARK CANCER INSTITUTE
02.16.16
Page 23 of 90
LUME-Lung 1 was an international, randomized, double-blind, phase III trial assessing the 
efficacy and safety of docetaxel plus nintedanib as second line therapy for non-small-cell lung 
cancer (NSCLC).  In total, 1314 patients with Stage IIIB/IV or recurrent NSCLC (all histologies) 
who had progressed after 1st line chemotherapy were randomized in 1:1 fashion to either receive 
Nintedanib 200 mg BID + Docetaxel (n=655) or Placebo BID + Docetaxel (n=659). 
LUME-Lung 1 met its primary endpoint by showing a statistically significant improvement of 
PFS for all patients regardless of histology (median PFS 3.4 versus 2.7 months; HR 0.79, 
p=0.0019) for Nintedanib in combination with docetaxel.
A significant improvement in OS was demonstrated in patients with adenocarcinoma (HR 0.83, 
p=0.0359, median 10.3 to 12.6 months).
Patients with a poor prognosis defined as time since start of 1st line therapy <9 months also 
experienced significant OS improvement from the addition of nintedanib to docetaxel (HR 0.75, 
p=0.0073, median OS 7.9 to 10.9 months).
The predominant adverse events were nausea, diarrhoea, vomiting, abdominal pain and fatigue 
of mostly low to moderate intensity after monotherapy with nintedanib (BIBF1120). Dose 
limiting toxicities were dose dependent hepatic enzyme elevations that were reversible after 
discontinuation of nintedanib (BIBF1120) treatment. These liver enzyme elevations were only in 
few cases accompanied by a simultaneous increase of bilirubin. In general common terminology 
criteria for adverse events (CTCAE version 3, grade three liver enzyme increases were reported 
in the dose groups of 250 mg twice daily or higher. They also were reversible and usually 
occurred within the first two months of treatment. 
Hypertension or thromboembolic events were rare and did not suggest an increased frequency as 
a consequence of therapy with nintedanib (BIBF1120) (19).
LUME-Lung 2 was a similar randomized, double-blind, phase III study of nintedanib plus 
pemetrexed versus placebo plus pemetrexed in patients with advanced non-squamous non-small 
cell lung cancer after failure of first line chemotherapy.
Based on a preplanned futility analysis of investigator-assessed PFS, enrolment was halted after 
713/1300 planned patients had been enrolled. The analysis (based on conditional power for PFS 
by investigator assessment) suggested that the study was futile and that the primary endpoint of 
centrally assessed PFS would likely not be met. The futility analysis was based on conditional 
power; there was no formal testing of null hypothesis as planned for primary analysis no safety 
issues were identified.
Even though the study was stopped prematurely, the primary endpoint of this Phase III trial was 
met; treatment with nintedanib plus pemetrexed resulted in a significant prolongation of centrally 
reviewed PFS compared with placebo plus pemetrexed (median PFS 4.4 vs. 3.6 months with a 
HR 0.83; p=0.0435). The disease control rate was also increased significantly in nintedanib-
treated patients. There was no improvement in OS in nintedanib-treated patients. Nintedanib 200 
mg bid in combination with pemetrexed had an acceptable and manageable safety profile, with 
no new or unexpected safety findings. The most frequent AEs were reversible increases in liver 
enzymes and gastrointestinal events (20).
APPROVED RPCI Institutional Review Board: 10/17/2016


Roswell Park Cancer Institute Study No.: 
                                                                                       I 265514
PRIVATE AND CONFIDENTIAL INFORMATION OF ROSWELL PARK CANCER INSTITUTE
02.16.16
Page 24 of 90
1.6.3
Ovarian Cancer
A randomized phase II maintenance trial in ovarian cancer in which the efficacy and safety of 
nine months of continuous twice daily doses of nintedanib (BIBF1120) following chemotherapy 
was investigated, has identified the potential activity of nintedanib (BIBF1120) with a 36-week 
PFS of 16.3 % compared to 5.0 % in the control group. The safety profile was consistent with 
findings previously reported for nintedanib (BIBF1120) administered as monotherapy as 
mentioned above (21).
Nintedanib was evaluated in a Phase III randomized, placebocontrolled, doubleblind, 
multicentre ovarian study with 1366 patients.  Patients received nintedanib plus paclitaxel and 
carboplatin or placebo plus paclitaxel and carboplatin for six cycles. This was followed by 
monotherapy nintedanib or placebo for up to 120 weeks. The trial met its primary endpoint by 
demonstrating a statistically significant improvement in progression-free survival (HR 0.84; 
95%CI 0.72 - 0.98; p=0.0239, median PFS 17.3 months for nintedanib and 16.6 months for 
placebo). Overall survival data are immature but currently show no trend in either direction. 
Main adverse events were GI side effects and increased hematological toxicity (22).
1.6.4
Renal Cell Cancer
Nintedanib has been studied in a randomized phase II study in metastatic clear cell RCC with 
sunitinib as the control arm.  Similar efficacy was seen in both arms of this study. AEs observed 
more frequent in the nintedanib arm included diarrheal, nausea, fatigue and infection, whereas 
AEs more frequent in the sunitinib arm consisted of bleeding, anaemia, hypertension, hand-foot 
syndrome and stomatitis (23).
1.6.5
Hepatocellular Cancer
The efficacy and safety of nintedanib versus sorafenib in Asian Patients with Advanced 
Hepatocellular Carcinoma was investigated in a randomized phase II trial. Nintedanib showed 
similar efficacy to sorafenib, with a favorable and manageable AE profile. More patients in the 
sorafenib arm had severe AEs and drug-related AEs compared with patients in the nintedanib 
arm, and more patients in the sorafenib arm required dose reduction compared with the 
nintedanib arm. Nintedanib AEs were manageable; in the nintedanib arm there were fewer 
hypertension, palmar-plantar erythrodysesthesia syndrome, and transaminase elevation events 
(24).
1.6.6
Colorectal Cancer
A Phase I/II, open-label, randomized study of nintedanib plus mFOLFOX6 compared to 
bevacizumab plus mFOLFOX6 in 120 patients with metastatic colorectal cancer was performed, 
demonstrating an acceptable safety profile of nintedanib, 200 mg po bid, in combination with 
mFOLFOX6. In comparison to bevacizumab, nintedanib showed a similar magnitude of efficacy, 
a similar safety/tolerability profile, a similar exposure and dose intensity of mFOLFOX6 (25). 
This is in contrast to multiple prior trials of small molecule inhibitors of VEGFR-2 with 
demonstrated increased toxicity and, as a result, decreased efficacy (26).
APPROVED RPCI Institutional Review Board: 10/17/2016


Roswell Park Cancer Institute Study No.: 
                                                                                       I 265514
PRIVATE AND CONFIDENTIAL INFORMATION OF ROSWELL PARK CANCER INSTITUTE
02.16.16
Page 25 of 90
A Phase III study is going to start in late 2014 to evaluate the efficacy of nintedanib as compared 
to placebo in patients with metastatic colorectal cancer (mCRC) after failure of previous 
treatment with standard chemotherapy and biological agents (ClinicalTrials.gov Identifier: 
NCT02149108). Data from this phase III study of single agent nintedanib in the refractory 
setting will be instructive as to the single agent activity of nintedanib in refractory colorectal 
cancer.
For more details please refer to the investigator drug brochure for nintedanib (BIBF1120).
1.7
Correlative Studies
Rationale/justification: A significant challenge in the development and clinical use of VEGF 
pathway inhibitors is the lack of reliable biomarkers that can predict for biological activity, 
patient response and benefit, and toxicity(27). However, results from several prospective and 
retrospective trials analyzing patient blood following the treatment of VEGF RTKIs suggest that 
consistent changes in the levels of circulating proteins following treatment may be tailored to a 
particular drug, and have the potential as a surrogate biomarker in guiding both dosing and 
patient outcome(28-30). This study will evaluate several circulating angiogenic factors (CAFs) in 
patient plasma using ELISA methods. CAFs will include VEGF, sVEGFR 1/2, PlGF, GMCSF, 
Leptin, IL-1a, IL-8, IL-6, FGFb, Osteopontin, Pentraxin-3, which have been chosen because of 
previous studies demonstrating i) plasma changes which may correlate to patient response, ii) the 
potential involvement in resistance or compensatory pathways following VEGF pathway 
inhibition, and iii) the potential for disruption based on FGF pathway inhibition (including with 
Nintedanib) (31-34).
1.8
Risks and/or Benefits
1.8.1
Nintedanib (BIBF1120)
The risks of therapy with nintedanib (BIBF1120) in adult patients are primarily related to:
•
the gastro-intestinal tract (nausea, vomiting, diarrhoea, abdominal pain)
•
increases in liver enzymes (AST, ALT, GGT)
•
fatigue, asthenia and anorexia
Liver enzymes must be followed closely during treatment with nintedanib (BIBF1120).
Therapy with the trial drugs must be interrupted in the event of relevant hepatic toxicity and 
further treatment is to be withheld until recovery of the abnormal laboratory parameters.
Impairment of immune and of kidney function, thromboembolic events and GI perforations are 
considered possible side effects of treatment with nintedanib (BIBF1120) as they have been 
reported for some other drugs in the class of angiogenesis inhibitors. Thus far these side effects 
have been observed in the trials conducted with nintedanib (BIBF1120), but not to a relevant 
degree. Hypertension is also supposed to be a possible side effect of VEGFR inhibitors and a 
slightly increased frequency of hypertension has been observed in the trials with nintedanib 
(BIBF1120) to a mild to moderate degree and only few cases of CTCAE grade 3 or 4 
APPROVED RPCI Institutional Review Board: 10/17/2016


Roswell Park Cancer Institute Study No.: 
                                                                                       I 265514
PRIVATE AND CONFIDENTIAL INFORMATION OF ROSWELL PARK CANCER INSTITUTE
02.16.16
Page 26 of 90
hypertension have been observed. With respect to bleeding as one of the potentially serious side 
effects of antiangiogenesis agents in the LUME –Lung 1 trial involving 1314 patients more 
bleeding events were reported for nintedanib-treated squamous cell carcinoma (SCC) patients 
(all grades: 17.1% vs. 10.9%; grade ≥3: 2.9% vs. 1.3%) than for those with adenocarcinoma (all 
grades: 10.9% vs. 11.1%; grade ≥3: 1.5% vs. 1.3%). Fatal bleeding events, serious skin 
reactions, thrombosis, and perforations occurred at a low frequency and were balanced between 
both arms regardless of histology.
Based upon a non-clinical safety study in vitro, nintedanib (BIBF1120) may have a potential risk 
of phototoxicity (skin and eyes) in vivo. Few cases of photosensitivity reactions (less than 1 %) 
and of CTCAE grade 1 intensity only have been reported from the clinical studies to date. If 
adequate precautions are taken (avoidance of prolonged ultraviolet (UV) exposure, use of broad 
spectrum sunscreen and sunglasses), treatment with nintedanib (BIBF1120) is considered safe.
1.8.2
Capecitabine
Common side effects associated with the use of capecitabine include:
•
diarrhea, stomatitis, hand foot syndrome, fatigue, lymphopenia, neutropenia, anemia, 
thrombocytopenia, alopecia, erythema, and rash
•
hepatic insufficiency with hyperbilirubinemia has been observed
•
dizziness, headaches, fatigue, anorexia, conjunctivitis, and epistaxis have also been 
observed
•
Cardiovascular side effects have included myocardial infarction/ischemia, angina, 
dysrhythmias, cardiac arrest, cardiac failure, sudden death, electrocardiographic changes, 
and cardiomyopathy.
The major clinical side effects observed after therapy with capecitabine are distinct from  
nintedanib (BIBF1120) induced adverse events, yet some overlap may occur e.g. gastrointestinal 
toxicity or hepatotoxicity (please refer to the labels included in the investigator site file for listed 
adverse events of capecitabine). In view of the low potential for drug-drug interactions of 
nintedanib (BIBF1120), it is not likely that enhanced toxicity due to pharmacokinetic interaction 
between the drug and the cytotoxic chemotherapy will occur. However, due to the partially 
overlapping toxicity profile, the occurrence of nausea, vomiting and diarrhoea may be increased.
2
RATIONALE
Fluoropyrimidines, such as 5-FU and capecitabine, remain among the most active 
chemotherapeutics in colorectal cancer and are administered across lines of therapy, as is the 
case with anti-angiogenics, such as bevacizumab. In colorectal cancer, as in other malignancies, 
anti-angiogenic therapy is most commonly administered with chemotherapy due to additive 
benefit. As described previously, there is data to suggest activity, as measured by maintenance of 
stable disease, when 5-fu or capecitabine is combined with anti-angiogenic therapy, even after 
progression on prior fluoropyrimidine containing regimens. Further, on the whole, the PFS and 
OS results from trials in the refractory setting which combine the two therapeutic classes appear 
APPROVED RPCI Institutional Review Board: 10/17/2016


Roswell Park Cancer Institute Study No.: 
                                                                                       I 265514
PRIVATE AND CONFIDENTIAL INFORMATION OF ROSWELL PARK CANCER INSTITUTE
02.16.16
Page 27 of 90
superior to the results from administration of anti-angiogenic therapy alone. Though caution 
must be exercised in such cross-trial comparisons, as differences in the populations studied have 
great potential for bias, one might hypothesize that combining capecitabine with nintedanib has 
potential to offer greater benefit than nintedanib alone, in multiple settings.
Capecitabine is most frequently administered in a three week cycle, as a single agent or in 
combination with other chemotherapeutics. It is dosed twice daily for two weeks, followed by a 
1 week rest. In the treatment of colorectal cancer, capecitabine has demonstrated equivalent 
activity to 5-FU in both the adjuvant and metastatic settings (35, 36). When capecitabine and 
infusional 5-FU are combined with additional agents, capecitabine demonstrates a comparatively 
greater incidence of hand-foot syndrome as well as slightly higher incidence of diarrhea, but 
lesser rates of stomatitis and cytopenia (37). In a US population, the approved dose of 1250 mg/m2 
BID is regarded as causing excess toxicity and 1000 mg/m2 is most commonly employed. In this 
study, we plan to combine nintedanib with capecitabine at the standard 1000 mg/m2 dose. 
Nintedanib will be administered at a dose 25% below the recommended Phase II dose due to 
concern for overlapping toxicity, namely diarrhea. This would represent a novel combinatorial 
oral chemotherapeutic regimen.
The primary objective will be to assess anti-tumor activity of nintedanib and capecitabine when 
given in combination. Secondary objectives will include assessment of the toxicity of the agents 
in combination, identification of biomarkers predictive of benefit, along with a development of a 
novel PK/PD biomarker driven approach to elucidate the optimal dosing regimen of nintedanib 
and capecitabine.
The combination of nintedanib and capecitabine would be relevant for treatment in the refractory 
setting and potentially in future investigations as maintenance therapy after initial bevacizumab-
based chemotherapy. All patients in this study are expected to have received prior anti-
angiogenic therapy with progression or intolerance. To date, there is no data on the efficacy of 
nintedanib in patients who have progressed on prior anti-angiogenic therapies. A placebo 
controlled study of nintedanib in the refractory setting is being conducted, as described 
(ClinicalTrials.gov Identifier: NCT02149108). If the placebo controlled study demonstrates a 
clinical benefit, this current combination may be able to build upon those findings, if this 
combination demonstrates tolerability. Should the placebo controlled study fail to demonstrate 
benefit, this regimen may yet create an avenue for further investigation via potentiation of 
nintedanib monotherapy, as previously suggested.
3
OBJECTIVES
3.1
Phase 1
3.1.1
Primary Objective
•
To estimate the maximum tolerated dose (MTD) and examine the dose-limiting toxicities of 
nintedanib when administered with capecitabine within the study population and, establish 
the Recommended Phase II Dose (RP2D).
APPROVED RPCI Institutional Review Board: 10/17/2016


Roswell Park Cancer Institute Study No.: 
                                                                                       I 265514
PRIVATE AND CONFIDENTIAL INFORMATION OF ROSWELL PARK CANCER INSTITUTE
02.16.16
Page 28 of 90
3.2
Phase II
3.2.1
Primary Objective
•
To assess progression free survival at 18 weeks. This will be assessed via the Response 
Evaluation Criteria in Solid Tumors (RECIST) version 1.1 guidelines after every 3 cycles 
(9 weeks) of therapy.
3.2.2
Secondary Objectives
•
To assess median progression free survival. This will be assessed via the Response 
Evaluation Criteria in Solid Tumors (RECIST) version 1.1 guidelines after every 3 cycles 
(9 weeks) of therapy].
•
To assess median overall survival from the date of enrollment to the time of death will be 
documented.
•
To assess the objective response rate as measured by RECIST v 1.1.
•
To assess the toxicity of dose regimen using the CTEP NCI Common Terminology Criteria 
for Adverse Events (CTCAE Version 4.0).
3.3
Tertiary Objectives of phase 1 and 2
•
Measurement of circulating angiogenic cytokines (CAFs): VEGF, sVEGFR 1/2, PlGF, 
GMCSF, Leptin, IL-1a, IL-8, IL-6, FGFb, Osteopontin and Pentraxin-3.
•
Measurement of drug levels and PK/PD modeling
4
METHODOLOGY
4.1
Study Design
This is an open-label, non-randomized, multicenter, Phase I/II study of nintedanib and 
capecitabine in patients with metastatic colorectal cancer refractory to irinotecan and oxaliplatin 
based therapy. The study will include a Phase I dose-finding portion, followed by a non-
randomized Phase II component. Nintedanib and capecitabine are both oral formulations, to be 
taken twice daily as prescribed in the present study. Nintedanib will be administered at a fixed 
dose as dictated in the protocol. The total daily dose of capecitabine will be calculated based 
upon actual body weight and split into two comparable portions, and doses of both drugs are to 
be self-administered approximately 12 hours apart (+/- 2 hours), within 30 minutes of a meal. 
For the purposes of this study, a cycle will be defined as 3 weeks (i.e., 21 days). Nintedanib is to 
be self-administered twice daily for 21 days (i.e., 1 complete cycle), while capecitabine will be 
dosed cyclically, in a 2 weeks on / 1 week off fashion. Disease assessment will occur after every 
three cycles of therapy (9 weeks). For the Phase I study, patients will be evaluated for toxicity on 
days 1 and 8 of the first two cycles. Otherwise, all patients will be evaluated on day one of each 
cycle of therapy. Treatment will continue until disease progression, in the absence of undue 
toxicity.
APPROVED RPCI Institutional Review Board: 10/17/2016


Roswell Park Cancer Institute Study No.: 
                                                                                       I 265514
PRIVATE AND CONFIDENTIAL INFORMATION OF ROSWELL PARK CANCER INSTITUTE
02.16.16
Page 29 of 90
4.1.1
Phase I
A small initial Phase I lead-in will be conducted, utilizing a 3+3 design to determine the 
recommended phase II dose (RP2D). The Phase 1 portion provides limited toxicity information 
about the combination therapy in refractory metastatic colorectal cancer patients. The maximum 
tolerated (or administered) dose level from the Phase 1 will be utilized as the recommended 
Phase 2 dose. Two dose levels are planned, with dose level 2 expected to be the RP2D. Full 
details including the initial dosing strategies and dose escalation schema are present in Section 6.
4.1.2
Phase II
The RP2D from the Phase I study has been determined to be dose level 2. There is no formal 
interim analysis planned or early stopping rules. However, toxicity and safety outcomes will be 
regularly reviewed.
4.1.3
Correlative Studies
For both the Phase I and Phase II study, correlative blood will be drawn at baseline, cycle 1 day 
15, and cycle 3 day 1 for analysis of a panel of cytokines and growth factors (see below), to be 
correlated to PK data, for a select biomarker panel and outcomes. This will be performed only on 
the 1st 32 patients enrolled in the study only. Following administration of both nintedanib 
(BIBF1120) and capecitabine, PK samples for nintedanib will be collected on Day 1, Cycle 1 at 
pre-dose, and at 0.5-1 hr, 2-4 hr, 5-6 hr, and 6-8 hr post dose and Day 2 (trough level). In 
addition, PK samples will be collected on Day 15 at predose, 2-4 hr post-dose, and 5-6 hr post-
dose (Section 8.10). Circulating angiogenic cytokines (CAFs) will additionally be analyzed via 
blood collection on Day 1, Cycle 1 at pre-dose and 2-4 hr post-dose, on Day 15 2-4 hr post-dose 
and on Day 1, Cycle 3, 2-4 hr post-dose. Details of collection and timing are summarized in 
Section 8.11.
All participants will sign an informed consent prior to study related tests. All participants will 
meet the inclusion and exclusion criteria summarized in Section 5.1 and Section 5.2. Participants 
will be treated on an outpatient basis.
4.2
Target Accrual and Study Duration
It is expected that a total of 9 patients will be enrolled at two dose levels in the Phase I portion, 
with potential for a maximum of 18 patients. The number of participants required is a function of 
the unknown dose-toxicity relationship. Patients treated at the RP2D (n=6) will be included in 
the Phase II study analysis. Up to an additional 30 patients will be enrolled in the Phase II 
portion of the study, for a Phase II sample size of 36. Summarily, the study is expected to accrue 
39 patients (9 + 36 - 6). However, if toxicity is greater than expected, a maximum of 48 patients 
might be required (18 + 36 - 6). Enrollment is expected to be split between the two sites 
involved: Roswell Park Cancer Institute and City of Hope. Thus, in the case of 39 patients being 
enrolled, it is anticipated that approximately 20 patients would be enrolled at RPCI and 19 at 
City of Hope. Accrual is expected to take up to 2 years. Median PFS has historically stood at 
approximately 2 months and this study aims to provide a PFS rate at 18 weeks (~4 months) of 
40%. It is anticipated that patients will be on study for approximately 18 weeks.
APPROVED RPCI Institutional Review Board: 10/17/2016


Roswell Park Cancer Institute Study No.: 
                                                                                       I 265514
PRIVATE AND CONFIDENTIAL INFORMATION OF ROSWELL PARK CANCER INSTITUTE
02.16.16
Page 30 of 90
5
PARTICIPANT SELECTION
5.1
Inclusion Criteria
To be included in this study, participants must meet the following criteria:
1. Age ≥ 18 years of age.
2. Have an ECOG Performance Status of 0 – 1. Refer to Appendix B.
3. Have the following clinical laboratory values:
•
Hemoglobin ≥ 9 g/ dL
•
Absolute neutrophil count ≥ 1500/ mm3
•
Platelet count ≥ 100,000/ mm3
•
Creatinine ≤ 1.5 ULN AND CrCl > 50 mL/min by Cockcroft-Gault equation:
o
Males = (140 – age [yrs])(Body weight [kg])/(72)(serum creatinine [mg/dL])
o
Females = 0.85 * (140 – age [yrs])(Body weight [kg])/(72)(serum creatinine 
[mg/dL]) 
•
Bilirubin < ULN
•
AST / ALT ≤ 1.5 ULN if without liver metastases
•
AST/ ALT ≤ 2.5 x ULN if with liver metastases
•
Coagulation parameters: International normalized ratio (INR) ≤ 2, prothrombin time 
(PT) and partial thromboplastin time (PTT) < 1.5 X institutional ULN
4. Have measurable disease per RECIST 1.1 criteria.
5. Histologically or cytologically proven adenocarcinoma of the colon or rectum.
6. Prior progression following a fluoropyrimidine-based therapy and progression following 
or intolerance to irinotecan and oxaliplatin, as well as anti-EGFR therapy (e.g., 
panitumumab or cetuximab) for RAS wild-type patients.
7. Ability to swallow and retain oral medication.
8. Participants of child-bearing potential must agree to use adequate contraceptive methods 
(e.g., hormonal or barrier method of birth control; abstinence) prior to study entry and for 
three months following completion of therapy. Should a woman become pregnant or 
suspect she is pregnant while she or her partner is participating in this study, she should 
inform her treating physician immediately.
9. Participant or legal representative must understand the investigational nature of this study 
and sign an Independent Ethics Committee/Institutional Review Board approved written 
informed consent form prior to receiving any study related procedure.


Roswell Park Cancer Institute Study No.: 
                                                                                       I 265514
PRIVATE AND CONFIDENTIAL INFORMATION OF ROSWELL PARK CANCER INSTITUTE
02.16.16
Page 31 of 90
5.2
Exclusion Criteria
Participants will be excluded from this study for the following:
1. Prior treatment with nintedanib.
2. Prior treatment with regorafenib.
3. Major injuries or surgery within the 4 weeks prior to initiation of therapy with incomplete 
wound healing or planned surgery during the on-study treatment period.
4. Uncontrolled hypertension: systolic blood pressure ≥ 160, diastolic blood pressure ≥ 90.
5. Urine Protein/creatinine ratio ≥ 1.0. Refer to Appendix E.
6. History of clinically significant hemorrhagic or thrombotic event within the past 
6 months, not including uncomplicated catheter-associated venous thrombosis. Patients 
on anti-coagulation are not permitted to be on any oral formulations (warfarin, 
rivaroxaban, dabigatran, etc.) due to concern for drug-drug interaction.
7. Unstable angina, symptomatic congestive heart failure or cardiac arrhythmia requiring 
anti-arrhythmic therapy (Beta-blockers, calcium channel blockers and digoxin are 
allowed).
8. History of cerebrovascular or myocardial ischemia within 6 months of initiation.
9. Known inherited predisposition to bleeding or thrombosis.
10. Known active or chronic hepatitis B or C or HIV.
11. Untreated brain metastases.
12. History of second primary malignancy diagnosed within 3 years prior to enrollment, 
excluding:
a.
In-situ cervical carcinoma
b. Superficial bladder cancer
c.
Non-melanoma skin cancer
d. Stage I breast cancer
e.
Low grade (Gleason ≤ 6) localized prostate cancer
f.
Any additional malignancy which has been in clinical remission for at least 1 
year.
13. Pregnant or nursing female participants.
14. Unwilling or unable to follow protocol requirements.
15. Any condition which in the Investigator’s opinion deems the participant an unsuitable 
candidate to receive study drug.
16. Received an investigational agent within 4 weeks prior to enrollment.
17. Phase I: History of intolerance to capecitabine at doses ≤ 1000 mg/m2 BID, as defined by 
documented ≥ grade 3 hand-foot syndrome; documented severe diarrhea requiring 
hospitalization; or other documented severe AEs attributable to capecitabine.
APPROVED RPCI Institutional Review Board: 10/17/2016


Roswell Park Cancer Institute Study No.: 
                                                                                       I 265514
PRIVATE AND CONFIDENTIAL INFORMATION OF ROSWELL PARK CANCER INSTITUTE
02.16.16
Page 32 of 90
18. Phase II: History of intolerance to capecitabine at doses below 1000 mg/m2 BID, as 
defined by documented ≥ grade 3 hand-foot syndrome; documented severe diarrhea 
requiring hospitalization; or other documented severe AEs attributable to capecitabine.
5.3
Inclusion of Women and Minorities
Both men and women and members of all races and ethnic groups are eligible for this study.
6
TREATMENT PLAN
6.1
Dosing and Administration
Treatment will be administered on an outpatient basis. Reported adverse events (AEs) and 
potential risks are described in Section 1.8. Appropriate dose modifications are described in 
Section 6.5.
In this study, a cycle will be defined as 21 days. Dosing for capecitabine will be established 
based upon actual body weight, with capecitabine being prescribed in oral (PO) tablet forms of 
500 mg or 150 mg. The administration will be twice daily for two weeks (the first 2 weeks of 
each 21 day cycle), followed by a 1 week rest. Capecitabine is to be taken with water, within 
30 minutes following a meal. The total daily dose will be calculated with dosing split so that 
comparable doses are administered, approximately 12 hours apart. The PM dose will be 12 hours 
(+/- 2 hours) after the AM dose. Doses will be rounded to the nearest 150 or 500 mg tablet 
increment, but may be rounded down at investigators discretion.
Nintedanib is available in 100 mg and 150 mg capsules, which will be administered twice daily 
for 21 days (i.e., 1 complete 3-week cycle). Both capecitabine and nintedanib may be taken 
together, with water, within 30 minutes following a meal. Doses should be separated by 
approximately 12 hours, with the PM dose being 12 hours (+/- 2 hours) after the AM dose.
Patients will be supplied with medication diaries to assess compliance. If a dose is missed, 
vomited or otherwise not ingested, it will not be replaced; rather, the patient will wait until the 
next scheduled dose to resume therapy. In the event that dosing is interrupted mid-cycle, the 
duration of the cycle will not be extended. Doses missed during the interruption will be captured 
as omitted rather than delayed.
6.2
Cohort Management
Phase I
The planned dose levels for Phase I are depicted in Table 2.
Table 2
Available Dose Levels
Dose level
Capecitabine a
Nintedanib b
-1
1500   mg/m2 PO daily 
(in two divided doses) 
150 mg PO bid
1
2000 mg/m2 PO daily
150 mg PO bid


Roswell Park Cancer Institute Study No.: 
                                                                                       I 265514
PRIVATE AND CONFIDENTIAL INFORMATION OF ROSWELL PARK CANCER INSTITUTE
02.16.16
Page 33 of 90
(in two divided doses)
2
2000 mg/m2 PO daily
(in two divided doses)
200 mg PO bid
a Capecitabine will be taken only on the first 14 days (followed by 7 days off) of the 21 day cycle.
b Nintedanib will be taken for the complete 21 day cycle.
Dose escalation will proceed in a 3+3 fashion. Standard 3+3 rules will be followed until the 
maximum tolerated (or administered) dose is found. Initially, 3 patients are enrolled at dose 
level 1. If no dose limiting toxicities (DLTs) are observed, then 3 new patients are escalated to 
dose level 2. If ≥ 2 DLTs are observed, then 3 new patients are de-escalated to dose level -1. If 
1 DLT is observed, then an additional 3 patients are enrolled at dose level 1. In those 6 patients 
at dose level 1, if ≤ 1 DLTs are observed we proceed to dose level 2; otherwise we proceed to 
dose level -1. The same basic principles are followed until the Phase II recommended dose is 
identified. Planned dose escalation will proceed according to Table 3.
Table 3
Dose Escalation Scheme
Number of Participants 
with a Dose-Limiting 
Toxicity at a Given Dose 
Level
Escalation Decision Rule
0 out of 3
Enter 3 participants at the next dose level.
≥ 2
Dose escalation will be stopped. This dose level will be declared the maximally 
administered dose (highest dose administered). Three additional participants will be 
entered at the next lowest dose level if only 3 participants were treated previously at 
that dose.
1 out of 3
Enter at least 3 more participants at this dose level. If 0 of these 3 participants 
experience a dose-limiting toxicity, proceed to the next dose level. If 1 or more of 
this group suffer a dose-limiting toxicity, then dose escalation is stopped, and this 
dose is declared the maximally administered dose. Three additional participants will 
be entered at the next lowest dose level if only 3 participants were treated previously 
at that dose.
≤ 1 out of 6 at highest dose 
level below the maximally 
administered dose
This is generally the recommended Phase 2 dose. At least 6 participants must be 
entered at the recommended Phase 2 dose.
The recommended Phase 2 dose will be considered tolerable if DLT(s) are observed in at most 
1 of 6 patients completing at least 1 treatment cycle at that dose level. Available toxicity 
information about these drugs suggests that Dose Level 2 will be the recommended Phase 2 dose, 
and that 9 patients will be required for the Phase 1. Dose escalation will not proceed beyond dose 
level 2. 
Phase II
APPROVED RPCI Institutional Review Board: 10/17/2016


Roswell Park Cancer Institute Study No.: 
                                                                                       I 265514
PRIVATE AND CONFIDENTIAL INFORMATION OF ROSWELL PARK CANCER INSTITUTE
02.16.16
Page 34 of 90
•
Nintedanib – treatment will be initiated at the RP2D orally twice daily, administered 
in a continuous fashion.
•
Capecitabine – treatment will be initiated at the RP2D orally twice daily, taken for 
14 days, followed by a 7 day break.
As in the Phase I study, therapy will be administered in 3 week cycles. Treatment will continue 
until progression, undue toxicity or at the physician/patient discretion. The primary endpoint is 
the PFS rate, defined as the proportion of patients who survive without disease progression (per 
RECIST criteria) for at least 18 weeks after the start of treatment. The 6 patients in Phase 1 
patients treated at the recommended Phase 2 dose will be included in Stage 1 of the Phase 2 
study. As of 1/29/16, dose level 2 has been determined to be the RP2D.
6.3
Criteria for Retreatment
The following criteria must be met prior to initiation of a cycle of therapy:
•
ANC > 1000 / mm3
•
Platelet count > 100,000 / mm3
•
AST and/or ALT CTCAE grade ≤ 5X ULN and bilirubin ≤ ULN
•
Any additional non-hematologic toxicity of grade ≥ 3 which is potentially attributable to 
either drug must have resolved to grade ≤ 1 (or baseline)
If a patient achieves a response or stable disease which is maintained ≥ 6 months and 
discontinues therapy for a reason other than progressive disease, he/she may be considered for 
retreatment within 3 months of cessation of therapy. This must be approved by the study PI prior 
to re-initiation of treatment.
6.4
Definition of Dose-Limiting Toxicity
Dose limiting toxicity will be defined as any event which meets the criteria below and occurs 
within the 1st cycle of therapy (21 days). 
The following drug-related adverse events will qualify as DLT if considered drug-related:
•
Non-hematologic toxicity ≥ Grade 3 (CTCAE v4) except: transient electrolyte 
abnormality, alopecia, sub-optimally treated nausea, vomiting or diarrhea, and isolated 
elevation of gamma glutamyl transpeptidase. In particular,
o
Gastrointestinal toxicity (e.g. nausea, vomiting, diarrhoea, abdominal pain) or 
hypertension ≥ CTCAE Grade 3 despite optimal supportive care/ intervention.
o
Nintedanib (BIBF1120) related liver toxicity except GGT*** as specified below:

AST/ALT > 5x ULN* independent of bilirubin

AST/ALT > 2.5 x ULN** together with total bilirubin > 1.5 ULN**
* corresponding to CTCAE Grade 3 toxicity
APPROVED RPCI Institutional Review Board: 10/17/2016


Roswell Park Cancer Institute Study No.: 
                                                                                       I 265514
PRIVATE AND CONFIDENTIAL INFORMATION OF ROSWELL PARK CANCER INSTITUTE
02.16.16
Page 35 of 90
** corresponding to CTCAE Grade 2 toxicity
*** An isolated GGT elevation with no corresponding ALT/AST increase will 
not be considered as DLT.
•
Hematological toxicity
o
CTCAE Grade 4 neutropenia that is uncomplicated (not associated with 
fever ≥ 38.5°C) only if continuing for > 7 days
o
CTCAE Grade 4 febrile neutropenia of any duration if associated with 
fever ≥ 38.5ºC
o
Platelet decrease to CTCAE Grade 4, or decrease to CTCAE Grade 3 associated 
with bleeding or requiring transfusions
•
Inability to resume nintedanib (BIBF1120) dosing within 14 days of stopping due to 
treatment related toxicity
•
In case adverse events with CTCAE Grade 3/4 were not judged as DLT from a clinical 
point of view, the Principle Investigator will obtain a confirmation from the individual 
investigator regarding the appropriateness of the judgment
Dose escalation will proceed within each cohort according to the scheme in Table 3.
Participants who do not have a DLT and who do not complete a full cycle of treatment (at least 
75% of the prescribed dose of both nintedanib and capecitabine) will be replaced in the study.
Management and dose modifications associated with the above AEs are outlined in Section 6.5 
and Section 6.5.2.
6.5
Dose Modifications
6.5.1
Treatment Delay
Treatment with both nintedanib (BIBF1120) and capecitabine must be interrupted in case any of 
the criteria listed in Table 4 is fulfilled.
APPROVED RPCI Institutional Review Board: 10/17/2016


Roswell Park Cancer Institute Study No.: 
                                                                                       I 265514
PRIVATE AND CONFIDENTIAL INFORMATION OF ROSWELL PARK CANCER INSTITUTE
02.16.16
Page 36 of 90
Table 4
Criteria to Interrupt Nintedanib and capecitabine due to an Adverse Event
If one criterion is met, nintedanib (BIBF1120) + capecitabine is to be interrupted 
•
Nausea of CTCAE grade ≥ 3 despite optimal supportive care
•
Vomiting of CTCAE grade ≥ 2 despite optimal supportive care
•
Diarrhoea of CTCAE grade ≥ 2 for more than 7 consecutive days despite optimal supportive care
•
AST and/or ALT > 3 X ULN conjunction with bilirubin of  > 1.5 X ULN
•
AST and/or ALT of CTCAE grade  >5 X ULN
•
Other non-hematological adverse event of CTCAE grade ≥ 3 considered drug-related*
•
Neutropenia and fever > 38.5°C
•
Neutropenia  CTCAE grade 4 for more than 7 days without fever
•
Platelets <50,000 /mm³ with clinically relevant bleeding
*Excluding palmar-plantar erythrodysesthesia or other AE which is attributed to capecitabine alone (see 
Table 6).
Criteria for reinitiating therapy
Criteria for reinitiating therapy: After therapy is stopped for toxicity, a patient is eligible to 
restart nintedanib (BIBF1120) and capecitabine if all the criteria listed in Table 5 are met.
Capecitabine should only be restarted if the patient still falls within days 1 - 14 of the cycle. It 
should not be reinitiated during the scheduled 7 days off. If criteria to reinitiate therapy fall 
within the scheduled 7 day off period, nintedanib may be reinitiated as a single agent to complete 
that cycle.
If a patient has to interrupt intake of nintedanib (BIBF1120) + capecitabine due to an adverse 
event for more than 14 days, the decision to restart therapy needs to be discussed and agreed 
upon between the investigator and the sponsor.
Table 5
Criteria to Restart Nintedanib and Capecitabine after Interruption
All criteria have to be met in order to restart nintedanib (BIBF1120) + capecitabine
•
Nausea CTCAE grade ≤ 2
•
Vomiting CTCAE grade ≤ 1
•
Diarrhea CTCAE grade < 2
•
AST and ALT CTCAE grade < 5 X ULN and bilirubin  ≤ 1X ULN 
•
No other non-hematological adverse event grade CTCAE ≥ 3 which is considered drug-related
•
Absolute neutrophil count of ≥ 1000 / mm3, without fever 
•
Platelets > 75,000 / mm3
APPROVED RPCI Institutional Review Board: 10/17/2016


Roswell Park Cancer Institute Study No.: 
                                                                                       I 265514
PRIVATE AND CONFIDENTIAL INFORMATION OF ROSWELL PARK CANCER INSTITUTE
02.16.16
Page 37 of 90
6.5.1.1 Capecitabine
Criteria for interruption of capecitabine alone (Table 6):
Table 6
Criteria for Interruption of Capecitabine Alone
Special Criteria for Interrupting Capecitabine Only
[Grading as per CTCAE (v4.0)]
•
Palmar-plantar erythrodysesthesia (PPE) (Hand-foot syndrome) ≥ CTCAE grade 2.
•
Additional grade 3 toxicity which is felt to be attributable to capecitabine alone
Criteria for reinitiating capecitabine: The AE of concern in Table 6 must have resolved to 
grade 1 or less prior to reinitiating capecitabine. As per missed doses, capecitabine should not be 
reinitiated on the 1 week of scheduled rest.
6.5.2
Dose Reduction
As initial measure for the management of side effects, treatment with nintedanib and 
capecitabine should be temporarily interrupted until the specific adverse reaction has resolved to 
levels that allow continuation of therapy. Nintedanib and capecitabine treatment may be resumed 
at a reduced dose. Dose adjustments of nintedanib based on individual safety and tolerability are 
recommended as described in Table 7 and Table 8.
The following dose levels will be used in case dose adjustments are required for management of 
undue toxicity.
Table 7
Nintedanib Dose Level Reduction Scheme1
Dose Level
Nintedanib
1
200 mg (2 x 100 mg) po bid(starting dose)
- 1
150 mg po bid
- 2
100 mg po, qAM and 150 mg po, qPM
- 32
100 mg po bid2
1
This table is based upon a phase 1 dose and/or recommended Phase 2 dose of 200 mg bid. The dose level would 
not proceed beyond dose level -2 in that circumstance. Should the recommended phase 2 dose be less than 
200 mg bid, dose levels would be adjusted accordingly.
2
Patients requiring greater than two dose reductions will be taken off protocol therapy. Dose level -3 would only 
be utilized in the case that nintedanib was initiated at a dose of less than 200 mg bid. 


Roswell Park Cancer Institute Study No.: 
                                                                                       I 265514
PRIVATE AND CONFIDENTIAL INFORMATION OF ROSWELL PARK CANCER INSTITUTE
02.16.16
Page 38 of 90
Table 8
Capecitabine Dose Level Reduction Scheme1
Dose Level
Capecitabine
1
2000 mg/m2/day (starting dose), divided bid
- 1
1500 mg/m2/day, divided bid
- 2
1250 mg/m2/day, divided bid
- 32
1000 mg/m2/day, divided bid2
1
This table is based upon a phase 1 dose and/or recommended Phase 2 dose of 2000 mg/m2/day. The dose level 
would not proceed beyond dose level -2 in that circumstance. Should the recommended phase 2 dose be less 
than 2000 mg/m2/day, dose levels would be adjusted accordingly.
2
Patients requiring greater than two dose reductions will be taken off protocol therapy. Dose level -3 would only 
be utilized in the case that capecitabine was initiated at a dose of less than 2000 mg/m2/day. 
Note: If the dose of nintedanib (BIBF1120) or capecitabine has to be reduced due to toxicity, it 
will stay on the lower dose level for the entire time of administration.
6.5.3
Management of specific AEs
•
Diarrhea
•
Nausea and vomiting
•
Liver Enzyme Elevations
Table 9
Recommended Dose Adjustments for Nintedanib (BIBF1120) and 
Capecitabine
CTCAE (v4.0) Adverse Reactions
Dose Adjustment
Diarrhea ≥ grade 2 for more than 7 consecutive days 
despite optimal antidiarrheal treatment
OR
Diarrhea ≥ grade 3 despite optimal antidiarrheal 
treatment
Vomiting ≥ grade 2
AND/OR
Nausea ≥ grade 3 despite optimal anti-emetic 
treatment
1st episode
•
Reduce 1 dose level
2nd episode
•
Reduce 1 further dose level
APPROVED RPCI Institutional Review Board: 10/17/2016


Roswell Park Cancer Institute Study No.: 
                                                                                       I 265514
PRIVATE AND CONFIDENTIAL INFORMATION OF ROSWELL PARK CANCER INSTITUTE
02.16.16
Page 39 of 90
AST and/or ALT elevations > 3 X ULN in 
conjunction with bilirubin of  > 1.5 X ULN
OR
AST and/or ALT elevations of  > 5 X ULN
3rd episode
•
Stop treatment
Management of all other AEs:
Table 10
Management of Additional Adverse Events for Either Drug
Grade of Event
During a Course of Therapy
Dose Adjustment for Next Cycle
≤ Grade 1
No change in dose.
Resume at same dose level
Grade 21
1st occurrence
Hold until ≤ Grade 1 
Resume at same dose level.
Grade 21
2nd occurrence
Hold until ≤ Grade 1
Resume at 1 dose level lower
Grade 21
3rd occurrence
Hold until ≤ Grade 1
Resume at 1 dose level lower
Grade 21
4th occurrence
Hold until ≤ Grade 1
Permanently discontinue
Grade 3
Hold until < Grade 22
Resume at 1 dose level lower, if 
indicated3
Grade 4
Discontinue permanently or, if physician 
deems it to be in the patient’s best interest 
to continue, interrupt until resolved to 
grade 0-1.
Permanently discontinue OR
Reduce capecitabine by 50% AND 
Reduce nintedanib 1 dose level
1
Excludes sub-optimally treated grade 2 diarrhea/ nausea and hypertension. At the investigator’s discretion, 
dose reduction of capecitabine may be pursued after the first occurrence of grade 2 Palmoplantar 
erythrodysesthesia.
2
Participants requiring a delay of > 2 weeks should go off protocol therapy.
3
Participants requiring > 2 dose reductions should go off protocol therapy.
Recommended management for nausea and vomiting: antiemetics.
Recommended management for diarrhea: Loperamide antidiarrheal therapy. Dosage schedule: 4 mg at first onset, 
followed by 2 mg with each loose motion until diarrhea-free for 12 hours (maximum dosage: 16 mg / 24 hours) 
Adjunct antidiarrheal therapy is permitted and should be recorded when used.
Of note, in many cases, it will be difficult to firmly establish one of the agents as being causative 
of the adverse event (i.e. fatigue, nausea or diarrhea). As suggested above, in these instances, 
temporary cessation and/or dose reductions of both nintedanib and capecitabine are to be carried 
out. In the circumstance that an adverse event, which is not otherwise described herein, is felt to 
be clearly attributed to one of the two agents, but not the other, the putative inciting agent should 
be held, with dose modification of that agent only, as appropriate.
Patients should PERMANENTLY discontinue treatment in the event of:
APPROVED RPCI Institutional Review Board: 10/17/2016


Roswell Park Cancer Institute Study No.: 
                                                                                       I 265514
PRIVATE AND CONFIDENTIAL INFORMATION OF ROSWELL PARK CANCER INSTITUTE
02.16.16
Page 40 of 90
•
Intolerable Adverse Events (CTCAE grade 3 or 4) that cannot be managed by dose 
reduction.
•
Withdrawal of informed consent.
•
AEs requiring a delay in therapy of > 2 weeks (except as above, in the case that a patient 
is felt to be deriving clinical benefit and, this is first discussed and agreed upon between 
the individual investigator and the principal investigator.).
6.6
General Concomitant Medication and Supportive Care
6.6.1
Additional precautions and supportive care.
•
Diarrhea
Diarrhea was the most frequently reported gastro-intestinal event and appeared in close 
temporal relationship with the administration of docetaxel in the clinical trial LUME-Lung 1. 
The majority of patients had mild to moderate diarrhoea. 6.3 % of the patients had diarrhoea 
of grade ≥3 in combination treatment compared to 3.6 % treated with docetaxel alone. 
Diarrhea should be treated at first signs with adequate hydration and antidiarrheal medicinal 
products, e.g. loperamide, and may require interruption, dose reduction or discontinuation of 
therapy with nintedanib.
•
Nausea and vomiting
Nausea and vomiting, mostly of mild to moderate severity, were frequently reported 
gastrointestinal adverse events in the clinical trial LUME-Lung 1. Interruption, dose 
reduction or discontinuation of therapy with nintedanib (BIBF1120) may be required despite 
appropriate supportive care. Supportive care for nausea and vomiting may include medicinal 
products with anti-emetic properties, e.g. glucocorticoids, anti-histamines or 5-HT3 receptor 
antagonists and adequate hydration.
In the event of dehydration, administration of electrolytes and fluids is required. Plasma 
levels of electrolytes should be monitored, if relevant gastrointestinal adverse events occur.
•
Neutropenia and Sepsis
A higher frequency of neutropenia of CTCAE grade > 3 was observed in patients treated 
with nintedanib (BIBF1120) in combination with docetaxel as compared to treatment with 
docetaxel alone in the clinical trial LUME-Lung 1. Subsequent complications such as sepsis 
or febrile neutropenia have been observed.
•
Hepatic Function
The safety and efficacy of nintedanib has not been studied in patients with moderate (Child 
Pugh B) or severe (Child Pugh C) hepatic impairment. Therefore treatment with nintedanib 
(BIBF1120) is not recommended in such patients. Administration of nintedanib was 
associated with an elevation of liver enzymes (ALT, AST, ALKP (alkaline phosphatase), and 
bilirubin, with a potentially higher risk for female patients.
APPROVED RPCI Institutional Review Board: 10/17/2016


Roswell Park Cancer Institute Study No.: 
                                                                                       I 265514
PRIVATE AND CONFIDENTIAL INFORMATION OF ROSWELL PARK CANCER INSTITUTE
02.16.16
Page 41 of 90
These increases were reversible in the majority of cases and not associated with clinically 
manifest liver disorders. Hepatic transaminases, ALKP and bilirubin levels are recommended 
to be closely monitored after start of therapy with nintedanib (BIBF1120) (periodically, i.e. 
in the combination phase with docetaxel at the beginning of each treatment cycle). If relevant 
liver enzyme elevations are measured, interruption, dose reduction or discontinuation of the 
therapy with nintedanib may be required (see Appendix C for procedures for follow-up for 
potential drug-induced liver injury).
6.6.2
Concomitant medications
Additional chemo-, immuno-, hormone- or radiotherapies are not allowed during the active 
treatment period of this trial. Palliative radiotherapy may be permitted for symptomatic control 
of pain from bone metastases after discussion with the Principle Investigator, provided that the 
radiotherapy does not affect target lesions, and the reason for the radiotherapy does not reflect 
progressive disease.
Metabolism of nintedanib by CYP450 enzymes plays only a minor role (5%). Additionally, 
nintedanib did not show relevant induction or inhibition of the major drug metabolizing 
cytochrome P450 enzymes and specifically no irreversible CYP3A4 inhibition. However, if co-
administered with nintedanib, strong P-gp inhibitors may increase exposure to nintedanib (e.g. 
ketoconazole or erythromycin). Thus, such medications are to be avoided unless deemed to be 
absolutely necessary. In such cases, patients should be monitored closely for tolerability of 
nintedanib. Management of side effects may require interruption, dose reduction or 
discontinuation of therapy with nintedanib.
Strong P-gp inducers, e.g. rifampicin, carbamazepine, phenytoin, and St. John’s Wort, may 
decrease exposure to nintedanib. Co-administration with Nintedanib and potential alternative 
therapies should be carefully considered.
Because there is a potential for interaction of drug with other concomitantly administered drugs, 
the electronic case report form (eCRF) must capture the concurrent use of all other drugs, over-
the-counter medications, or alternative therapies. The Investigator should be alerted by the study 
clinical research coordinator if the participant is taking any agent known to affect or with the 
potential to affect selected CYP450 isoenzymes, P-gp inducers or inhibitors.
Aluminum hydroxide and magnesium hydroxide containing products should be avoided while 
taking capecitabine. Investigation has documented increase plasma levels of capecitabine and 
one metabolite with the use of Maalox. Post marketing reports indicate that some patients taking 
both capecitabine and phenytoin experienced toxicity with elevated phenytoin levels. The level 
of phenytoin should be carefully monitored in patients taking capecitabine and phenytoin doses 
may need to be reduced.
During cycle 1 of the phase I study, the use of myeloid growth factors (including Neupogen and 
Neulasta) is not permitted. After cycle 1 and during the phase II study, growth factor support 
may be utilized at the discretion of the investigator.
Participants may be pretreated for nausea and vomiting with appropriate anti-emetics.
APPROVED RPCI Institutional Review Board: 10/17/2016


Roswell Park Cancer Institute Study No.: 
                                                                                       I 265514
PRIVATE AND CONFIDENTIAL INFORMATION OF ROSWELL PARK CANCER INSTITUTE
02.16.16
Page 42 of 90
Rescue medication to reverse the actions of nintedanib (BIBF1120) is not available. Potential 
side effects of nintedanib (BIBF1120) have to be treated symptomatically.
6.7
Duration of Treatment
Participants may remain on study and continue to receive treatment in the absence of disease 
progression, unacceptable toxicity or withdrawal from study, intercurrent illness that prevents 
further administration of treatment, participant demonstrates an inability/refusal to comply with 
oral medication regime, and participant withdraws from study.
6.8
Treatment Discontinuation
Upon treatment discontinuation all end of treatment evaluations and tests will be conducted. All 
participants who discontinue due to an AE must be followed until the event resolves or stabilizes. 
Appropriate medical care should be provided until signs and symptoms have abated, stabilized, 
or until abnormal laboratory findings have returned to acceptable or pre-study limits. The final 
status of the AE will be reported in the participant’s medical records and the appropriate eCRF.
Reasons for treatment discontinuation should be classified as follows:
•
Death
•
Progressive disease
•
Toxicity; related or unrelated toxicity
•
Investigator judgment
o
The Investigator may discontinue a participant if, in his/her judgment, it is in the 
best interest of the participant to do so.
•
Noncompliance
•
Participant voluntary withdrawal
o
A participant may withdraw from the study at any time, for any reason. If a 
participant discontinues treatment, an attempt should be made to obtain 
information regarding the reason for withdrawal.
•
Boehringer Ingelheim decision
•
NCCN decision
6.9
Compliance
Patients will be supplied with a medication diary to track self-administration of capecitabine and 
nintedanib (Appendix D). After the first cycle, nintedanib pill counts will be performed at the 
initiation of each subsequent cycle for reconciliation as well as to assess compliance.
APPROVED RPCI Institutional Review Board: 10/17/2016


Roswell Park Cancer Institute Study No.: 
                                                                                       I 265514
PRIVATE AND CONFIDENTIAL INFORMATION OF ROSWELL PARK CANCER INSTITUTE
02.16.16
Page 43 of 90
7
INVESTIGATIONAL PRODUCT
7.1
Active Substance and Source
Nintedanib is provided as soft gelatin capsules containing a suspension of milled active as the 
ethane sulphonate salt. It is available for clinical investigations in five dose strengths 
corresponding to 50 mg (brown, oval capsules), 100 mg (peach or orange, oblong capsules), 
125 mg (orange, oblong capsules), 150 mg (brown or orange, oblong capsules) and 200 mg 
(brown, oblong capsules). The capsule fill is composed of medium chain triglycerides, hard fat 
and lecithin in addition to the drug substance.
In oncological studies, the 100 mg and 150 mg capsules will be used either with the trial 
formulation (all capsules orange) or with the intended market formulation (100 mg: peach, 
150 mg: brown).
Capecitabine is supplied as biconvex, oblong, film-coated tables. Capecitabine is available in 
two strengths: 150 mg (light peach) or 500 mg (peach).
7.2
Drug Shipment
Nintedanib will be provided by Boehringer Ingelheim Pharmaceuticals, Inc. and shipped to the 
participating site. Boehringer Ingelheim will provide study specific drug order forms.
The date of receipt and the amount of drug received will be documented. Drug shipment records 
will be retained by the investigational pharmacist or designee.
Commercially available capecitabine will be used during this study. Patients will be given a 
prescription (or institutional support, case managers, as appropriate) to fill at the pharmacy of 
their choice prior to the start of each treatment cycle.
7.3
Storage and Stability
7.3.1
Nintedanib
The current shelf life for all dosage strengths and formulations of nintedanib is 60 months. The 
expiration date will be supplied in the shipping receipt or on the bottles. The capsules are 
packaged in child resistant high density polyethylene (HDPE) bottles and have to be stored 
below 30°C. The capsules should be protected from exposure to high humidity which is ensured 
by storage in the original package. Please refer to investigator’s brochure for complete details.
The Investigator or designate will be responsible for ensuring that the investigational, nintedanib, 
product is securely maintained in a locked, limited-access facility, as specified by Boehringer 
Ingelheim and in accordance with the applicable regulatory requirements.
Drug storage temperature will be maintained and recorded, as applicable.
7.4
Handling and Disposal
The Investigator or designee will be responsible for dispensing and accounting for all 
investigational drug provided by Boehringer Ingelheim exercising accepted medical and 
APPROVED RPCI Institutional Review Board: 10/17/2016


Roswell Park Cancer Institute Study No.: 
                                                                                       I 265514
PRIVATE AND CONFIDENTIAL INFORMATION OF ROSWELL PARK CANCER INSTITUTE
02.16.16
Page 44 of 90
pharmaceutical practices. Study drugs must be handled as cytotoxic agents and appropriate 
precautions taken per the institution’s environmentally safe handling procedures. All 
investigational drugs will be dispensed in accordance with the Investigator’s prescription or 
written order.
All products dispensed will be recorded on a product accountability record. Records of product 
lot numbers and dates received will be entered on a product accountability form. It is the 
Principal Investigator’s responsibility to ensure that an accurate record of investigational drug 
issued and returned is maintained.
Under no circumstances will the Investigator supply investigational drug to a third party or allow 
the investigational drug to be used in a manner other than as directed by this protocol.
8
STUDY PROCEDURES
8.1
Participant Registration
Eligibility of each participant will be established prior to enrollment.
Informed consent MUST be completed prior to receiving any study related procedures.
Unless otherwise defined in the written protocol text, all procedures/assessments will be 
conducted in accordance with RPCI Clinical Research Services Standard Operating Procedures.
8.2
Baseline Evaluations
The following will be performed within 2 weeks prior to first dose of study drug (unless 
otherwise noted):
•
Medical history (including all prior anti-tumoral therapy related to colorectal cancer)
•
Physical examination 
•
Vital signs (i.e., temperature, heart rate, respiratory rate, blood pressure, body weight, and 
height)
•
Hematology (i.e., complete blood count (CBC) with automated differentials)
•
Chemistry (i.e., complete metabolic panel (CMP): chloride, CO2, potassium, sodium, BUN, 
glucose, calcium, creatinine, total protein, albumin, total bilirubin, alkaline phosphatase, 
AST, ALT, A/G ratio, BUN/creatinine ratio, osmol (Calc), anion gap).
•
Pregnancy test serum in females of childbearing potential
•
Urine spot protein and urine spot creatinine levels (UPCR)
•
Coagulation studies - INR/PT, PTT
•
ECOG Performance Status (Appendix B)
•
Concomitant Medications: List any medications that were ongoing, or stopped, within 
1 week prior to first dose of study drug.
•
Baseline imaging – CT chest/abdomen/pelvis (within 4 weeks)
APPROVED RPCI Institutional Review Board: 10/17/2016


Roswell Park Cancer Institute Study No.: 
                                                                                       I 265514
PRIVATE AND CONFIDENTIAL INFORMATION OF ROSWELL PARK CANCER INSTITUTE
02.16.16
Page 45 of 90
8.3
Evaluations Performed On Therapy (Day 1 of each cycle, +/- 3 days)
•
Physical examination 
•
Vital signs (i.e., temperature, heart rate, respiratory rate, blood pressure, body weight)
•
Hematology (i.e., complete blood count (CBC) with automated differentials)
•
Chemistry (i.e., complete metabolic panel (CMP): chloride, CO2, potassium, sodium, BUN, 
glucose, calcium, creatinine, total protein, albumin, total bilirubin, alkaline phosphatase, 
AST, ALT, A/G ratio, BUN/creatinine ratio, osmol (Calc), anion gap).
•
Blood draw for PK and biomarker (first 32 patients only, on cycle 1 and 3). See sections 
8.10and 8.11 for collection time points.
•
ECOG Performance Status (Appendix B)
•
Concomitant Medications: List any ongoing medications with dose changes, as applicable.
•
Adverse events
•
CT scan of the chest/abdomen/pelvis with IV contrast (or if unable to receive IV contrast, a 
non-contrast CT of the chest + MRI of the abdomen/pelvis) every 9 weeks after Cycle- 1 Day 
1 (±7 days) 
•
CEA:
o
Cycle 1 – Day 1
o
Cycle 4 – Day 1
o
Every 3 cycles (on Day 1) from Cycle 4 onward.
•
Study Drug Reconciliation – Beginning with Cycle 2 – Day 1 (reconciliation for Cycle 1) 
and on Day 1 of all subsequent cycles prior to the initiation of a new cycle.
8.4
Evaluations Performed On Therapy (Day 2 cycle 1)
•
Blood draw for PK (first 32 patients only)
8.5
Evaluations Performed On Therapy (Day 8 of cycles 1 and 2, phase I only, +/- 3 days)
•
Physical examination 
•
Vital signs (i.e., temperature, heart rate, respiratory rate, blood pressure, body weight)
•
Chemistry (i.e., complete metabolic panel (CMP): chloride, CO2, potassium, sodium, BUN, 
glucose, calcium, creatinine, total protein, albumin, total bilirubin, alkaline phosphatase, 
AST, ALT, A/G ratio, BUN/creatinine ratio, osmol (Calc), anion gap).
•
Hematology (i.e., complete blood count (CBC) with automated differentials).
•
Adverse events
•
Concomitant Medications: List any ongoing medications with dose changes, as applicable.
8.6
Evaluations Performed On Therapy (Day 15 of cycle 1)
•
Blood draw(s) for PK and biomarker (CAFs on first 32 patients only)
APPROVED RPCI Institutional Review Board: 10/17/2016


Roswell Park Cancer Institute Study No.: 
                                                                                       I 265514
PRIVATE AND CONFIDENTIAL INFORMATION OF ROSWELL PARK CANCER INSTITUTE
02.16.16
Page 46 of 90
•
Concomitant Medications: List any ongoing medications with dose changes, as applicable.
•
Adverse events
8.7
Evaluations Performed at End of Treatment (30 +/- 7 days post last dose of study 
drug)
The following evaluations will be performed following treatment discontinuation. In the case of 
persistent drug-related toxicity, patients will be followed every 28 days until resolution or 
satisfactory stabilization is achieved. Telephone contact is acceptable.
•
Physical examination, including vital signs (i.e., temperature, heart rate, respiratory rate, 
blood pressure, body weight)
•
Hematology (i.e., complete blood count (CBC) with automated differentials) 
•
Chemistry (i.e., complete metabolic panel (CMP): chloride, CO2, potassium, sodium, BUN, 
glucose, calcium, creatinine, total protein, albumin, total bilirubin, alkaline phosphatase, 
AST, ALT, A/G ratio, BUN/creatinine ratio, osmol (Calc), anion gap).
•
Concomitant medication: List any ongoing medications with dose changes, as applicable
•
Adverse events
•
Drug reconciliation
8.8
Medical Record Review
Every 6 months for overall survival.
8.9
Schedule of Procedures and Observations
The schedule of procedures and observations for this study is summarized in Table 11 (Phase I) 
and Table 12 (Phase II) below.
Note: Except for cycle 1- day 1 and day 2 procedures, all other procedures may be 
performed ± 3 days from the proposed date. Disease assessment (CT imaging) may be performed 
up to 7 days prior to day 1 of the corresponding cycle.
APPROVED RPCI Institutional Review Board: 10/17/2016


Roswell Park Cancer Institute Study Number:
I 265514
PRIVATE AND CONFIDENTIAL INFORMATION OF ROSWELL PARK CANCER INSTITUTE
02.16.16
Page 47 of 90
Table 11
Phase I: Schedule of Procedures and Observations 
Evaluation
Baseline1
Cycle 1
Cycle 2
Cycle 3
Cycle 4
Further 
Cycles
End of 
Treatment2
Follow-Up3
Day
1
2
8
15
1
8
1
1
1
Medical History
X
Pre-Existing Conditions
X
Physical Examination , including 
vital signs (i.e., temperature, heart 
rate, respiratory rate, blood 
pressure, body weight, and 
height)4
X
X
X
X
X
X
X
X
X
Hematology5
X
X
X
X
X
X
X
X
X
Chemistry6
X
X
X
X
X
X
X
X
X
INR/PT, PTT
X
CEA
X
X
X11
Urine Sample for Urine Protein 
Creatinine Ratio (UPCR)
X
Pharmacokinetic Sampling7
X
X
X
Biomarker Sampling7
X
X
X
Pregnancy Test (Serum)8
X
ECOG Performance Status
X
X
X
X
X
X
CT Chest/Abdomen/Pelvis9
X
X
X9
Study Drug Reconciliation12
X
X
X
X
X
Concomitant Medications
X10
X
X
X
X
X
X
X
X
X
Survival Assessment 
X
Adverse Events
X
X
X
X
X
X
X
X
X
1
Performed within 2 weeks prior to first dose of study drug.
2
Follow-up safety evaluations will occur 30 days (± 7 days) after last dose of study drug. In the case of persistent drug-related toxicity, patients will be followed every 
28 days until resolution or satisfactory stabilization is achieved. Telephone contact is acceptable.


Roswell Park Cancer Institute Study Number:
I 265514
PRIVATE AND CONFIDENTIAL INFORMATION OF ROSWELL PARK CANCER INSTITUTE
02.16.16
Page 48 of 90
Evaluation
Baseline1
Cycle 1
Cycle 2
Cycle 3
Cycle 4
Further 
Cycles
End of 
Treatment2
Follow-Up3
Day
1
2
8
15
1
8
1
1
1
3
Medical record review every 6 months to assess overall survival.
4
Height collected at baseline only.
5
Hematology ( complete blood count (CBC) with automated differentials)
6
Chemistry (complete metabolic panel (CMP): chloride, CO2, potassium, sodium, BUN, glucose, calcium, creatinine, total protein, albumin, total bilirubin, alkaline 
phosphatase, AST, ALT, A/G ratio, BUN/creatinine ratio, osmol (Calc), anion gap).
7
Pharmacokinetic samples and biomarker samples will be collected according to Section 8.10 and Section 8.11, respectively.
8
For women of child-bearing potential only.
9
Baseline imaging within 4 weeks prior to treatment start. Additional scans will be taken every 9 weeks after cycle 1 –day 1 (± 7days). CT chest + MRI abdomen/pelvis 
is acceptable for disease assessment, if patients are unable to undergo a contrast enhanced CT.
10
Medications ongoing, or stopped, within 1 week prior to first dose of study drug.
11
CEA is to be performed every 3 cycles from cycle 4 onward (i.e. cycle 4, 7, 10…)
12
Study drug reconciliation from previous cycle, prior to starting new cycle.


Roswell Park Cancer Institute Study Number:
I 265514
PRIVATE AND CONFIDENTIAL INFORMATION OF ROSWELL PARK CANCER INSTITUTE
02.16.16
Page 49 of 90
Table 12
Phase II: Schedule of Procedures and Observations
Evaluation
Baseline1
Cycle 1
Cycle 2
Cycle 3
Cycle 4
Further Cycles
End of 
Treatment2
Follow-
Up3
Day 
1
2
15
1
1
1
1
Medical History
X
Pre-Existing Conditions
X
Physical Examination , 
including vital signs (i.e., 
temperature, heart rate, 
respiratory rate, blood 
pressure, body weight, and 
height)4
X
X
X
X
X
X
X
Hematology5
X
X
X
X
X
X
X
Chemistry6
X
X
X
X
X
X
X
INR/PT, PTT
X
CEA
X
X
X11
Urine Sample for Urine 
Protein Creatinine Ratio 
(UPCR)
X
Pharmacokinetic Sampling7
X
X
X
Biomarker Sampling7
X
X
X
Pregnancy Test (Serum)8
X
ECOG Performance Status
X
X
X
X
X
X
CT chest/abdomen/pelvis9
X
X
X9
Study Drug Reconciliation12
X
X
X
X
X
Concomitant Medications
X10
X
X
X
X
X
X
X
Survival Assessment
X
Adverse Events
X
X
X
X
X
X
X


Roswell Park Cancer Institute Study Number:
I 265514
PRIVATE AND CONFIDENTIAL INFORMATION OF ROSWELL PARK CANCER INSTITUTE
02.16.16
Page 50 of 90
Evaluation
Baseline1
Cycle 1
Cycle 2
Cycle 3
Cycle 4
Further Cycles
End of 
Treatment2
Follow-
Up3
Day 
1
2
15
1
1
1
1
1
Performed within 2 weeks prior to treatment start.
2
Follow-up safety evaluations will occur 30 days (± 7 days) after last dose of study drug. In the case of persistent drug-related toxicity, patients 
will be followed every 28 days until resolution or satisfactory stabilization is achieved. Telephone contact is acceptable.
3
Medical record review every 6 months to assess overall survival.
4
Height collected at baseline only.
5
Hematology ( complete blood count (CBC) with automated differentials)
6
Chemistry (complete metabolic panel (CMP): chloride, CO2, potassium, sodium, BUN, glucose, calcium, creatinine, total protein, albumin, 
total bilirubin, alkaline phosphatase, AST, ALT, A/G ratio, BUN/creatinine ratio, osmol (Calc), anion gap).
7
Pharmacokinetic samples and biomarker samples will be collected according to Section 8.10and Section 8.11, respectively.
8
For women of child-bearing potential only.
9
Baseline imaging within 4 weeks prior to treatment start. Additional scans will be taken every 9 weeks after cycle 1 –day 1 (± 7days). CT 
chest + MRI abdomen/pelvis is acceptable for disease assessment, if patients are unable to undergo a contrast enhanced CT.
10
Medications ongoing, or stopped, within 1 week prior to first dose of study drug.
11
CEA is to be performed every 3 cycles from cycle 4 onward (i.e. cycle 4, 7, 10…)
12
Study drug reconciliation from previous cycle, prior to starting new cycle.


Roswell Park Cancer Institute Study Number:                                                                                               I 265514
PRIVATE AND CONFIDENTIAL INFORMATION OF ROSWELL PARK CANCER INSTITUTE
02.16.16
Page 51 of 90
8.10 Pharmacokinetic Blood Sample Collection and Processing
Whole blood samples for pharmacokinetic (PK) analysis of nintedanib levels will be collected 
via venipuncture. This will only be performed on the first 32 patients enrolled in the study.
Samples for pharmacokinetic analysis (PK) of nintedanib levels will be collected using 1, 10 mL 
purple EDTA collection tube.
Pharmacokinetic sample (PK) collection will be obtained on:
•
Cycle 1/Day 1 – Pre-dosing: PK
•
Cycle 1/Day 1 – 0.5-1 hr post-dosing: PK
•
Cycle 1/Day 1 – 2-4 hr post-dosing: PK
•
Cycle 1/Day 1 – 5-6 hr post-dosing: PK
•
Cycle 1/Day 1 – 7-8 hr post-dosing: PK 
•
Cycle 1/Day 2 – Pre-dosing: PK
•
Cycle 1/Day 15 – Pre-dosing: PK
•
Cycle 1/Day 15 – 2-4 hr post-dosing: PK
•
Cycle 1/Day 15 – 5-6 hr post-dosing: PK
Note: All dosing dates and times must be recorded on the study medication diary and in the 
eCRF for all doses taken from the first dose to the day of the last PK sample.
NOTE: Any samples that have been hemolyzed should be re-drawn if possible.
Nintedanib is degraded by plasma esterases; therefore, whole blood samples should be 
immediately maintained in an ice bath until centrifuged. Centrifugation for separation of plasm 
should be done within 60 min after sampling: 
•
Centrifuge whole blood samples as soon as possible at 4°C using a refrigerated centrifuge 
at approximately 3000 rpm for about 10 min.
•
Transfer at least 500 μL of the supernatant plasma into polypropylene vials (e.g., Nunc 
cryo-tubes, 1.8 mL).
NOTE: Strictly avoid contamination with erythrocytes: If this occurs, the specimen must be 
centrifuged again.
Plasma will be aliquoted into 2 cryovials per time-point. The screw cap polypropylene cryogenic 
tube will be labeled with the participant’s MR number,(for RPCI participants) participant’s 
initials, participant’s study number, clinical study number, protocol time point, dose, and 
protocol day. The samples will immediately be frozen at - 70ºC or below until analyzed.
Samples collected at RPCI will be processed and stored at RPCI’s Hematological Procurement 
Facility. Frozen samples will then be analyzed in RPCI’s Bioanalytics, Metabolomics & 
Pharmacokinetic Core Facility:
APPROVED RPCI Institutional Review Board: 10/17/2016


Roswell Park Cancer Institute Study Number:                                                                                               I 265514
PRIVATE AND CONFIDENTIAL INFORMATION OF ROSWELL PARK CANCER INSTITUTE
02.16.16
Page 52 of 90
Roswell Park Cancer Institute
Bioanalytics, Metabolomics & Pharmacokinetic Core Facility 
Center for Genetics and Pharmacology, Room L1-140
Regarding Study #: I 265514
Elm & Carlton Streets
Buffalo, New York 14263
PKPDcore@RoswellPark.org
Note: All laboratories housing research samples need to maintain current, study-specific 
Temperature 
Logs 
and 
Sample 
Tracking 
and 
Shipping 
Logs. 
The 
Principal 
Investigator/Laboratory Manager must ensure that the stated lab(s) have a process in place to 
document 
the 
receipt/processing/storage/shipping 
of 
study-related 
samples/specimens 
(ICH 8.3.25). This is required for both observational and interventional clinical studies collecting 
clinical samples.
NETWORK SITES: Follow directions above for sample collection and processing. The 
cryogenic tubes will be labeled with the Subject ID # (unique to Network patients), initials, the 
participant’s study number, clinical study number, protocol time point, dose, and protocol day. 
Frozen samples will be shipped via Fed Express Overnight on dry ice with delivery on Mon-Fri. 
NO SATURDAY DELIVERY. All samples should be shipped batched at the end of the study 
to the address below with shipping log:
Roswell Park Cancer Institute
Bioanalytics, Metabolomics & Pharmacokinetic Core Facility 
Center for Genetics and Pharmacology, Room L1-140
 Regarding Study #: I 265514
Elm & Carlton Streets
Buffalo, New York 14263
PKPDcore@RoswellPark.org 
For additional information regarding the handling of pharmacokinetic samples please contact 
RPCI’s Bioanalytics, Metabolomics & Pharmacokinetic Core Facility laboratory at 716-845-3303 
(Tel) or 716-845-1579 (Fax).
8.11 Biomarker Blood Sample Collection and Processing
Whole blood samples for biomarker analysis (CAF: Circulating Angiogenic Factors) will be 
collected via venipuncture. This will only be performed on the first 32 patients enrolled in the 
study.
Samples for biomarker analysis (CAF) will be collected using 1, 10 mL green-top heparinized 
collection tube and 1, 10 mL purple EDTA collection tube.
Biomarker sample (CAF) collection will be obtained on:
•
Cycle 1/Day 1 – Pre-dosing: CAF
APPROVED RPCI Institutional Review Board: 10/17/2016


Roswell Park Cancer Institute Study Number:                                                                                               I 265514
PRIVATE AND CONFIDENTIAL INFORMATION OF ROSWELL PARK CANCER INSTITUTE
02.16.16
Page 53 of 90
•
Cycle 1/Day 1 – 2-4 hr post-dosing: CAF
•
Cycle 1/Day 15 – 2-4 hr post-dosing: CAF
•
Cycle 3/Day 1 – 2-4 hr post-dosing: CAF
Plasma will be separated from whole blood within 30 minutes following the extraction 
(collection tubes are to be centrifuged at 1000g for 10 min at room temperature). Plasma will be 
aliquoted into 3 cryovials (approximately 1 mL/cryovial) per time-point. The screw cap 
polypropylene cryogenic tube will be labeled with the participant’s MR number,(for RPCI 
participants) participant’s initials, participant’s study number, clinical study number, protocol 
time point, dose, and protocol day. The samples will immediately be frozen at -70ºC or below 
until analyzed. Samples collected at RPCI will be processed and stored at RPCI’s Hematological 
Procurement Facility. Frozen CAF samples will then be analyzed in RPCI’s Genitourinary 
Malignancies Laboratory by Dr. John Ebos:
Roswell Park Cancer Center
Genitourinary Malignancies Laboratory
GCDC Bldg. 5th Floor, Rm. 545A
Attn: John Ebos – I 265514
Elm & Carlton Streets
Buffalo, NY 14263
Tel: 716-845-4464
Fax: 716-845-3879
John.Ebos@RoswellPark.org 
Note: All laboratories housing research samples need to maintain current, study-specific 
Temperature Logs and Sample Tracking and Shipping Logs. The Principal 
Investigator/Laboratory Manager must ensure that the stated lab(s) have a process in place to 
document the receipt/processing/storage/shipping of study-related samples/specimens 
(ICH 8.3.25). This is required for both observational and interventional clinical studies collecting 
clinical samples.
NETWORK SITES: Follow directions above for sample collection and processing. The 
cryogenic tubes will be labeled with the Subject ID # (unique to Network patients), initials, the 
participant’s study number, clinical study number, protocol time point, dose, and protocol day. 
The samples will immediately be frozen at -70ºC or below (samples are to be stored until 
requested for batch mailing). Samples are to be batch shipped frozen at the end of study with 
shipping log, on dry ice.
Frozen samples will be shipped via Fed Express Overnight on dry ice with delivery on Mon-Fri. 
NO SATURDAY DELIVERY. Do not ship on a Friday or the day before a holiday.
APPROVED RPCI Institutional Review Board: 10/17/2016


Roswell Park Cancer Institute Study Number:                                                                                               I 265514
PRIVATE AND CONFIDENTIAL INFORMATION OF ROSWELL PARK CANCER INSTITUTE
02.16.16
Page 54 of 90
Address shipments and any questions regarding specimen processing to:
Roswell Park Cancer Center
Genitourinary Malignancies Laboratory
GCDC Bldg. 5th Floor, Rm. 545A
Attn: John Ebos – I 265514
Elm & Carlton Streets
Buffalo, NY 14263
Tel: 716-845-4464
Fax: 716-845-3879
John.Ebos@RoswellPark.org
9
EFFICACY EVALUATIONS
9.1
Objective Tumor Response
All protocol-defined imaging studies must be performed at the investigative site or sponsor-
approved facility using protocol-defined parameters. The same method of assessment and the 
same technique should be used to characterize each identified and reported lesion at baseline and 
during follow-up. RECIST 1.1 will be used to assess objective tumor response. Evaluation will 
be carried out for both the phase I and II study portions.
9.2
Target Lesions
All measurable lesions up to a maximum of 2 lesions per organ and 5 lesions in total, 
representative of all involved organs, will be identified as target lesions and recorded and 
measured at baseline. Target lesions will be selected on the basis of their size. Lesions with the 
longest diameter (short axis for lymph nodes) and are ≥ 10 mm (CT and MRI), ≥ 15 mm lymph 
nodes, > 20 mm CXR and are for accurate repetitive measurements (either by imaging 
techniques or clinically) will be chosen. A sum of the longest diameter (short axis for lymph 
nodes) of all target lesions will be calculated and reported as the baseline sum diameters. This 
will be used as reference to further characterize the objective tumor response of the measurable 
dimension of the disease.
•
Complete Response (CR): Disappearance of all target lesions. Any lymph nodes must have 
a reduction in short axis to < 10 mm. Changes in tumor measurements must be confirmed by 
repeat studies performed no less than 9 weeks after the criteria for response are first met.
•
Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, 
taking as reference the baseline sum diameters. Changes in tumor measurements must be 
confirmed by repeat studies performed no less than 9 weeks after the criteria for response are 
first met.
•
Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, 
taking as references the smallest sum on study (this includes the baseline sum if that is the 
smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate 
an absolute increase of at least 5 mm. The appearance of one or more new lesions is also 
considered progression.
APPROVED RPCI Institutional Review Board: 10/17/2016


Roswell Park Cancer Institute Study Number:                                                                                               I 265514
PRIVATE AND CONFIDENTIAL INFORMATION OF ROSWELL PARK CANCER INSTITUTE
02.16.16
Page 55 of 90
•
Stable Disease (SD): Neither sufficient shrinkage to qualify for PR, nor sufficient increase to 
qualify for PD, taking as reference the smallest sum diameter while on study. Participants 
having a documented response with no confirmation of the response will be listed with stable 
disease.
9.3
Non-Target Lesions
All other small lesions (longest diameter < 10 mm or lymph nodes ≥ 10 mm to < 15 mm short 
axis) and non-measurable lesions (i.e., leptomeningeal disease, ascites, pleural or pericardial 
effusion, inflammatory breast disease, lymphangitic involvement of skin or lung, blastic bone 
lesions, or abdominal masses / abdominal organomegaly identified by physical exam that is not 
measurable by imaging) should be identified as non-target lesions and indicated as present in the 
source documents at baseline. The general location will also be documented on the images 
drawing a regularly-shaped Region of Interest. Measurements of the non-target lesions will not 
be performed, but the presence or absence of each should be noted throughout follow-up and 
evaluation.
•
Complete Response: Disappearance of all non-target lesions and normalization of tumor 
marker level, if applicable. All lymph nodes must be non-pathological in size (< 10 mm short 
axis).
•
Non-Complete Response/Non-Progressive Disease: Persistence of 1 or more non-target 
lesion(s) and/or maintenance of tumor marker level above the upper limits of normal.
•
Progressive Disease: Appearance of 1 or more new lesions or the unequivocal progression 
of existing non-target lesions. Although a clear progression of non-target lesions is 
exceptional, in such circumstances, the opinion of the treating physician should prevail and 
the progression status should be confirmed at a later time.
9.4
Evaluation of Response
Time point response assessments will be performed every 9 weeks (timed to coincide with the 
end of a cycle) with a confirmatory assessment (required for non-randomized trials) within 9 
weeks after a PR or CR is deemed. To determine time point response, refer to Table 13 and 
below.
APPROVED RPCI Institutional Review Board: 10/17/2016


Roswell Park Cancer Institute Study Number:                                                                                               I 265514
PRIVATE AND CONFIDENTIAL INFORMATION OF ROSWELL PARK CANCER INSTITUTE
02.16.16
Page 56 of 90
Table 13
Time Point Response Criteria (+/- non-target disease)
Target Lesions
Non-Target Lesions
New Lesions
Overall Response
CR
CR
No
CR
CR
Non-CR/Non-PD
No
PR
CR
Not evaluated
No
PR
PR
Non-PD or not all evaluated
No
PR
SD
Non-PD or not all evaluated
No
SD
Not all evaluated
Non-PD
No
NE
PD
Any
Yes or No
PD
Any
PD
Yes or No
PD
Any
Any
Yes
PD
Table 14
Time Point Response Criteria (non-target disease only)
Non-Target Lesions
New Lesions
Overall Response
CR
No
CR
Non-CR/non-PD
No
Non-CR/non-PD1
Not all evaluated
No
NE
Unequivocal PD
Yes or No
PD
Any
Yes
PD
1
Non-CR/non-PD is preferred over SD for non-target disease since SD is used as endpoint for assessment of 
efficacy in trials so to assign this category when no lesions can be measured is not advised.
The best overall response is the best response recorded from the start of study treatment until 
patients are removed from the study for any reason (the end of treatment taking into account any 
requirement for confirmation). In general, the participant’s best response assignment will depend 
on the achievement of both measurement and confirmation criteria and will be determined by 
combining the participant’s status of target lesions, non-target lesions, and new lesions.
•
Residual Disease: Provide the appropriate information that pertains to this study.
•
Symptomatic Deterioration: Participants with global deterioration of health status requiring 
discontinuation of treatment without objective evidence of disease progression at that time, 
and not related to study treatment or other medical conditions should be reported as 
progressive disease due to “symptomatic deterioration.” Every effort should be made to 
document objective progression even after discontinuation of treatment due to symptomatic 
deterioration. Symptomatic deterioration that may lead to discontinuation of treatment 
include, but is not limited to, symptoms such as:
•
Weight loss > 10% of body weight.
•
Worsening 
of 
disease-related 
symptoms 
(e.g., worsening 
dyspnea, 
increasing 
pain/increasing requirement for narcotic analgesics).
•
Decline in performance status of > 1 level on ECOG scale.
APPROVED RPCI Institutional Review Board: 10/17/2016


Roswell Park Cancer Institute Study Number:                                                                                               I 265514
PRIVATE AND CONFIDENTIAL INFORMATION OF ROSWELL PARK CANCER INSTITUTE
02.16.16
Page 57 of 90
9.5
Confirmation Measurement
Response will be confirmed within 9 weeks.
9.6
Guidelines for Evaluation of Measurable Disease
All measurements should be taken and recorded in metric notation using a ruler or calipers. All 
baseline evaluations should be performed as closely as possible to the beginning of treatment and 
never more than 4 weeks before the beginning of the treatment.
The same method of assessment and the same technique should be used to characterize each 
identified and reported lesion at baseline and during follow-up. Imaging-based evaluation is 
preferred to evaluation by clinical examination unless the lesion(s) being followed cannot be 
imaged but are assessable by clinical exam.
•
Clinical Lesions: Clinical lesions will only be considered measurable when they are 
superficial (e.g., skin nodules and palpable lymph nodes) and ≥ 10 mm diameter as assessed 
using calipers (e.g., skin nodules). In the case of skin lesions, documentation by color 
photography, including a ruler to estimate the size of the lesion, is recommended.
•
Chest x-ray: Lesions on chest x-ray are acceptable as measurable lesions when they are 
clearly defined and surrounded by aerated lung. However, CT is preferable.
•
Conventional CT and MRI: This guideline has defined measurability of lesions on CT scan 
based on the assumption that CT slice thickness is 5 mm or less. If CT scans have slice 
thickness greater than 5 mm, the minimum size for a measurable lesion should be twice the 
slice thickness. MRI is also acceptable in certain situations (e.g., for body scans).
Use of MRI remains a complex issue. MRI has excellent contrast, spatial, and temporal 
resolution; however, there are many image acquisition variables involved in MRI, which greatly 
impact image quality, lesion conspicuity, and measurement. Furthermore, the availability of MRI 
is variable globally. As with CT, if an MRI is performed, the technical specifications of the 
scanning sequences used should be optimized for the evaluation of the type and site of disease. 
Furthermore, as with CT, the modality used at follow-up should be the same as was used at 
baseline and the lesions should be measured/assessed on the same pulse sequence. It is beyond 
the scope of the RECIST guidelines to prescribe specific MRI pulse sequence parameters for all 
scanners, body parts, and diseases. Ideally, the same type of scanner should be used and the 
image acquisition protocol should be followed as closely as possible to prior scans. Body scans 
should be performed with breath-hold scanning techniques, if possible.
•
PET-CT: At present, the low dose or attenuation correction CT portion of a combined PET-
CT is not always of optimal diagnostic CT quality for use with RECIST measurements. 
However, if the site can document that the CT performed as part of a PET-CT is of identical 
diagnostic quality to a diagnostic CT (with IV and oral contrast), then the CT portion of the 
PET-CT can be used for RECIST measurements and can be used interchangeably with 
conventional CT in accurately measuring cancer lesions over time. Note, however, that the 
PET portion of the CT introduces additional data which may bias an investigator if it is not 
routinely or serially performed.
APPROVED RPCI Institutional Review Board: 10/17/2016


Roswell Park Cancer Institute Study Number:                                                                                               I 265514
PRIVATE AND CONFIDENTIAL INFORMATION OF ROSWELL PARK CANCER INSTITUTE
02.16.16
Page 58 of 90
•
Ultrasound: Ultrasound is not useful in assessment of lesion size and should not be used as a 
method of measurement. Ultrasound examinations cannot be reproduced in their entirety for 
independent review at a later date and, because they are operator dependent, it cannot be 
guaranteed that the same technique and measurements will be taken from one assessment to 
the next. If new lesions are identified by ultrasound in the course of the study, confirmation 
by CT or MRI is advised. If there is concern about radiation exposure at CT, MRI may be 
used instead of CT in selected instances.
•
Endoscopy, Laparoscopy: The utilization of these techniques for objective tumor evaluation 
is not advised. However, such techniques may be useful to confirm complete pathological 
response when biopsies are obtained or to determine relapse in trials where recurrence 
following complete response (CR) or surgical resection is an endpoint.
•
Tumor Markers: Tumor markers alone cannot be used to assess response. If markers are 
initially above the upper normal limit, they must normalize for a participant to be considered 
in complete clinical response.
•
Cytology, Histology: These techniques can be used to differentiate between partial responses 
(PR) and complete responses (CR) in rare cases (e.g., residual lesions in tumor types, such as 
germ cell tumors, where known residual benign tumors can remain).
The cytological confirmation of the neoplastic origin of any effusion that appears or worsens 
during treatment when the measurable tumor has met criteria for response or stable disease is 
mandatory to differentiate between response or stable disease (an effusion may be a side effect of 
the treatment) and progressive disease.
•
FDG-PET: While FDG-PET response assessments need additional study, it is sometimes 
reasonable to incorporate the use of FDG-PET scanning to complement CT scanning in 
assessment of progression (particularly possible 'new' disease). New lesions on the basis of 
FDG PET imaging can be identified according to the following algorithm:
•
Negative FDG-PET at baseline, with a positive FDG-PET at follow-up is a sign of PD based 
on a new lesion.
•
No FDG-PET at baseline and a positive FDG-PET at follow-up: If the positive FDG-PET at 
follow-up corresponds to a new site of disease confirmed by CT, this is PD. If the positive 
FDG-PET at follow-up is not confirmed as a new site of disease on CT, additional follow-up 
CT scans are needed to determine if there is truly progression occurring at that site (if so, the 
date of PD will be the date of the initial abnormal FDG-PET scan). If the positive FDG-PET 
at follow-up corresponds to a pre-existing site of disease on CT that is not progressing on the 
basis of the anatomic images, this is not PD.
•
FDG-PET may be used to upgrade a response to a CR in a manner similar to a biopsy in 
cases where a residual radiographic abnormality is thought to represent fibrosis or scarring. 
The use of FDG-PET in this circumstance should be prospectively described in the protocol 
and supported by disease-specific medical literature for the indication. However, it must be 
acknowledged that both approaches may lead to false positive CR due to limitations of FDG-
PET and biopsy resolution/sensitivity.
APPROVED RPCI Institutional Review Board: 10/17/2016


Roswell Park Cancer Institute Study Number:                                                                                               I 265514
PRIVATE AND CONFIDENTIAL INFORMATION OF ROSWELL PARK CANCER INSTITUTE
02.16.16
Page 59 of 90
Note: A ‘positive’ FDG-PET scan lesion means one which is FDG avid with an uptake greater 
than twice that of the surrounding tissue on the attenuation corrected image.
10
SAFETY EVALUATION
10.1 Adverse Events
10.1.1 Definition
An adverse event or adverse experience (AE) is defined as any untoward medical occurrence 
(including an exacerbation of a pre-existing condition) associated with the use of a drug in 
humans, whether or not considered drug related (i.e., the event does not necessarily have to have 
a causal relationship with the treatment). Therefore, an AE can be ANY unfavorable and 
unintended sign (including an abnormal laboratory finding), symptom, or disease temporally 
associated with the use of a medicinal (investigational) product, whether or not considered 
related to the medicinal (investigational) product (attribution of ‘unrelated’, ‘unlikely’, 
‘possible’, ‘probable’, or ‘definite’). In addition, each study site will also be responsible for 
reporting causality of AEs to Boehringer Ingelheim as per Section 10.2.1).
An AE is considered “unexpected” if it is not listed in the investigator brochure or is not listed at 
the specificity or severity that has been observed; or if an investigator brochure is not required or 
available, is not consistent with the risk information described in the general investigational plan 
in other study-related documents.
10.1.1.1 Diagnosis Versus Signs and Symptoms
If known, a diagnosis should be recorded on the CRF rather than individual signs and symptoms 
(e.g., record only liver failure or hepatitis rather than jaundice, asterixis, and elevated 
transaminases). However, if a constellation of signs and/or symptoms cannot be clinically 
characterized as a single diagnosis or syndrome at the time of reporting, each individual event 
should be recorded as an AE or SAE on the CRF. If a diagnosis is subsequently established, it 
should be reported as follow-up information.
10.1.1.2 Adverse Events Occurring Secondary to Other Events
In general, AEs occurring secondary to other events (e.g., cascade events or clinical sequelae) 
should be identified by their primary cause. For example, if severe diarrhea is known to have 
resulted in dehydration, it is sufficient to record only diarrhea as an AE or SAE on the CRF.
However, clinically significant AEs occurring secondary to an initiating event that are separated 
in time should be recorded as independent events on the CRF. For example, if a severe 
gastrointestinal hemorrhage leads to renal failure, both events should be recorded separately on 
the CRF.
10.1.1.3 Abnormal Laboratory Values
Only clinically significant laboratory abnormalities that require active management will be 
recorded as AEs or SAEs on the CRF (e.g., abnormalities that require study drug dose 
APPROVED RPCI Institutional Review Board: 10/17/2016


Roswell Park Cancer Institute Study Number:                                                                                               I 265514
PRIVATE AND CONFIDENTIAL INFORMATION OF ROSWELL PARK CANCER INSTITUTE
02.16.16
Page 60 of 90
modification, discontinuation of study treatment, more frequent follow-up assessments, further 
diagnostic investigation, etc.).
If the clinically significant laboratory abnormality is a sign of a disease or syndrome 
(e.g., alkaline phosphatase and bilirubin 5 x the upper limit of normal associated with 
cholecystitis), only the diagnosis (e.g., cholecystitis) needs to be recorded on the Adverse Event 
CRF.
If the clinically significant laboratory abnormality is not a sign of a disease or syndrome, the 
abnormality itself should be recorded as an AE or SAE on the CRF. If the laboratory abnormality 
can be characterized by a precise clinical term, the clinical term should be recorded as the AE or 
SAE. For example, an elevated serum potassium level of 7 mEq/L should be recorded as 
“hyperkalemia”
Observations of the same clinically significant laboratory abnormality from visit to visit should 
not be repeatedly recorded as AEs or SAEs on the CRF, unless their severity, seriousness, or 
etiology changes.
10.1.1.4 Preexisting Medical Conditions (Baseline Conditions)
A preexisting medical condition should be recorded as an AE or SAE only if the frequency, 
severity, or character of the condition worsens during the study. When recording such events on 
an Adverse Event CRF, it is important to convey the concept that the preexisting condition has 
changed by including applicable descriptors (e.g., “more frequent headaches”).
10.1.1.5 Vital Signs, ECG and Physical Examination Results
Changes in vital signs, ECG and physical examination test results will be recorded as an AE in 
the CRF, if they are judged clinically relevant by the investigator.
10.2 Adverse Events of Special Interests (AESI)
The following events are considered as Protocol-specified events of special interests:
•
Any gastrointestinal and non-gastrointestinal perforation, leakage, fistula 
formation, or abscess.
In such cases the following additional information will need to be collected, documented in 
the respective comment field of the CRF page and the respective narratives of the SAE, and 
be forwarded to Boehringer Ingelheim:
o
Location of perforation, leakage, fistula, abscess
o
Location/extent of abdominal tumor manifestations
o
Imaging & reports (CT, ultrasound, endoscopy, pathology, etc.)
o
Prior surgery (location, wound healing complications)
o
Concomitant diseases with GI involvement (e.g., M Crohn, vasculitis, tuberculosis, 
diverticulitis)
APPROVED RPCI Institutional Review Board: 10/17/2016


Roswell Park Cancer Institute Study Number:                                                                                               I 265514
PRIVATE AND CONFIDENTIAL INFORMATION OF ROSWELL PARK CANCER INSTITUTE
02.16.16
Page 61 of 90
o
Thromboembolic events (or predisposition)
•
Drug-induced liver injury.
Drug-induced liver injury is under constant surveillance by sponsors and regulators and is 
considered a protocol-specified adverse event of special interest (AESI). Timely detection, 
evaluation, and follow-up of laboratory alterations of selected liver laboratory parameters to 
distinguish an effect of the investigational drug from other causes are important for patient 
safety and for the medical and scientific interpretation of the finding.
The following are considered as protocol-specified AESI:
o
An elevation of ALT and / or AST > 5x ULN without bilirubin elevation measured in 
the same blood draw sample
o
An elevation of AST and/or ALT > 2.5 fold ULN combined with an elevation of 
bilirubin to > 1.5 fold ULN measured in the same blood draw sample
Patients showing the above laboratory abnormalities need to be followed up until the 
protocol specific retreatment criteria have been met and according to Appendix C 
[Boehringer Ingelheim: Procedures for the follow-up of drug-induced liver injury (DILI)].
Protocol-specified AESI are to be reported to Boehringer Ingelheim an expedited manner similar 
to Serious Adverse Events (Section 10.4), even if they do not meet any of the seriousness 
criteria.
10.2.1 Grading and Relationship to Drug
The descriptions and grading scales found in the CTEP Version 4 of the NCI Common 
Terminology Criteria for Adverse Events (CTCAE) will be utilized for AE reporting. CTEP
Version 4 of the CTCAE is identified and located at:
http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm.
AEs not covered by specific terminology listed should be reported with common medical 
terminology, and documented according to the grading scales provided in the CTCAE Version 4.
The relationship of event to study drug will be documented by the Investigator as follows:
•
Unrelated: The event is clearly related to other factors such as the participant’s clinical state, 
other therapeutic interventions or concomitant drugs administered to the participant.
•
Unlikely: The event is doubtfully related to investigational agent(s). The event was most 
likely related to other factors such as the participant’s clinical state, other therapeutic 
interventions, or concomitant drugs.
•
Possible: The event follows a reasonable temporal sequence from the time of drug 
administration, but could have been produced by other factors such as the participant’s 
clinical state, other therapeutic interventions or concomitant drugs.
•
Probable: The event follows a reasonable temporal sequence from the time of drug 
administration, and follows a known response pattern to the study drug. The event cannot be 
APPROVED RPCI Institutional Review Board: 10/17/2016


Roswell Park Cancer Institute Study Number:                                                                                               I 265514
PRIVATE AND CONFIDENTIAL INFORMATION OF ROSWELL PARK CANCER INSTITUTE
02.16.16
Page 62 of 90
reasonably explained by other factors such as the participant’s clinical state, therapeutic 
interventions or concomitant drugs.
•
Definite: The event follows a reasonable temporal sequence from the time of drug 
administration, follows a known response pattern to the study drug, cannot be reasonably 
explained by other factors such as the participant’s condition, therapeutic interventions or 
concomitant drugs; AND occurs immediately following study drug administration, improves 
upon stopping the drug, or reappears on re-exposure.
Boehringer Ingelheim Reporting Requirements
•
The severity of the AE should be judged based on the following:
•
The severity of adverse events should be classified and recorded in the eCRF according 
to the Common Terminology Criteria for Adverse Events (CTCAE) CTEP Version 4 of 
the NCI CTCAE located at: 
http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm Causal 
relationship of adverse event
Medical judgment should be used to determine the relationship, considering all relevant factors, 
including pattern of reaction, temporal relationship, de-challenge or re-challenge, confounding 
factors such as concomitant medication, concomitant diseases and relevant history. Assessment 
of causal relationship must be recorded for each adverse event.
Causality will be reported as either “Yes” or “No”:
Yes:
There is a reasonable causal relationship between the investigational product 
administered and the AE (“Yes” is equivalent to: Possible, Probable or, Definite).
No:
There is no reasonable causal relationship between the investigational product 
administered and the AE (“No” is equivalent to Unrelated or Unlikely).
10.2.2 Reporting Adverse Events
Table 15
Guidelines for Routine Adverse Event Reporting for Phase 1 Studies 
(Regardless of Expectedness)
Attribution
Grade 1
Grade 2
Grade 3
Grade 4
Unrelated
X
X
X
X
Unlikely
X
X
X
X
Possible
X
X
X
X
Probable
X
X
X
X
Definite
X
X
X
X


Roswell Park Cancer Institute Study Number:                                                                                               I 265514
PRIVATE AND CONFIDENTIAL INFORMATION OF ROSWELL PARK CANCER INSTITUTE
02.16.16
Page 63 of 90
Table 16
Guidelines for Routine Adverse Event Reporting Phase 2 Studies (Regardless 
of Expectedness)
Attribution
Grade 1
Grade 2
Grade 3
Grade 4
Unrelated
X
X
Unlikely
X
X
Possible
X
X
X
X
Probable
X
X
X
X
Definite
X
X
X
X
Routine AEs occurring from the date the participant signs the study consent until 30 days after 
the last intervention or until the event has resolved, the study participant is lost to follow-up, the 
start of a new treatment, or until the study investigator assesses the event(s) as stable or 
irreversible, will be reported. New information will be reported after it is received.
10.3 Serious Adverse Events
10.3.1 Definition
A serious adverse event (SAE) is any adverse event (experience) that in the opinion of either the 
investigator or sponsor results in ANY of the following:
•
Death.
•
A life-threatening adverse event (experience). Any AE that places a participant or 
participants, in the view of the Investigator or sponsor, at immediate risk of death from the 
reaction as it occurred. It does NOT include an AE that, had it occurred in a more severe 
form, might have caused death.
•
Inpatient hospitalization or prolongation of existing hospitalization (for > 24 hours).
•
A persistent or significant disability/incapacity or substantial disruption of the ability to 
conduct normal life functions.
•
A congenital anomaly or birth defect.
•
Important Medical Event (IME) that, based upon medical judgment, may jeopardize the 
participant and may require medical or surgical intervention to prevent one of the outcomes 
listed above.
Patients may be hospitalized for administrative or social reasons during the trial (e.g. days on 
which infusion takes place, long distance from home to site). These and other hospitalizations 
planned at the beginning of the trial do not need to be reported as an SAE.
10.3.2 Reporting Serious Adverse Events
All new SAEs occurring from the date the participant signs the study consent until 30 days after 
the last intervention or a new treatment is started, whichever comes first, will be reported. The 
RPCI SAE Source Form is to be completed with all available information, including a brief 
narrative describing the SAE and any other relevant information. 


Roswell Park Cancer Institute Study Number:                                                                                               I 265514
PRIVATE AND CONFIDENTIAL INFORMATION OF ROSWELL PARK CANCER INSTITUTE
02.16.16
Page 64 of 90
SAEs occurring after the 30 day follow-up period that the investigator determines to be possibly, 
probably or definitely related to the study intervention should be reported.
SAEs identified as an Unanticipated Problem by the Investigator must be reported. Please refer 
to Section 10.6 for details on reporting Unanticipated Problems.
10.4 Investigator Reporting: Notifying Boehringer Ingelheim (BI) and NCCN
The principle investigator at each respective site will report all SAEs and non-serious AEs which 
are relevant to a reported SAEs and AESIs by fax using a MEDWATCH 3500A form with the 
completed BI FAX Cover Sheet to BI Unique Entry Point and NCCN, as detailed below in 
accordance with the following timelines:
•
Within 5 calendar days upon receipt of initial and follow-up SAEs containing at least one 
fatal or immediately life-threatening event.
•
Within 10 calendar days upon receipt of any other initial and follow-up SAEs.
Boehringer Ingelheim Pharmaceuticals, Inc.
900 Ridgebury Road
Ridgefield, CT  06877
Fax: 1-203-837-4329
AND
NCCN at
ORPReports@nccn.org
Or
Fax: (215) 358-7699
For each adverse event, the investigator will provide the onset date, end date, intensity, treatment 
required, outcome, seriousness, and action taken with the investigational drug. The investigator 
will determine the relationship and expectedness with the investigational drug to all AEs as 
defined in the listed adverse event section of Boehringer Ingelheim’s (BI’s) Investigator 
Brochure for the Product.
The investigator does not need to actively monitor patients for adverse events once the clinical 
trial has ended. However, if the investigator becomes aware of an SAE(s) that occurred after the 
patient has completed the clinical trial (including any protocol specified follow-up period), it 
should be reported to BI if considered relevant by the investigator.
10.5 Follow-Up for Serious Adverse Events
All related SAEs should be followed to their resolution, until the study participant is lost to 
follow-up, the start of a new treatment, or until the study investigator assesses the event(s) as 
stable or irreversible. New information will be reported when it is received.
APPROVED RPCI Institutional Review Board: 10/17/2016


Roswell Park Cancer Institute Study Number:                                                                                               I 265514
PRIVATE AND CONFIDENTIAL INFORMATION OF ROSWELL PARK CANCER INSTITUTE
02.16.16
Page 65 of 90
10.6 Unanticipated Problems
10.6.1 Definition
An Unanticipated Problem (UP) is any incident, experience, or outcome that meets all of the 
following criteria:
•
Unexpected (in terms of nature, severity, or frequency) given:
a) The research procedures that are described in the study-related documents, including 
study deviations, as well as issues related to compromise of participant privacy or 
confidentiality of data.
b) The characteristics of the participant population being studied.
•
Related or possibly related to participation in the research (possibly related means there is a 
reasonable possibility that the incident, experience, or outcome may have been caused by the 
procedures involved in the research).
•
Suggests that the research places participants or others at a greater risk of harm (including 
physical, psychological, economic, or social harm) than was previously known or recognized 
and if in relation to an AE is also deemed Serious per Section 10.3.
10.6.2 Reporting Unanticipated Problems
Unanticipated problem reporting will begin at the time of participant consent. The Unanticipated 
Problem Form will be submitted to the CRS Compliance Office within 1 business day of 
becoming aware of the Unanticipated Problem.
When becoming aware of new information about an Unanticipated Problem, submit the updated 
information to CRS Compliance with an updated Unanticipated Problem Form. The site 
Investigator or designated research personnel will report all unanticipated problems, whether 
related or unrelated to the investigational agent(s) to the IRB in accordance with their local 
institutional guidelines.
10.7 FDA Reporting
When RPCI is the IND holder the following describes the FDA reporting requirements by 
timeline for AEs and new safety findings that meet the criteria outlined below:
Within 7 Calendar Days
Any adverse event that meets ALL the following criteria:
•
Related or possibly related to the use of the study drug;
•
Unexpected; and
•
Fatal or life-threatening.
APPROVED RPCI Institutional Review Board: 10/17/2016


Roswell Park Cancer Institute Study Number:                                                                                               I 265514
PRIVATE AND CONFIDENTIAL INFORMATION OF ROSWELL PARK CANCER INSTITUTE
02.16.16
Page 66 of 90
Within 15 Calendar Days
Any adverse event that meets ALL the following criteria:
•
Related or possibly related to the use of the study drug;
•
Unexpected; and
•
Serious but not fatal or life-threatening;
Or, meets ANY of the following criteria:
•
A previous adverse event that is not initially deemed reportable but is later found to fit the 
criteria for reporting (report within 15 days from when event was deemed reportable).
•
Any findings from other studies, including epidemiological studies, pooled analysis of 
multiple studies, or other clinical studies conducted with the study drug that suggest a 
significant risk in humans exposed to the drug.
•
Any findings from animal or in vitro testing that suggest a significant risk for human 
participants including reports of mutagenicity, teratogenicity, or carcinogenicity or reports of 
significant organ toxicity at or near the expected human exposure.
•
Any clinically important increase in the rate of occurrence of a serious, related or possibly 
related adverse event over that listed in the protocol or investigator brochure.
Sponsors are also required to identify in IND safety reports, all previous reports concerning 
similar adverse events and to analyze the significance of the current event in the light of the 
previous reports.
Reporting Process
The principal investigator or designee will complete and submit a FDA Form 3500A MedWatch 
for any event that meets the above criteria. Forms will be submitted to the CRS Compliance 
Office via email to CRSCompliance@RoswellPark.org. Network Sites refer to Appendix A.
11 DATA AND SAFETY MONITORING
Phase 1 studies will be reviewed at the scheduled RPCI Phase 1 meetings and the minutes are 
forwarded to the IRB for review. Phase I meets on a regular basis per the RPCI Data Safety 
Monitoring Plan.
The RPCI Data and Safety Monitoring Board will assess the progress of the study, the safety 
data, and critical efficacy endpoints. The DSMB will review the study annually and will make 
recommendations that include but not limited to; (a) continuation of the study, (b) modifications 
to the design (c) or termination of the study. Per request, all annual DSMB study outcomes will 
be made available to NCCN and BI.
12 STATISTICAL METHODOLOGY
This is a Phase I/II study. The Phase 1 is included to compensate for the current lack of toxicity 
information about nintedanib and capecitabine combination treatment. A standard 3+3 dose 
escalation design is considered, where a maximum of 18 patients are enrolled.
APPROVED RPCI Institutional Review Board: 10/17/2016


Roswell Park Cancer Institute Study Number:                                                                                               I 265514
PRIVATE AND CONFIDENTIAL INFORMATION OF ROSWELL PARK CANCER INSTITUTE
02.16.16
Page 67 of 90
Phase II is a single arm – single stage study, where a total of n=36 (including 6 treated at the 
RP2D in Phase I) patients with refractory metastatic colorectal cancer will be enrolled and 
treated with a combination of nintedanib and capecitabine, as previously outlined. There is no 
formal interim analysis planned or early stopping rules. However, toxicity and safety outcomes 
will be regularly reviewed.
Endpoints
•
Phase I 
o
Primary: Establishment of the recommended phase II dose.
•
Phase II
o
Primary: The primary endpoint is the progression free survival (PFS) at 18 weeks. 
This will be assessed via the Response Evaluation Criteria in Solid Tumors (RECIST) 
version 1.1 guidelines after every 3 cycles (9 weeks) of therapy.
o
Secondary: Median progression free survival will be established. Median overall 
survival from the date of enrollment to the time of death will be documented. 
Aggregate rates of adverse events as measured by CTCAE v 4.0 will be recorded to 
objectively measure toxicities of the two agents.
The primary objectives of this study are:
o
Phase I: To estimate the maximum tolerated dose (MTD) and examine the dose-
limiting toxicities of nintedanib when administered with capecitabine within the study 
population and, establish the Recommended Phase II Dose (RP2D).
o
Phase II: To assess progression free survival at 18 weeks. This will be assessed via 
the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 guidelines 
after every 3 cycles (9 weeks) of therapy.
12.1 Sample Size Determination
A maximum of 48 participants, 18 in Phase I and up to 30 additional patients for Phase II will be 
enrolled in this study. The number of participants required is a function of the unknown dose-
limiting toxicity relationship and 18-week PFS rate. Accrual is expected to take 2 years.
Sample Size Justification: 
In Phase I, using the standard 3+3 design, there will be a minimum of 9 and maximum of 
18 patients enrolled.
In Phase II, the sample size calculations are based on the primary analysis of the 18-week PFS 
rate. Historically, the 18-week PFS rate is 5% and 25% for refractory metastatic colorectal 
cancer patients treated with placebo and regorafenib, respectively. The combination of 
nintedanib and capecitabine is expected to provide an 18-week PFS of at least 40% in patients 
with refractory metastatic colorectal cancer. The sample size calculation is based on testing 
hypotheses concerning the proportion of the treated population alive and progression free 
18 weeks after enrollment. Let p represent the proportion of patients surviving with no evidence 
APPROVED RPCI Institutional Review Board: 10/17/2016


Roswell Park Cancer Institute Study Number:                                                                                               I 265514
PRIVATE AND CONFIDENTIAL INFORMATION OF ROSWELL PARK CANCER INSTITUTE
02.16.16
Page 68 of 90
of disease progression by RECIST at 18 weeks after start of treatment. A true PFS rate of less 
than p0 = 0.25 is considered unacceptable and evidence of such will deem the treatment not 
worthy of further study, as regorafenib has historically achieved this success rate. The null and 
alternative hypotheses to be tested are H0: p = p0 versus H1: p > p0.
This single-stage design requires a total of 36 evaluable patients to achieve approximately 
 
  
power to detect a difference of at least Δ percentage points (p0 versus p0 + Δ). For calculations in 
this study, p0 = 0.25, α = 0.10, 1 - β = 0.80 and Δ = 0.17. With these design parameters, the 
sample size was calculated using PASS v11 (38).
12.2 Demographics and Baseline Characteristics
Descriptive statistics (as appropriate: n, percent, mean, median, min and max) will be used to 
summarize demographic and baseline characteristics.
12.3 Efficacy Analysis
Objective tumor response will be tabulated overall (and by dose level if appropriate). Only 
participants who have completed at least 2 cycles will be evaluable for response.
Primary Analysis: 
The Phase I portion of the study begins by enrolling 3 patients at Dose Level 1 (see Table 2). 
Standard 3+3 rules will be followed until the maximum tolerated (or administered) dose is found. 
The recommended Phase 2 dose will be considered tolerable if DLT(s) are observed in at most 1 
of 6 patients completing at least 2 treatment cycles at that dose level. Available toxicity 
information about these drugs suggests that Dose Level 2 will be the recommended Phase 2 dose, 
and that 9 patients will be required for the Phase 1. The 6 Phase 1 patients treated at the 
recommended Phase 2 dose will be included in Stage 1 of the Phase 2 study.
The Phase 2 study’s primary endpoint is the PFS rate, defined as the proportion of patients who 
survive without disease progression (per RECIST criteria) for least 18-weeks after the start of 
treatment. Patients who progress or die (due to disease or any cause) prior to 18-weeks will be 
counted as failures.
The following hypothesis about the true 18-week PFS rate (p) will be evaluated using a one-
sided exact binomial test: 
H0: p = 0.25 versus H1: p > 0.25.
If 
 or fewer PFS responses are observed among the total 
 evaluable patients, the 
  	

  
	  
therapy will be deemed ineffective; otherwise, it will be concluded that the therapy is promising. 
The analysis will be conducted in SAS v9.4 (Cary, NC) at a nominal significance level of 
α=0.10.
Secondary Analysis: In Phase II the secondary outcomes include: overall (OS) and progression 
free (PFS) survival, and toxicities. A survival event is defined as a patient who experiences death 
from cancer or any cause, while a patient is considered censored if they are alive at the end of the 
APPROVED RPCI Institutional Review Board: 10/17/2016


Roswell Park Cancer Institute Study Number:                                                                                               I 265514
PRIVATE AND CONFIDENTIAL INFORMATION OF ROSWELL PARK CANCER INSTITUTE
02.16.16
Page 69 of 90
study or at last visit before being lost to follow-up. The survival time is defined as the time from 
treatment until the survival event or censoring. The PFS will be as defined in the primary 
analysis. The OS and PFS are considered bivariate time-to-event data, and will be summarized 
using standard Kaplan-Meier methods. Estimates of median OS and PFS will be obtained with 
corresponding 90% confidence intervals. If the true median OS or PFS with the new treatment is 
10.2 or 3.0 months, a 60% improvement over historical controls (6.4 and 1.9 month median OS 
and PFS, respectively); then Phase II estimates of the median will have interval widths of 
approximately 9.9 or 3.2 months for OS and PFS, receptively. The observed toxicities and 
adverse events will be reported as frequencies and relative frequencies, with toxicity rates 
estimated by 90% Wilson confidence intervals. If the true overall toxicity or adverse event rate is 
0.10 to 0.50; then Phase II estimates of these rates will have interval widths of approximately 
0.17 to 0.26.
12.4 Safety Analysis
DLTs are the primary endpoint of this study and are used in the estimation of the MTD and the 
accompanying of the dose escalation decisions. However, no formal analyses of DLTs are 
planned. Participants who do not have a DLT and who do not complete a full cycle of treatment 
will be considered non-evaluable for DLT.
12.4.1 Adverse Event
The frequency of toxicities will be tabulated by grade across all dose levels and cycles. The 
frequency of toxicities will also be tabulated for the dose estimated to be the MTD. All 
participants who receive any study treatment will be considered evaluable for toxicity.
12.5 Interim Analysis and Criteria for Early Termination of the Study
The first portion of this study is a Phase 1 study and as such will be monitored and discussed by 
RPCI’s Phase 1 Committee, which meets on a regular basis per the RPCI Data Safety Monitoring 
Plan. Drug safety will be monitored and evaluated continuously throughout the study including 
30 day safety follow-up period by obtaining, reviewing and analyzing data on AEs, changes in 
laboratory values, vital signs, electrocardiograms (ECGs), and physical examination findings. 
Potential early termination decisions are an inherent part of the Phase 1 study monitoring.
There is no formal interim analysis planned or early termination criteria for the Phase II study. 
However, toxicity and safety outcomes will be regularly reviewed.
12.6 Pharmacokinetic or Pharmacokinetic/Pharmacodynamic Analysis
PK/PD Modeling:
A mechanistic PK/PD model will be developed to characterize the time course of nintedanib 
concentrations in relation to target decreases in sVEGFR-2 and FGF23. Subsequently, diagnostic 
plots will be created to ascertain whether a trend exists among sVEGFR-2 levels, FGF23, and 
progression free survival (PFS). If trends exist, these endpoints will also be included in the 
PK/PD model. A variety of compartmental population PK models will be evaluated using a 
nonlinear mixed effects modeling approach. The PK models explored will be described by the 
APPROVED RPCI Institutional Review Board: 10/17/2016


Roswell Park Cancer Institute Study Number:                                                                                               I 265514
PRIVATE AND CONFIDENTIAL INFORMATION OF ROSWELL PARK CANCER INSTITUTE
02.16.16
Page 70 of 90
estimation of mean structural parameters (e.g., plasma volumes of distribution and clearances), 
the magnitude of inter-individual variability (IIV) in these parameters, and residual variability 
(RV). The model for IIV will be assumed that the variance is proportional with respect to the 
typical value of the PK parameter. This analysis will include evaluation of the influence of a 
limited number of patient covariates, such as demographics along with other cofactors, on the 
variability in select PK/PD parameters. Based on our sparse sampling approach, prior 
information on PK parameters and variances can be used with a Bayesian estimation method.  
For comparisons of hierarchical models, the change in the minimum value of the objective 
function (MVOF), a statistic that is proportional to minus twice the log likelihood of the data, 
will be examined. A change in the MVOF of greater than 7.88 between two hierarchical models 
represents a statistical difference at a p-level of 0.005 for the addition of one parameter (df = 1). 
The goodness-of-fit analyses will be additionally assessed by: (1) scatterplots of measured 
concentrations and weighted residuals versus population predicted concentrations, and weighted 
residuals versus time since first and last dose; (2) scatterplots of measured concentrations, 
individual weighted residuals, and absolute individual weighted residuals versus individual 
predicted concentrations; (3) the precisions of the parameter estimates as measured by the 
percent standard error of the mean (%SEM = standard error/parameter estimate * 100% ); (4) 
changes in the estimates of IIV and RV; and (5) histograms, boxplots, and plots of quantiles of 
individual and population weighted residuals versus quantiles of the normal distribution (QQ 
plots).
13
ETHICAL AND REGULATORY STANDARDS
13.1 Ethical Principles
This study will not be initiated until the protocol and informed consent document(s) have been 
reviewed and approved by a properly constituted Institutional Review Board (IRB) or 
Independent Ethics Committee (IEC) at each investigational site. Each participant (or legal 
guardian) shall read, understand, and sign an instrument of informed consent prior to 
performance of any study-specific procedure. It is the responsibility of the investigator to ensure 
that the participant is made aware of the investigational nature of the treatment and that informed 
consent is given.
The Investigator is responsible for the retention of the participant log and participant records; 
although personal information may be reviewed by authorized persons, that information will be 
treated as strictly confidential and will not be made publicly available. The investigator is also 
responsible for obtaining participant authorization to access medical records and other applicable 
study specific information according to Health Insurance Portability and Accountability Act 
regulations (where applicable).
This study will be conducted in compliance with all applicable laws and regulations of the state 
and/or country and institution where the participant is treated, in accordance with the Declaration 
of Helsinki, Good Clinical Practice, and according to the guidelines in this protocol, including 
attached appendices.
APPROVED RPCI Institutional Review Board: 10/17/2016


Roswell Park Cancer Institute Study Number:                                                                                               I 265514
PRIVATE AND CONFIDENTIAL INFORMATION OF ROSWELL PARK CANCER INSTITUTE
02.16.16
Page 71 of 90
13.2 Informed Consent
The Investigator (or IRB specified designee) is responsible for obtaining written consent from 
each participant or the participant's legally authorized representative in accordance with ICH-
GCP guidelines using the approved informed consent form, before any study specific procedures 
(including screening procedures) are performed. The informed consent form acknowledges all 
information that must be given to the participant according to ICH-GCP, including the purpose 
and nature of the study, the expected efficacy and possible side effects of the treatment(s), and 
specifying that refusal to participate will not influence further options for therapy. Any additional 
information that is applicable to the study must also be included. Additional national or 
institutionally mandated requirements for informed consent must also be adhered to. The 
participant should also be made aware that by signing the consent form, processing of sensitive 
clinical trial data and transfer to other countries for further processing is allowed.
The Investigator shall provide a copy of the signed consent form to the participant and the signed 
original shall be maintained in the Investigator File. A copy of the signed consent form must be 
filed in the participant file. At any stage, the participant may withdraw from the study and such a 
decision will not affect any further treatment options.
14
STUDY RESPONSIBILITIES
14.1 Data Collection
Data entry into the database is to be completed in a timely fashion (within 30 days) after the 
participant’s clinic visit. If an AE is considered serious it is captured on both the Adverse Event 
page and the Serious Adverse Event Source Form, which is handled in an expedited fashion.
Data management activities will be performed using eClinical. eClinical is a suite of software 
tools that enables the collection, cleaning and viewing of clinical trial data. CRS data 
management will design the study-specific database and facilitate its development by the 
eClinical Information Technology team. Once the database design is approved by the 
Investigator, Statistician, and Clinical Research Coordinator, the database will be put into 
production and data entry can begin. Data can be entered and changed only by those with the 
rights to do so into the eCRFs (via the EXPeRT Module). eClinical is compliant with all relevant 
technical aspects of relevant GCP guidelines.
•
The system can generate accurate copies of stored data and audit trail information in human 
readable form.
•
System access is limited to authorized individuals through the controlled assignment of 
unique ID and password combinations.
•
The system is designed to periodically force users to change their passwords and verifies that 
user ID and password combinations remain unique.
•
The system automatically generates a permanent time-stamped audit trail of all user 
interactions.
When data entry is complete, data management will review the data and will query any missing, 
incomplete, or invalid data points for resolution by the Clinical Research Coordinator and 
APPROVED RPCI Institutional Review Board: 10/17/2016


Roswell Park Cancer Institute Study Number:                                                                                               I 265514
PRIVATE AND CONFIDENTIAL INFORMATION OF ROSWELL PARK CANCER INSTITUTE
02.16.16
Page 72 of 90
Investigator. Once all queries have been resolved, the data can be released to the statistician for 
analysis.
14.2 Maintenance of Study Documents
Essential documents will be retained per RPCI’s policy for 6 years from the study termination 
date. These documents could be retained for a longer period, however, if required by the 
applicable local regulatory requirements or by an agreement with RPCI.
15 ADMINISTRATIVE RULES
15.1 Revisions to the Protocol
RPCI may make such changes to the protocol as it deems necessary for safety reasons or as may 
be required by the U.S. FDA or other regulatory agencies. Revisions will be submitted to the 
IRB/ERC for written approval before implementation.
15.2 Termination of the Study
It is agreed that, for reasonable cause, either the RPCI Investigators or NCCN or Boehringer 
Ingelheim, may terminate this study, provided a written notice is submitted within the time 
period provided for in the Clinical Trial Agreement. In addition, RPCI may terminate the study 
at any time upon immediate notice if it believes termination is necessary for the safety of 
participants enrolled in the study.
15.3 Confidentiality
Any data, specimens, forms, reports, video recordings, and other records that leave the site will 
be identified only by a participant identification number (Participant ID, PID) to maintain 
confidentiality. All records will be kept in a limited access environment. All computer entry and 
networking programs will be done using PIDs only. Information will not be released without 
written authorization of the participant.
APPROVED RPCI Institutional Review Board: 10/17/2016


Roswell Park Cancer Institute Study Number:                                                                                               I 265514
PRIVATE AND CONFIDENTIAL INFORMATION OF ROSWELL PARK CANCER INSTITUTE
02.16.16
Page 73 of 90
16 APPENDICES


Roswell Park Cancer Institute Study Number:                                                                                               I 265514
PRIVATE AND CONFIDENTIAL INFORMATION OF ROSWELL PARK CANCER INSTITUTE
02.16.16
Page 74 of 90
Appendix A
Instructions for Network Sites
1.
CONTACT INFORMATION
All questions related to the protocol or study implementation should be directed to:
Roswell Park Cancer Institute
CRS Network Office
ASB K 104
Buffalo, New York 14263
Telephone:
Monday - Friday; 7: 00 AM to 4: 00 PM EST
716-845-8084
After hours, weekends, and holidays request the RPCI Investigator
716-845-2300
Fax: 716-845-8743
2.
INFORMED CONSENT
•
Informed consent must be obtained by the site Investigator/designee from any participants 
wishing to participate, prior to any research procedures or treatment.
•
An informed consent template is provided by RPCI and can be amended to reflect 
institutional requirements.
•
All consent changes must be reviewed by RPCI Network Office prior to submission to the 
site IRB.
•
The informed consent must be IRB approved.
•
Always check that the most up to date version of the IRB approved consent is being used.
•
Within 5 business days, notify the RPCI Network Office of all participant withdrawals or 
consent to limited study participation and appropriately document the discontinuation and the 
reason(s) why.
3.
PARTICIPANT REGISTRATION
The participant completes the Gender, Race, and Ethnicity Form and this is placed in the study 
binder.
RPCI does not grant exceptions to eligibility criteria.
Phase 1 Protocol Registration Instructions
Contact the RPCI Network Monitor to verify that a slot is available in the open cohort when a 
participant has been identified. Do not have the participant sign consent prior to verifying an 
open slot.
•
After the participant signs consent, the Subject Screening and Enrollment Log must be faxed 
or emailed to the RPCI Network Monitor within 1 business day. The RPCI Network Monitor 
APPROVED RPCI Institutional Review Board: 10/17/2016


Roswell Park Cancer Institute Study Number:                                                                                               I 265514
PRIVATE AND CONFIDENTIAL INFORMATION OF ROSWELL PARK CANCER INSTITUTE
02.16.16
Page 75 of 90
will confirm receipt of the Subject Screening and Enrollment Log and email the participant 
ID number.
•
When the participant has met eligibility, a signed eligibility checklist and other requested 
documentation will be faxed or emailed to the RPCI Network Monitor.
•
Within 1 business day of receipt of the eligibility check list, the RPCI Network Monitor will 
fax or email the cohort assignment and dose level.
•
An email must be sent by the site to confirm receipt of the cohort assignment and to provide 
the planned treatment start date.
Phase 2 Protocol Registration Instructions
The Subject Screening and Enrollment Log must be faxed or emailed to the RPCI Network 
Office within 1 business day of the date the participant is consented. Once the Investigator has 
determined that eligibility has been met, complete the eligibility check list and fax or email it to 
the RPCI Network Monitor at 716-845-8743.
4.
STUDY DEVIATIONS
•
If a deviation has occurred to eliminate hazard, this must be reported to the RPCI Network, 
site IRB and any other regulatory authority involved in the study.
•
ANY study deviation will be recorded on the Study Deviation Log.
•
Participants inadvertently enrolled with significant deviation(s) from the study-specified 
criteria will be removed from the study, at the discretion of the Principle Investigator.
5.
STUDY DOCUMENTATION
•
Study documents must be filled out completely and correctly. Ditto marks are not allowed.
•
If an entry has been documented in error put a single line through the entry and initial and 
date the change. The RPCI Network Monitor must be able to read what has been deleted.
•
Do NOT use white-out, magic marker, scratch-outs.
•
Do NOT erase entries.
•
Use only black ink for documentation on the accountability form and any other study forms.
•
It is the responsibility of RPCI to inform the Investigator/ institution as to when these 
documents no longer need to be retained. If, for any reason, the Investigator desires to no 
longer maintain the study records, they may be transferred to another institution, another 
investigator, or to RPCI upon written agreement between the Investigator and RPCI.
APPROVED RPCI Institutional Review Board: 10/17/2016


Roswell Park Cancer Institute Study Number:                                                                                               I 265514
PRIVATE AND CONFIDENTIAL INFORMATION OF ROSWELL PARK CANCER INSTITUTE
02.16.16
Page 76 of 90
6.
DRUG ACCOUNTABILITY
Drug accountability must be strictly maintained.
•
Responsibility rests solely with the Investigator but can be delegated as appropriate (e.g., to 
pharmacy personnel).
•
A drug accountability record form (DARF) will record quantities of study drug received, 
dispensed to participants and wasted, lot number, date dispensed, participant ID number and 
initials, quantity returned, balance remaining, manufacturer, expiration date, and the initials 
of the person dispensing the medication.
•
Study drug supply will only be used in accordance with the IRB approved study.
•
Drug accountability forms are protocol and agent specific, they are study source documents 
and will be used to verify compliance with the study.
•
An inventory count must be performed with each transaction. Any discrepancies shall be 
documented and explained.
•
Drug accountability forms must be stored with study related documents.
•
Each medication provided for this study and each dosage form and strength must have its 
own DARF.
•
Dispensing the wrong study supply is considered a medication error.
•
NEVER replace investigational agents with commercial product.
•
Do NOT “transfer”, “borrow” or “replace” supplies between studies.
7.
SERIOUS ADVERSE EVENT REPORTING
The site Investigator or designated research personnel will report all SAEs, whether related or 
unrelated to the investigational agent(s) to the IRB in accordance with their local institutional 
guidelines. The site will notify the RPCI Network Monitor within 1 business day of being made 
aware of the SAE. A preliminary written report must follow within 1 business day of the first 
notification using the following forms:
•
RPCI SAE Source form
•
MedWatch 3500A 
Boehringer Ingelheim Pharmaceuticals, Inc.
900 Ridgebury Road
Ridgefield, CT  06877
Fax: 1-203-837-4329
AND
NCCN at
ORPReports@nccn.org
or
Fax: (215) 358-7699
APPROVED RPCI Institutional Review Board: 10/17/2016


Roswell Park Cancer Institute Study Number:                                                                                               I 265514
PRIVATE AND CONFIDENTIAL INFORMATION OF ROSWELL PARK CANCER INSTITUTE
02.16.16
Page 77 of 90
A complete follow-up report must be sent to the RPCI Network Monitor when new information 
becomes available.
•
If this is a Phase 1 study the site Investigator or designated research personnel will complete 
and send the Serious Adverse Event / Possible Dose Limiting Toxicity Memo to notify the 
appropriate 
RPCI 
personnel 
of 
an 
SAE 
or 
potential 
DLT 
via 
email: 
Phase1DLTnetwork@Roswellpark.org.
8.
UNANTICIPATED PROBLEM REPORTING
An unanticipated problem (UP) is any incident, experience, or outcome that meets all of the 
criteria in Section 10.6.
For all adverse events occurring that are unanticipated and related or possibly related to the 
research drug, biologic or intervention, the participating physician or delegated research staff 
from each site will notify their local IRB in accordance with their local institutional 
guidelines. The site must also notify the RPCI Network Monitor within 1 business day of being 
made aware of the Unanticipated Problem by completing the RPCI Unanticipated Problem 
Report Form and faxing or emailing it to the RPCI Network Monitor.
9.
DATA AND SAFETY MONITORING
Weekly or bi-weekly teleconferences will be scheduled to review participant adverse events and 
study status. The site Investigator and study coordinator are expected to attend.


Roswell Park Cancer Institute Study Number:                                                                                               I 265514
PRIVATE AND CONFIDENTIAL INFORMATION OF ROSWELL PARK CANCER INSTITUTE
02.16.16
Page 78 of 90
Appendix B
ECOG Performance Status Scores
Description
Status
Fully active, able to carry on all pre-disease performance without restriction.
0
Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or 
sedentary nature, e.g., light housework, office work.
1
Ambulatory and capable of all self-care but unable to carry out any work activities.
2
Capable of only limited self-care, confined to bed or chair more than 50% of waking hours.
3
Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair.
4
Dead
5
APPROVED RPCI Institutional Review Board: 10/17/2016


Roswell Park Cancer Institute Study Number:                                                                                               I 265514
PRIVATE AND CONFIDENTIAL INFORMATION OF ROSWELL PARK CANCER INSTITUTE
02.16.16
Page 79 of 90
Appendix C
Drug-Induced Liver Injury Follow-Up Procedures
Procedures for the follow-up of a potential DILI case 
(Hy`s Law case) in IIS with nintedanib (BIBF 1120)
______________________________________________________________________________
Introduction
Drug-induced liver injury
Drug-induced liver injury (DILI) has been the most frequent single cause of safety-related drug 
marketing withdrawals for the past 50 years (e.g., iproniazid), continuing to the present (e.g., 
ticrynafen, benoxaprofen, bromfenac, troglitazone, nefazodone). Accordingly, detection of drug-
induced liver injury of an investigational compound has become an important aspect of patient´s 
safety guarding in drug development.
The US-FDA has published a Guidance for Industry entitled, “Drug-Induced Liver Injury: 
Premarketing Clinical Evaluation” 
(http://www.fda.gov/downloads/Drugs/.../Guidances/UCM174090.pdf ) which outlines the 
detection, evaluation, follow-up and reporting of drug-induced liver injury in clinical trials. 
Drugs that have the potential for inducing severe liver injury may be identified by marked peak 
aminotransferase elevations (10x-, 15xULN), or the combination of hepatocellular injury 
(aminotransferase elevation ≥3xULN) and altered liver function (hyperbilirubinemia ≥2xULN) 
which is defined as potential “Hy´s law case” if not explained by other causes including evidence 
of biliary obstruction (i.e., significant elevation of alkaline phosphatase, ALP, >2X ULN) or some 
other explanation of the injury (e.g., viral hepatitis, alcohol hepatitis, concomitant use of other known 
hepatotoxic drugs). This constellation predicts a poor outcome and although very rare, these 
potential cases have to be well characterized as soon as being identified as other confounding 
conditions may be the cause.
In further consideration of this FDA Guidance, any potential “Hy’s Law case” has to be reported 
in an expedited manner to the FDA (i.e., even before all other possible causes of liver injury have 
been excluded) and be followed-up appropriately. The follow-up includes a detailed clinical 
evaluation and identification of possible alternative etiologies for the “Hy´s Law case” 
constellation such as concomitant diseases (e.g. Hepatitis B) and/or other concomitant therapies 
that might potentially be hepatotoxic.
Although rare, a potential for drug-induced liver injury is under constant surveillance by 
sponsors and regulators. Therefore, this study requires timely detection, evaluation, and follow-
up of laboratory alterations of selected liver laboratory parameters to ensure patients´ safety.
The concept below has been worked out by Boehringer Ingelheim (BI) in order to guard patient´s 
safety and to respond to regulatory requirements. It is the basis for all clinical studies and should 
be applied as appropriate.
APPROVED RPCI Institutional Review Board: 10/17/2016


Roswell Park Cancer Institute Study Number:                                                                                               I 265514
PRIVATE AND CONFIDENTIAL INFORMATION OF ROSWELL PARK CANCER INSTITUTE
02.16.16
Page 80 of 90
Definition
The following changes in the laboratory values are considered to be a protocol-specific 
significant adverse event for all patients with normal values for ALT/AST at baseline:
•
an elevation of ALT and / or AST > 5x ULN without bilirubin elevation measured in the 
same blood draw sample
•
an elevation of AST and/or ALT >2.5 fold ULN combined with an elevation of bilirubin 
to >1.5 fold ULN measured in the same blood draw sample
These definitions are in line with the current dose reduction recommendations as outlined in all 
study protocols for BIBF 1120.
Patients showing these laboratory abnormalities need to be followed up until the protocol 
specific retreatment criteria have been met.
For patients with elevated ALT/AST values at baseline special considerations apply, if they are 
eligible for inclusion into the trial, e.g. if liver metastasis are present and do not qualify as 
exclusion criterion. For those special cases the BI contact person should be involved.
Procedures
1. Protocol-specified significant events are to be reported in an expedited manner similar as 
Serious Adverse Events, even if they do not meet any of the seriousness criteria and 
documented in the eCRF.
2. Replication of the following laboratory tests for confirmation within 48 hours:
•
AST, ALT
•
Bilirubin measurement (total and direct bilirubin)
•
Alkaline Phosphatase
•
Haptoglobin
•
Complete blood count and cell morphology
•
Reticulocyte count
•
CK
•
LDH
The results of these repeated laboratory tests must be documented on the eCRF /CRF forms and 
reported immediately via the SAE form to BI.
APPROVED RPCI Institutional Review Board: 10/17/2016


Roswell Park Cancer Institute Study Number:                                                                                               I 265514
PRIVATE AND CONFIDENTIAL INFORMATION OF ROSWELL PARK CANCER INSTITUTE
02.16.16
Page 81 of 90
The investigator will report all SAEs and non-serious AEs which are relevant to reported SAEs 
and AESIs by fax using BI IIS SAE form or MedWatch 3500A form, and completed BI SAE Fax 
Cover sheet to BI Unique Entry Point as detailed below:
Boehringer Ingelheim Pharmaceuticals, Inc.
900 Ridgebury Road
Ridgefield, CT  06877
Fax: 1-203-837-4329
3. An evaluation of the patient within 48 hours with respect to but not limited to:
•
Abdominal ultrasound or clinically appropriate other imaging and investigations adequate 
to rule out biliary tract, pancreatic,  intra- or extrahepatic pathology, e.g. bile duct stones,  
neoplasm, hepatic tumour involvement, biliary tract, pancreatic or intrahepatic pathology, 
vascular hepatic conditions such as portal vein thrombosis or right heart failure. These 
data need to be collected, documented in the respective field of the eCRF / CRF / 
additional documentation form, and the respective SAE form has to be updated and 
forwarded to BI.
•
Detailed history of current symptoms and concurrent diagnoses and medical history.
•
Detailed history of concomitant drug use (including non-prescription medications, herbal 
and dietary supplement preparations and e.g., steroids as concomitant supportive 
treatment), alcohol use, recreational drug use, and special diets detailed history of 
exposure to environmental chemical agents.
•
In case that both imaging and laboratory value did not unequivocally confirm cholestasis 
as the reason of ALT / AST increase, in particular if AP < 2x ULN, then please complete 
the following laboratory tests:
•
Clinical chemistry:
•
Alkaline phosphatase, cholinesterase (either plasma or red blood cell), albumin, PT or 
INR, CK, CK-MB, coeruloplasmin*, α-1 antitrypsin*, transferrin, ferritin, amylase*, 
lipase*, fasting glucose*, cholesterol, triglycerides
•
Serology:
•
Hepatitis A (Anti-IgM, Anti-IgG), Hepatitis B (HBsAg, Anti-HBs, DNA), Hepatitis C 
(Anti-HCV, RNA if Anti-HCV positive), Hepatitis D (Anti-IgM, Anti-IgG)*, Hepatitis E 
(Anti-HEV, Anti-HEV IgM, RNA if Anti-HEV IgM positive)*, Anti-Smooth Muscle 
antibody (titer)*, Anti-nuclear antibody (titer)*, Anti-LKM (liver-kidney microsomes) 
antibody*, Anti-mitochondrial antibody*, Epstein Barr Virus (VCA IgG, VCA IgM), 
cytomegalovirus (IgG, IgM), herpes simplex virus (IgG, IgM), varicella (IgG, IgM), 
parvovirus (IgG, IgM)
•
Hormones, tumor marker:
APPROVED RPCI Institutional Review Board: 10/17/2016


Roswell Park Cancer Institute Study Number:                                                                                               I 265514
PRIVATE AND CONFIDENTIAL INFORMATION OF ROSWELL PARK CANCER INSTITUTE
02.16.16
Page 82 of 90
•
TSH*
•
Hematology:
•
Thrombocytes*, eosinophils*
* If clinically indicated and, in case that additional investigations are needed (e.g., 
immunocompromised patients).
4. Initiate close observation of all patients with elevated liver enzyme and bilirubin 
elevations by repeat testing of ALT, AST,  bilirubin (with fractionation into total and 
direct) and AP at least weekly until the laboratory values return to normal or to the values 
as defined in the protocol.
5. In case that transaminases and/or bilirubin increase despite cessation of the experimental 
therapy, more frequent intervals will be warranted. Depending on further laboratory 
changes, additional parameters identified e.g. by reflex testing will be followed up based 
on medical judgement and Good Clinical Practices.
APPROVED RPCI Institutional Review Board: 10/17/2016


Roswell Park Cancer Institute Study Number:                                                                                               I 265514
PRIVATE AND CONFIDENTIAL INFORMATION OF ROSWELL PARK CANCER INSTITUTE
02.16.16
Page 83 of 90
Appendix D
Study Medication Diary for Nintedanib
Protocol No.: ________________
Patient Name: ______________________________
Cycle ________ ID# ___________
Medical Record No.: _________________________
Please complete this calendar on a daily basis. Take the AM and PM doses approximately 12 hours (+/- 2 hours) apart.  Take with water 
within 30 minutes after the end of a meal.  Both Nintedanib and Capecitabine may be taken at the same time.  If a dose is missed write 
“0” in the # taken box. If your dose changes, record the new dose on the day it changed on the study calendar.
Start Date: __________ 
Nintedanib per dose #100mg: _______ #150mg: _______
 (Total daily dose = ______mg)
Capecitabine per dose #150mg: ______ #500mg: _______
 (Total daily dose = ______mg)
Cycle Day
Day 1
Day 2
Day 3 
Day 4
Day 5
Day 6 
Day 7
Date
Nintedanib
AM
PM
AM
PM
AM
PM
AM
PM
AM
PM
AM
PM
AM
PM
Time Dose Taken
100mg #
150mg #
Capecitabine
AM
PM
AM
PM
AM
PM
AM
PM
AM
PM
AM
PM
AM
PM
Time Dose Taken:
150mg #
500mg #
Cycle Day
Day 8
Day 9
Day 10
Day 11
Day 12
Day 13
Day 14
Date
Nintedanib
AM
PM
AM
PM
AM
PM
AM
PM
AM
PM
AM
PM
AM
PM
Time Dose Taken:
100mg #
150mg #
Capecitabine
AM
PM
AM
PM
AM
PM
AM
PM
AM
PM
AM
PM
AM
PM
Time Dose Taken:
150mg #
500mg #
Cycle Day
Day 15
Day 16
Day 17
Day 18
Day 19
Day 20
Day 21
Date
Nintedanib
AM
PM
AM
PM
AM
PM
AM
PM
AM
PM
AM
PM
AM
PM
Time Dose Taken:
100mg #
150mg #
Capecitabine
AM
PM
AM
PM
AM
PM
AM
PM
AM
PM
AM
PM
AM
PM
Time Dose Taken:
X
X
X
X
X
X
X
X
X
X
X
X
X
X
150mg #
X
X
X
X
X
X
X
X
X
X
X
X
X
X
500mg #
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Bring this calendar and your pill bottles (including any unused pills) with you to all scheduled study appointments.
Clinical Research Services 
APPROVED RPCI Institutional Review Board: 10/17/2016


Roswell Park Cancer Institute Study Number:                                                                                               I 265514
PRIVATE AND CONFIDENTIAL INFORMATION OF ROSWELL PARK CANCER INSTITUTE
02.16.16
Page 84 of 90
Study Medication Diary for Nintedanib: Coordinator Use Only
Protocol No.: ________________
Patient Name: ______________________________
Cycle ________ ID# ___________
Medical Record No.: _________________________
Coordinator use only
Nintedanib #1 ________________
Date of return: __________________
# of pills
(dispensed: _______     --   returned: _______)
       
_____________________________________     x   100   =    % adherence: __________
# of pills scheduled _______        
Coordinator use only
Capecitabine #2 _______________
Date of return: __________________
# of pills
(dispensed: _______     --   returned: _______)
       
_____________________________________     x   100   =    % adherence: __________
# of pills scheduled _______        
Patient signature: _________________________________________                           Date: ____________
Investigator signature: _____________________________________                           Date: ____________
Clinical Research Services
APPROVED RPCI Institutional Review Board: 10/17/2016


Roswell Park Cancer Institute Study Number:                                                                                               I 265514
PRIVATE AND CONFIDENTIAL INFORMATION OF ROSWELL PARK CANCER INSTITUTE
02.16.16
Page 85 of 90
Appendix E
Procedure for Obtaining a Urine Protein/ Creatinine Ratio
1. Obtain at least 4 ml of a random urine sample (does not have to be a 24-hour urine)
2. Determine protein concentration (mg/dL)
3. Determine creatinine concentration (mg/dL)
4. Divide #2 by #3 above: urine protein / creatinine ratio = protein concentration (mg /dL) /
Creatinine concentration (mg/dL)
The UPC directly correlates with the amount of protein excreted in the urine per 24 hr (i.e., a 
UPC of 1 should be equivalent to 1 g protein in a 24 hr urine collection)
Protein and creatinine concentrations should be available on standard reports of urinalyses, not 
dipsticks. If protein and creatinine concentrations are not routinely reported at an Institution, 
their measurements and reports may need to be requested.
APPROVED RPCI Institutional Review Board: 10/17/2016


Roswell Park Cancer Institute Study Number:                                                                                               I 265514
PRIVATE AND CONFIDENTIAL INFORMATION OF ROSWELL PARK CANCER INSTITUTE
02.16.16
Page 86 of 90
17
REFERENCES
1.
Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64(1):9-
29. Epub 2014/01/09. doi: 10.3322/caac.21208. PubMed PMID: 24399786.
2.
Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, 
Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F. 
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N 
Engl J Med. 2004;350(23):2335-42. Epub 2004/06/04. doi: 10.1056/NEJMoa032691
350/23/2335 [pii]. PubMed PMID: 15175435.
3.
Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, Alberts SR, Schwartz 
MA, Benson AB, 3rd. Bevacizumab in combination with oxaliplatin, fluorouracil, and 
leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the 
Eastern Cooperative Oncology Group Study E3200. J Clin Oncol. 2007;25(12):1539-44. Epub 
2007/04/20. doi: 10.1200/JCO.2006.09.6305. PubMed PMID: 17442997.
4.
Bennouna J, Sastre J, Arnold D, Osterlund P, Greil R, Van Cutsem E, von Moos R, 
Vieitez JM, Bouche O, Borg C, Steffens CC, Alonso-Orduna V, Schlichting C, Reyes-Rivera I, 
Bendahmane B, Andre T, Kubicka S. Continuation of bevacizumab after first progression in 
metastatic colorectal cancer (ML18147): a randomised phase 3 trial. The Lancet Oncology. 
2013;14(1):29-37. Epub 2012/11/22. doi: 10.1016/S1470-2045(12)70477-1. PubMed PMID: 
23168366.
5.
Van Cutsem E, Tabernero J, Lakomy R, Prenen H, Prausova J, Macarulla T, Ruff P, van 
Hazel GA, Moiseyenko V, Ferry D, McKendrick J, Polikoff J, Tellier A, Castan R, Allegra C. 
Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase 
III randomized trial in patients with metastatic colorectal cancer previously treated with an 
oxaliplatin-based regimen. J Clin Oncol. 2012;30(28):3499-506. Epub 2012/09/06. doi: 
10.1200/JCO.2012.42.8201. PubMed PMID: 22949147.
6.
Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, Humblet Y, 
Bouche O, Mineur L, Barone C, Adenis A, Tabernero J, Yoshino T, Lenz HJ, Goldberg RM, 
Sargent DJ, Cihon F, Cupit L, Wagner A, Laurent D. Regorafenib monotherapy for previously 
treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, 
placebo-controlled, phase 3 trial. Lancet. 2013;381(9863):303-12. Epub 2012/11/28. doi: 
10.1016/S0140-6736(12)61900-X. PubMed PMID: 23177514.
7.
Chen HX, Mooney M, Boron M, Vena D, Mosby K, Grochow L, Jaffe C, Rubinstein L, 
Zwiebel J, Kaplan RS. Phase II multicenter trial of bevacizumab plus fluorouracil and leucovorin 
in patients with advanced refractory colorectal cancer: an NCI Treatment Referral Center Trial 
TRC-0301. 
J 
Clin 
Oncol. 
2006;24(21):3354-60. 
Epub 
2006/07/20. 
doi: 
10.1200/JCO.2005.05.1573. PubMed PMID: 16849749.
8.
Vincenzi B, Santini D, Russo A, Spoto C, Venditti O, Gasparro S, Rizzo S, Zobel BB, 
Caricato M, Valeri S, Coppola R, Tonini G. Bevacizumab in association with de Gramont 5-
fluorouracil/folinic acid in patients with oxaliplatin-, irinotecan-, and cetuximab-refractory 
APPROVED RPCI Institutional Review Board: 10/17/2016


Roswell Park Cancer Institute Study Number:                                                                                               I 265514
PRIVATE AND CONFIDENTIAL INFORMATION OF ROSWELL PARK CANCER INSTITUTE
02.16.16
Page 87 of 90
colorectal cancer: a single-center phase 2 trial. Cancer. 2009;115(20):4849-56. Epub 2009/07/25. 
doi: 10.1002/cncr.24540. PubMed PMID: 19626652.
9.
Samson B LJ, Nguyen NT, Sperlich C, Berbiche D, Tournigand C. SUNCAP, a phase II 
study with sunitinib and capecitabine in patients with metastatic colorectal cancer (MCRC) 
refractory to previous treatment with 5FU/irinotecan/oxaliplatin. 2011 Gastrointestinal Cancers 
Symposium  J Clin Oncol 29: 2011 (suppl 4; abstr 545).
10.
Tang PA, Cohen SJ, Kollmannsberger C, Bjarnason G, Virik K, MacKenzie MJ, 
Lourenco L, Wang L, Chen A, Moore MJ. Phase II clinical and pharmacokinetic study of 
aflibercept in patients with previously treated metastatic colorectal cancer. Clin Cancer Res. 
2012;18(21):6023-31. Epub 2012/09/15. doi: 10.1158/1078-0432.CCR-11-3252. PubMed PMID: 
22977191.
11.
Jonker DJ, O'Callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, Au HJ, Berry SR, Krahn 
M, Price T, Simes RJ, Tebbutt NC, van Hazel G, Wierzbicki R, Langer C, Moore MJ. Cetuximab 
for the treatment of colorectal cancer. N Engl J Med. 2007;357(20):2040-8. Epub 2007/11/16. 
doi: 10.1056/NEJMoa071834. PubMed PMID: 18003960.
12.
Bjorge JD, Jakymiw A, Fujita DJ. Selected glimpses into the activation and function of 
Src kinase. Oncogene. 2000;19(49):5620-35. PubMed PMID: 11114743.
13.
Nel AE. T-cell activation through the antigen receptor. Part 1: signaling components, 
signaling pathways, and signal integration at the T-cell antigen receptor synapse. The Journal of 
allergy and clinical immunology. 2002;109(5):758-70. PubMed PMID: 11994696.
14.
Seddon B, Legname G, Tomlinson P, Zamoyska R. Long-term survival but impaired 
homeostatic proliferation of Naive T cells in the absence of p56lck. Science. 
2000;290(5489):127-31. PubMed PMID: 11021796.
15.
Hilberg F, Roth GJ, Krssak M, Kautschitsch S, Sommergruber W, Tontsch-Grunt U, 
Garin-Chesa P, Bader G, Zoephel A, Quant J, Heckel A, Rettig WJ. BIBF 1120: triple 
angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res. 
2008;68(12):4774-82. doi: 10.1158/0008-5472.CAN-07-6307. PubMed PMID: 18559524.
16.
Stopfer P, Rathgen K, Bischoff D, Ludtke S, Marzin K, Kaiser R, Wagner K, Ebner T. 
Pharmacokinetics and metabolism of BIBF 1120 after oral dosing to healthy male volunteers. 
Xenobiotica; the fate of foreign compounds in biological systems. 2011;41(4):297-311. doi: 
10.3109/00498254.2010.545452. PubMed PMID: 21204634.
17.
Mross K, Stefanic M, Gmehling D, Frost A, Baas F, Unger C, Strecker R, Henning J, 
Gaschler-Markefski B, Stopfer P, de Rossi L, Kaiser R. Phase I study of the angiogenesis 
inhibitor BIBF 1120 in patients with advanced solid tumors. Clin Cancer Res. 2010;16(1):311-9. 
doi: 10.1158/1078-0432.CCR-09-0694. PubMed PMID: 20028771.
18.
Reck M, Kaiser R, Eschbach C, Stefanic M, Love J, Gatzemeier U, Stopfer P, von Pawel 
J. A phase II double-blind study to investigate efficacy and safety of two doses of the triple 
angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small-cell lung cancer. 
APPROVED RPCI Institutional Review Board: 10/17/2016


Roswell Park Cancer Institute Study Number:                                                                                               I 265514
PRIVATE AND CONFIDENTIAL INFORMATION OF ROSWELL PARK CANCER INSTITUTE
02.16.16
Page 88 of 90
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 
2011;22(6):1374-81. doi: 10.1093/annonc/mdq618. PubMed PMID: 21212157.
19.
Reck M, Kaiser R, Mellemgaard A, Douillard J-Y, Orlov S, Krzakowski M, von Pawel J, 
Gottfried M, Bondarenko I, Liao M, Gann C-N, Barrueco J, Gaschler-Markefski B, Novello S. 
Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-
small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. 
The Lancet Oncology. 2014;15(2):143-55. doi: http://dx.doi.org/10.1016/S1470-2045(13)70586-
2.
20.
Hanna NH, Kaiser R, Sullivan RN, Aren OR, Ahn M-J, Tiangco B, Zvirbule Z, Barrios 
CH, Demirkazik A, Gaschler-Markefski B, Voccia I, Barrueco J, Kim J-H. Lume-lung 2: A 
multicenter, randomized, double-blind, phase III study of nintedanib plus pemetrexed versus 
placebo plus pemetrexed in patients with advanced nonsquamous non-small cell lung cancer 
(NSCLC) 
after 
failure 
of 
first-line 
chemotherapy. 
ASCO 
Meeting 
Abstracts. 
2013;31(15_suppl):8034.
21.
Ledermann JA, Rustin GJ, Hackshaw A, Kaye SB, Jayson G, Gabra H, James LE, Bell S, 
Temple G. A randomized phase II placebo-controlled trial using maintenance therapy to evaluate 
the vascular targeting agent BIBF 1120 following treatment of relapsed ovarian cancer (OC). 
ASCO Meeting Abstracts. 2009;27(15S):5501.
22.
du Bois A, Kristensen G, Ray-Coquard I, Reub A, Pignata S, Columbo N, al e. AGO-
OVAR 12: A randomized placebo-controlled GCIG/ENGOT-Intergroup phase III trial of 
standard frontline chemotherapy +/- nintedanib for advanced ovarian cancer. Int J Gynecol 
Cancer. 2013;23(8 Suppl 1):7-8.
23.
Eisen T, Shparyk Y, Jones R, MacLeod NJ, Temple G, Finnigan H, Kaiser R, Studeny M, 
Loembe AB, Bondarenko I. Phase II efficacy and safety study of nintedanib versus sunitinib in 
previously untreated renal cell carcinoma (RCC) patients. ASCO Meeting Abstracts. 
2013;31(15_suppl):4506.
24.
Yen C, Kim T, Feng Y, Chao Y, Lin D, Stiudeny M, Hocke J, Huang D, Ryoo B, Cheng 
A. Efficacy and safety of nintedanib in Asian patients with advanced hepatoccellular carcinoma 
(HCC): A randomised Phase II trial. European Journal of Cancer. 2013;49(Supplement 2).
25.
Van Cutsem E, editor. A phase I/II, open-label, randomised study of BIBF 1120 plus 
mFOLFOX6 compared to bevacizumab plus mFOLFOX6 in patients with metastatic colorectal 
cancer. European Multidisciplinary Cancer Congress; 2011 September 23-27; Stockholm, 
Sewden.
26.
Ebos JM, Kerbel RS. Antiangiogenic therapy: impact on invasion, disease progression, 
and 
metastasis. 
Nature 
reviews 
Clinical 
oncology. 
2011;8(4):210-21. 
doi: 
10.1038/nrclinonc.2011.21. PubMed PMID: 21364524.
27.
Jahangiri A, Aghi MK. Biomarkers predicting tumor response and evasion to anti-
angiogenic therapy. Biochim Biophys Acta. 2012;1825(1):86-100. Epub 2011/11/10. doi: 
10.1016/j.bbcan.2011.10.004. PubMed PMID: 22067555.
APPROVED RPCI Institutional Review Board: 10/17/2016


Roswell Park Cancer Institute Study Number:                                                                                               I 265514
PRIVATE AND CONFIDENTIAL INFORMATION OF ROSWELL PARK CANCER INSTITUTE
02.16.16
Page 89 of 90
28.
Zurita AJ, Jonasch E, Wang X, Khajavi M, Yan S, Du DZ, Xu L, Herynk MH, McKee 
KS, Tran HT, Logothetis CJ, Tannir NM, Heymach JV. A cytokine and angiogenic factor (CAF) 
analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell 
carcinoma. Ann Oncol. 2012;23(1):46-52. Epub 2011/04/06. doi: 10.1093/annonc/mdr047. 
PubMed PMID: 21464158; PubMed Central PMCID: PMC3276320.
29.
Nikolinakos PG, Altorki N, Yankelevitz D, Tran HT, Yan S, Rajagopalan D, Bordogna 
W, Ottesen LH, Heymach JV. Plasma cytokine and angiogenic factor profiling identifies markers 
associated with tumor shrinkage in early-stage non-small cell lung cancer patients treated with 
pazopanib. Cancer Res. 2010;70(6):2171-9. Epub 2010/03/11. doi: 10.1158/0008-5472.CAN-09-
2533. PubMed PMID: 20215520.
30.
Hanrahan EO, Lin HY, Kim ES, Yan S, Du DZ, McKee KS, Tran HT, Lee JJ, Ryan AJ, 
Langmuir P, Johnson BE, Heymach JV. Distinct patterns of cytokine and angiogenic factor 
modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non-
small-cell lung cancer. J Clin Oncol. 2010;28(2):193-201. Epub 2009/12/02. doi: 
10.1200/JCO.2009.22.4279. 
PubMed 
PMID: 
19949019; 
PubMed 
Central 
PMCID: 
PMC3040010.
31.
Okamoto I, Kaneda H, Satoh T, Okamoto W, Miyazaki M, Morinaga R, Ueda S, 
Terashima M, Tsuya A, Sarashina A, Konishi K, Arao T, Nishio K, Kaiser R, Nakagawa K. 
Phase I safety, pharmacokinetic, and biomarker study of BIBF 1120, an oral triple tyrosine 
kinase inhibitor in patients with advanced solid tumors. Mol Cancer Ther. 2010;9(10):2825-33. 
Epub 2010/08/07. doi: 10.1158/1535-7163.MCT-10-0379. PubMed PMID: 20688946.
32.
Capdevila J, Carrato A, Tabernero J, Grande E. What could Nintedanib (BIBF 1120), a 
triple inhibitor of VEGFR, PDGFR, and FGFR, add to the current treatment options for patients 
with metastatic colorectal cancer? Crit Rev Oncol Hematol. 2014. Epub 2014/06/14. doi: 
10.1016/j.critrevonc.2014.05.004. PubMed PMID: 24924525.
33.
Ebos JM, Lee CR, Christensen JG, Mutsaers AJ, Kerbel RS. Multiple circulating 
proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with 
antitumor efficacy. Proc Natl Acad Sci U S A. 2007;104(43):17069-74. Epub 2007/10/19. doi: 
10.1073/pnas.0708148104. PubMed PMID: 17942672; PubMed Central PMCID: PMC2040401.
34.
Mittal K, Ebos J, Rini B. Angiogenesis and the tumor microenvironment: vascular 
endothelial growth factor and beyond. Semin Oncol. 2014;41(2):235-51. Epub 2014/05/03. doi: 
10.1053/j.seminoncol.2014.02.007. PubMed PMID: 24787295.
35.
Scheithauer W, McKendrick J, Begbie S, Borner M, Burns WI, Burris HA, Cassidy J, 
Jodrell D, Koralewski P, Levine EL, Marschner N, Maroun J, Garcia-Alfonso P, Tujakowski J, 
Van Hazel G, Wong A, Zaluski J, Twelves C. Oral capecitabine as an alternative to i.v. 5-
fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III 
trial. Ann Oncol. 2003;14(12):1735-43. Epub 2003/11/25. PubMed PMID: 14630678.
36.
Hoff PM, Ansari R, Batist G, Cox J, Kocha W, Kuperminc M, Maroun J, Walde D, 
Weaver C, Harrison E, Burger HU, Osterwalder B, Wong AO, Wong R. Comparison of oral 
capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 
APPROVED RPCI Institutional Review Board: 10/17/2016


Roswell Park Cancer Institute Study Number:                                                                                               I 265514
PRIVATE AND CONFIDENTIAL INFORMATION OF ROSWELL PARK CANCER INSTITUTE
02.16.16
Page 90 of 90
patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol. 
2001;19(8):2282-92. Epub 2001/04/17. PubMed PMID: 11304782.
37.
Cassidy J, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Rittweger 
K, Gilberg F, Saltz L. XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal 
cancer: NO16966 updated results. Br J Cancer. 2011;105(1):58-64. Epub 2011/06/16. doi: 
10.1038/bjc.2011.201. PubMed PMID: 21673685; PubMed Central PMCID: PMC3137415.
38.
Hintze J. PASS 11. Kaysville, Utah: NCSS, LLC; 2011.
APPROVED RPCI Institutional Review Board: 10/17/2016